Checkpoint regulator antagonists

By developing antagonists that specifically bind TIGIT, PD-1 and PD-L1, blocking the signaling of these checkpoint regulators, solving the problem that the host has difficulty eliminating cancer cells, and significantly improving anti-tumor immune response and cancer treatment Effect.

CN109988237BActive Publication Date: 2024-11-08SUZHOU ZELGEN BIOPHARML
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201810723340.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2017-12-29
Filing Date
2018-07-04
Publication Date
2024-11-08
Estimated Expiration
2038-07-04

AI Technical Summary

Technical Problem

In the existing cancer treatment methods, it is difficult for the host to effectively eliminate cancer cells, and the anti-tumor immune response is easily affected by resistance, resulting in poor treatment effect.

Method used

Develop antibodies or antigen-binding moieties thereof, with antagonists specifically binding to TIGIT, PD-1 and PD-L1, enhance the anti-tumor immune response by blocking the signaling of these checkpoint regulators.

Benefits of technology

Effectively reduce regulatory T cells in tumors, enhance the host's anti-tumor immune response, and improve the effect of cancer treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0001718999540000331
    Figure BDA0001718999540000331
  • Figure BDA0001718999540000711
    Figure BDA0001718999540000711
  • Figure BDA0001718999540000721
    Figure BDA0001718999540000721
Patent Text Reader

Abstract

Disclosed are checkpoint regulator antagonists that specifically bind to TIGIT, PD-1, and / or PD-L1. Also disclosed are methods of making and using the checkpoint regulator inhibitors, including monospecific, bispecific, and trispecific checkpoint regulator antagonists thereof.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application claims priority to U.S. patent application Ser. No. 15 / 858,963, filed Dec. 29, 2017. The entire contents of the above application are incorporated herein by reference. Technical Field

[0002] The present application relates generally to cancer treatment, and in particular, to checkpoint regulator antagonists, including anti-T cell Ig and ITIM domain (TIGIT) inhibitors, PD-1 inhibitors, PD-L1 inhibitors, including bispecific and trispecific checkpoint regulator antagonists thereof, that are capable of modulating pathways involved in anti-tumor immunity. Background Art

[0003] The inability of the host to eliminate cancer cells remains a major problem. Although a growing number of therapeutic monoclonal antibodies have been approved for the treatment of various cancers, the emergence of resistance to these antibodies is frequently observed given the many different molecular pathways involved in cancer growth and progression to metastasis. While the immune system is a primary mechanism for preventing cancer, cancer cells can resist immune surveillance. Natural control mechanisms have been identified that limit T cell activation to prevent collateral damage due to unrestricted T cell activity. This process has been exploited by tumor cells to evade immune responses. Restoring the ability of immune effector cells, particularly T cells, to recognize and eliminate cancer is a major goal of immunotherapy.

[0004] T cell Ig and ITIM domain (TIGIT) proteins are immunomodulators that can block T cell immunity against cancer cells. TIGIT antagonists and other immune checkpoint antagonists interfere with (or inhibit) the activity of immune checkpoint regulators, so that, as a result of binding to the checkpoint regulator or its ligand, signaling through the checkpoint regulator receptor is blocked or inhibited. In addition to TIGIT, other immune checkpoint regulators include the TIGIT ligands CD112 and CD155, PD-1 and its ligands PD-L1 and PD-L2; CTLA-4 and its ligands B7-1 and B7-2; TIM-3 and its ligand galectin-9; LAG-3 and its ligands, including liver sinusoidal endothelial cell lectin (LSECtin) and galectin-3; CD122 and its CD122R ligand; B7H3, B and T lymphocyte attenuator (BTLA), and VISTA.

[0005] There is a need for improved therapeutic binding antagonists or antibodies and methods of treating cancer and chronic viral infections with these agents. The drugs used in such improved treatment methods may comprise antibodies or antibody fragments that specifically bind to TIGIT, PD-1 and / or PD-L1 and reverse or partially reverse TIGIT-, PD-1 and / or PD-L1-mediated suppression of anti-tumor or anti-viral immune responses.

[0006] Given the limitations of the host's ability to eliminate cancer cells, a need exists for more effective compositions and methods for cancer treatment. Summary of the Invention

[0007] summary

[0008] One aspect of the present application relates to an antibody or antigen-binding portion thereof, comprising: (1) a heavy chain variable region, wherein the heavy chain variable region comprises three complementarity determining regions (HCDRs): HCDR1, HCDR2, and HCDR3, wherein HCDR1 has an amino acid sequence having about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% to about 100% homology to an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 6, SEQ ID NO: 11, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 20, and SEQ ID NO: 23, wherein HCDR2 has an amino acid sequence having about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% to about 100% homology to an amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 21, and SEQ ID NO: NO:24 has an amino acid sequence with about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% to about 100% homology, and wherein HCDR3 has an amino acid sequence with about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% to about 100% homology to an amino acid sequence selected from SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:14, SEQ ID NO:19, SEQ ID NO:22, and SEQ ID NO:25;and (2) a light chain variable region, wherein the light chain variable region comprises three complementarity determining regions (LCDRs): LCDR1, LCDR2, and LCDR3, wherein LCDR1 has an amino acid sequence having about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% to about 100% homology to an amino acid sequence selected from the group consisting of SEQ ID NO: 26, SEQ ID NO: 29, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID NO: 39, SEQ ID NO: 42, and SEQ ID NO: 45, and wherein LCDR2 has an amino acid sequence having about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% to about 100% homology to an amino acid sequence selected from the group consisting of SEQ ID NO: 27, SEQ ID NO: 30, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 40, SEQ ID NO: 43, and SEQ ID NO: NO:46 has an amino acid sequence that is about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% to about 100% homologous, and wherein LCDR3 has an amino acid sequence that is about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% to about 100% homologous to an amino acid sequence selected from SEQ ID NO:28, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:38, SEQ ID NO:41, SEQ ID NO:44, and SEQ ID NO:47, wherein the antibody, or antigen-binding portion thereof, specifically binds human TIGIT.;

[0009] In some embodiments, the antibody or antigen-binding portion thereof comprises: (1) a heavy chain variable region having an amino acid sequence about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% to about 100% homologous to an amino acid sequence selected from the group consisting of SEQ ID NO: 107, SEQ ID NO: 109, SEQ ID NO: 111, SEQ ID NO: 113, SEQ ID NO: 115, SEQ ID NO: 117, SEQ ID NO: 119, SEQ ID NO: 121, SEQ ID NO: 123, and SEQ ID NO: 125; and (2) a light chain variable region having an amino acid sequence about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% to about 100% homologous to an amino acid sequence selected from the group consisting of SEQ ID NO: 108, SEQ ID NO: 110, SEQ ID NO: 112, SEQ ID NO: 114, SEQ ID NO: 116, SEQ ID NO: 118, SEQ ID NO: 120, SEQ ID NO: 122, SEQ ID NO: 124, and SEQ ID NO: The amino acid sequence of NO:126 has an amino acid sequence with about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% to about 100% homology, wherein the antibody or its antigen binding portion specifically binds to human TIGIT.

[0010] Another aspect of the present application relates to an antibody, or antigen-binding portion thereof, comprising: (1) a heavy chain variable region, wherein the heavy chain variable region comprises three complementarity determining regions (HCDRs): HCDR1, HCDR2, and HCDR3, wherein HCDR1 has an amino acid sequence that is about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% to about 100% homologous to an amino acid sequence selected from the group consisting of SEQ ID NO: 48, SEQ ID NO: 51, SEQ ID NO: 54, SEQ ID NO: 56, and SEQ ID NO: 59, wherein HCDR2 has an amino acid sequence that is about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% to about 100% homologous to an amino acid sequence selected from the group consisting of SEQ ID NO: 49, SEQ ID NO: 52, SEQ ID NO: 57, and SEQ ID NO: 60, and wherein HCDR3 has an amino acid sequence that is about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% to about 100% homologous to an amino acid sequence selected from the group consisting of SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: NO:55, SEQ ID NO:58, and SEQ ID NO:61; and (2) a light chain variable region, wherein the light chain variable region comprises three complementarity determining regions (LCDRs): LCDR1, LCDR2, and LCDR3, wherein LCDR1 has an amino acid sequence having about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% to about 100% homology to an amino acid sequence selected from the group consisting of SEQ ID NO:62, SEQ ID NO:65, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, and SEQ ID NO:73, wherein LCDR2 has an amino acid sequence having about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% to about 100% homology to an amino acid sequence selected from the group consisting of SEQ ID NO:63, SEQ ID NO:66, SEQ ID NO:71, and SEQ ID NO:72; NO:74 has an amino acid sequence with about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% to about 100% homology, and wherein LCDR3 has an amino acid sequence with about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% to about 100% homology to an amino acid sequence selected from SEQ ID NO:64, SEQ ID NO:67, SEQ ID NO:72 and SEQ ID NO:75, wherein the antibody, or antigen-binding portion thereof, specifically binds to human PD-1.

[0011] In some embodiments, the antibody or antigen-binding portion thereof comprises: (1) a heavy chain variable region having an amino acid sequence that is about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% to about 100% homologous to an amino acid sequence selected from the group consisting of SEQ ID NO: 127, SEQ ID NO: 129, SEQ ID NO: 131, SEQ ID NO: 133, SEQ ID NO: 135, and SEQ ID NO: 137; and (2) a light chain variable region having an amino acid sequence that is about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% to about 100% homologous to an amino acid sequence selected from the group consisting of SEQ ID NO: 128, SEQ ID NO: 130, SEQ ID NO: 132, SEQ ID NO: 134, SEQ ID NO: 136, and SEQ ID NO: 138, wherein the antibody or antigen-binding portion thereof specifically binds to human PD-1.

[0012] Another aspect of the present application relates to an antibody, or antigen-binding portion thereof, comprising: (1) a heavy chain variable region, wherein the heavy chain variable region comprises three complementarity determining regions (HCDRs): HCDR1, HCDR2, and HCDR3, wherein HCDR1 has an amino acid sequence that is about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% to about 100% homologous to an amino acid sequence selected from the group consisting of SEQ ID NO: 76, SEQ ID NO: 79, SEQ ID NO: 85, and SEQ ID NO: 88, wherein HCDR2 has an amino acid sequence that is about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% to about 100% homologous to an amino acid sequence selected from the group consisting of SEQ ID NO: 77, SEQ ID NO: 80, SEQ ID NO: 82, SEQ ID NO: 84, SEQ ID NO: 86, and SEQ ID NO: 89, and wherein HCDR3 has an amino acid sequence that is about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% to about 100% homologous to an amino acid sequence selected from the group consisting of SEQ ID NO: 78, SEQ ID NO: NO:81, SEQ ID NO:83, SEQ ID NO:87 and SEQ ID NO:90; and (2) a light chain variable region, wherein the light chain variable region comprises three complementarity determining regions (LCDRs): LCDR1, LCDR2 and LCDR3, wherein LCDR1 has an amino acid sequence having about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% to about 100% homology to an amino acid sequence selected from the group consisting of SEQ ID NO:91, SEQ ID NO:94, SEQ ID NO:98, SEQ ID NO:101 and SEQ ID NO:104, wherein LCDR2 has an amino acid sequence having about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% to about 100% homology to an amino acid sequence selected from the group consisting of SEQ ID NO:92, SEQ ID NO:95, SEQ ID NO:99, SEQ ID NO:102 and SEQ ID NO:103, NO: 105 has an amino acid sequence with about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% to about 100% homology, and wherein LCDR3 has an amino acid sequence with about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% to about 100% homology to an amino acid sequence selected from SEQ ID NO: 93, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 100, SEQ ID NO: 103, and SEQ ID NO: 106, wherein the antibody, or antigen-binding portion thereof, specifically binds human PD-L1.

[0013] In some embodiments, the antibody, or antigen-binding portion thereof, comprises: (1) a heavy chain variable region having an amino acid sequence about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% to about 100% homologous to an amino acid sequence selected from the group consisting of SEQ ID NO: 139, SEQ ID NO: 141, SEQ ID NO: 143, SEQ ID NO: 145, SEQ ID NO: 147, SEQ ID NO: 149, SEQ ID NO: 151, and SEQ ID NO: 153; and (2) a light chain variable region having an amino acid sequence about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% to about 100% homologous to an amino acid sequence selected from the group consisting of SEQ ID NO: 139, SEQ ID NO: 141, SEQ ID NO: 143, SEQ ID NO: 145, SEQ ID NO: 147, SEQ ID NO: 149, SEQ ID NO: 151, and SEQ ID NO: 153. The amino acid sequence of NO: 154 has an amino acid sequence with about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% to about 100% homology, wherein the antibody or antigen-binding portion thereof specifically binds to human PD-L1.

[0014] Another aspect of the present application relates to a bispecific antibody, comprising: a first antigen-binding domain, which comprises an antigen-binding portion of the anti-TIGIT, anti-PD-1 and / or anti-PD-L1 antibody of the present application; and a second antigen-binding domain, which comprises an antigen-binding portion of another anti-TIGIT, anti-PD-1 antibody and / or anti-PD-L1 antibody of the present application.

[0015] In one embodiment, the bispecific checkpoint modulator antagonist TP-M2T8P5 comprises: (1) a heavy chain variable region having an amino acid sequence that is about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% to about 100% homologous to the amino acid sequence in SEQ ID NO: 155; and (2) a variable light chain variable region having an amino acid sequence that is about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% to about 100% homologous to the amino acid sequence in SEQ ID NO: 156.

[0016] In another embodiment, the bispecific checkpoint modulator antagonist TP-M4T8P5 comprises: (1) a light chain variable region 2 / heavy chain variable region 1 (VL2 / VH1) having an amino acid sequence with about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% to about 100% homology to the amino acid sequence in SEQ ID NO: 157; and (2) a heavy chain variable region 2 / light chain variable region 1 (VH2 / VL1) having an amino acid sequence with about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% to about 100% homology to the amino acid sequence in SEQ ID NO: 158.

[0017] In another embodiment, the bispecific checkpoint modulator antagonist TP-M6T8P5 comprises: (1) a heavy chain variable region having an amino acid sequence about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% to about 100% homologous to the amino acid sequence in SEQ ID NO: 159; (2) a light chain variable region 2 / light chain constant region (VL2 / CL) having an amino acid sequence about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% to about 100% homologous to the amino acid sequence in SEQ ID NO: 160; and (3) a heavy chain variable region 1 / heavy chain constant region 1 (VH1 / CH1) having an amino acid sequence about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% to about 100% homologous to the amino acid sequence in SEQ ID NO: The amino acid sequence in NO: 161 has an amino acid sequence with about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% to about 100% homology.

[0018] In another embodiment, the bispecific checkpoint modulator antagonist TP-M6T8L8 comprises: (1) a heavy chain variable region having an amino acid sequence about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% to about 100% homologous to the amino acid sequence in SEQ ID NO: 162; (2) a light chain variable region 2 / light chain constant region (VL2 / CL) having an amino acid sequence about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% to about 100% homologous to the amino acid sequence in SEQ ID NO: 163; and (3) a heavy chain variable region 1 / heavy chain constant region 1 (VH1 / CH1) having an amino acid sequence about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% to about 100% homologous to the amino acid sequence in SEQ ID NO: The amino acid sequence in NO: 164 has an amino acid sequence with about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% to about 100% homology.

[0019] In another embodiment, the bispecific checkpoint modulator antagonist TP-M8T10P1 (TP-83) comprises: (1) a heavy chain variable region having an amino acid sequence about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% to about 100% homologous to the amino acid sequence in SEQ ID NO: 165; and (2) a light chain having an amino acid sequence about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% to about 100% homologous to the amino acid sequence in SEQ ID NO: 166.

[0020] In another embodiment, the bispecific checkpoint regulator antagonist TP-M9T10P1 (TP-93) comprises: (1) a heavy chain having about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% to about 100% homology to the amino acid sequence in SEQ ID NO: 167; and (2) a light chain having an amino acid sequence having about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% to about 100% homology to the amino acid sequence in SEQ ID NO: 168.

[0021] In another embodiment, the bispecific checkpoint modulator antagonist TP-M9T10P5 comprises: (1) a heavy chain having about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% to about 100% homology to the amino acid sequence in SEQ ID NO: 169; and (2) a light chain having an amino acid sequence having about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% to about 100% homology to the amino acid sequence in SEQ ID NO: 170.

[0022] In another embodiment, the bispecific checkpoint modulator antagonist TP-M10T8P5 (TP-92) comprises: (1) a heavy chain having about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% to about 100% homology to the amino acid sequence in SEQ ID NO: 171; and (2) a light chain variable region having an amino acid sequence having about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% to about 100% homology to the amino acid sequence in SEQ ID NO: 172.

[0023] In another embodiment, the bispecific checkpoint regulator antagonist TP-M10T8L8 comprises an amino acid sequence that is about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% to about 100% homologous to the amino acid sequence in SEQ ID NO: 173.

[0024] In another embodiment, the bispecific checkpoint modulator antagonist TP-M14T8P5 comprises: (1) a heavy chain variable region 2 / heavy chain constant region 1 (VH2 / CH1) having an amino acid sequence about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% to about 100% homologous to the amino acid sequence in SEQ ID NO: 174; (2) a variable light chain region 1 / heavy chain constant region 1 (VL1 / CH1) having an amino acid sequence about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% to about 100% homologous to the amino acid sequence in SEQ ID NO: 175; (3) a light chain variable region 2 / light chain constant region (VL2 / CL) having an amino acid sequence about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% to about 100% homologous to the amino acid sequence in SEQ ID NO: the amino acid sequence of NO:176 having an amino acid sequence of about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% to about 100% homology; and (4) a heavy chain variable region 1 / light chain constant region (VH1 / CL) having an amino acid sequence of about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% to about 100% homology to the amino acid sequence of SEQ ID NO:177.

[0025] In another embodiment, the bispecific checkpoint modulator antagonist TP-M14T8L8 comprises: (1) a heavy chain variable region 2 / heavy chain constant region 1 (VH2 / HC1) having an amino acid sequence about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% to about 100% homologous to the amino acid sequence of SEQ ID NO: 178; (2) a variable light chain region 1 / heavy chain constant region 2 (VL1 / HC2) having an amino acid sequence about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% to about 100% homologous to the amino acid sequence of SEQ ID NO: 179; (3) a light chain variable region 2 / light chain constant region (VL2 / CL) having an amino acid sequence about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% to about 100% homologous to the amino acid sequence of SEQ ID NO: an amino acid sequence having about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% to about 100% identity to the amino acid sequence in NO: 180; and (4) a heavy chain variable region 1 / light chain constant region (VH1 / CL) having an amino acid sequence having about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% to about 100% identity to the amino acid sequence in SEQ ID NO: 181.

[0026] Another aspect of the present application relates to a nucleic acid encoding the antibody, antigen-binding fragment thereof, or bispecific antibody of the present application.

[0027] Another aspect of the present application relates to an expression vector comprising the nucleic acid of the present application.

[0028] Another aspect of the present application relates to a host cell transformed with the expression vector of the present application.

[0029] Another aspect of the present application relates to methods of producing anti-TIGIT antibodies, anti-PD-1 antibodies, anti-PD-L1 antibodies, antigen-binding fragments thereof, including monospecific, bispecific and trispecific checkpoint regulator antagonists, and combinations thereof.

[0030] Another aspect of the present application relates to a method for reducing or depleting regulatory T cells in a tumor of a subject in need thereof, comprising administering to the subject an effective amount of the antibody, antibody fragment or bispecific checkpoint regulator antagonist of the present application. BRIEF DESCRIPTION OF THE DRAWINGS

[0031] Figure 1 Shown are the results of competition between anti-TIGIT monoclonal antibodies (mabs) for TIGIT and PVR (CD155), the TIGIT ligand.

[0032] Figure 2 Anti-TIGIT mouse monoclonal antibodies were shown to enhance human T cell function.

[0033] Figure 3A -C shows the CDR sequence of anti-TIGIT mouse monoclonal antibody ( Figure 3A ); anti-PD-1 mouse monoclonal antibody ( Figure 3B ); and anti-PD-L1 mouse monoclonal antibody ( Figure 3C ).

[0034] Figure 4A -H shows several embodiments of anti-TIGIT antibody variable domain sequences ( Figure 4A -C); anti-PD-1 antibody variable domain sequence ( Figure 4D -E); anti-PD-L1 antibody variable domain sequence ( Figure 4F -H).

[0035] Figure 5A -G shows exemplary dual-specific checkpoint regulator antagonist sequences against PD1 and TIGIT.

[0036] Figure 6 Binding of anti-TIGIT mouse monoclonal antibodies to cells expressing full-length human TIGIT (hu TIGIT) is shown.

[0037] Figure 7It was shown that anti-TIGIT monoclonal antibodies blocked the interaction between hu TIGIT and its ligand human PVR (CD155) in a cell-based assay.

[0038] Figure 8 Anti-TIGIT monoclonal antibodies were shown to enhance IFN-γ production by human PBMCs.

[0039] Figure 9 Anti-TIGIT monoclonal antibodies were shown to enhance the proliferation of primary human T cells.

[0040] Figure 10A Binding of anti-TIGIT monoclonal antibodies to hu TIGIT and cyno-hu TIGIT in a cell-based assay is shown. Figure 10B Anti-TIGIT monoclonal antibodies were shown to inhibit antibody binding to hu TIGIT and cyno-hu TIGIT in a cell-based assay.

[0041] Figure 11A Anti-PD-1 monoclonal antibodies were shown to block the interaction between human PD-1 and human PD-L1. Figure 11B Anti-PD-1 monoclonal antibodies were shown to block the interaction between cyno hu PD-1 and cyno hu PD-L1.

[0042] Figure 12A Binding of anti-PD-1 monoclonal antibodies to hu PD-L1 is shown. Figure 12B Binding of anti-PD-1 monoclonal antibody to cyno-hu PD-L1 is shown.

[0043] Figure 13A -C shows the binding affinity of anti-PD-1 antibodies to human PD-1, including the PD-01 monoclonal antibody ( Figure 13A ), PD-02 monoclonal antibody ( Figure 13B ) and benchmark (BM) anti-PD-1 mAb ( Figure 13C ).

[0044] Figure 14 It was shown that anti-PD-1 monoclonal antibodies enhanced IFN-γ production by human PBMCs.

[0045] Figure 15 Shown is increased IFN-γ production by human PBMCs by a combination of anti-TIGIT and anti-PD-1 monoclonal antibodies.

[0046] Figure 16A and 16B Showing increased proliferation of human T cells by a combination of anti-TIGIT and anti-PD-1 monoclonal antibodies.

[0047] Figures 17A-17N show a variety of different bispecific checkpoint regulator antagonists M1-M14, in which: (1) the VH1 and VL1 regions correspond to anti-PD1, anti-PD-L1 or any other monoclonal antibody variable domains; and (2) the VH2 and VL2 regions correspond to anti-TIGIT variable domains.

[0048] Figures 18A-18J Various trispecific checkpoint regulator antagonists are shown, where: (1) the VH1 and VL1 regions correspond to anti-TIGIT variable domains; (2) the VH2 and VL21 regions correspond to anti-PD1, anti-PD-L1 or any other monoclonal antibody variable domains; and (3) the circular region corresponds to AMG386 or any other biological peptide.

[0049] Figure 19A -D is used to identify cells that can block PD-1 binding ( Figure 19A , Figure 19B ) and TIGIT ( Figure 19C , Figure 19D )'s results from a screening assay for a bispecific antibody.

[0050] Figures 20A-20B The bispecific antibodies (TP-83, TP-92 and TP-B) were shown to block the binding of PD-L1 to PD-1 ( Figure 20A ) and blocking the binding of PVR to TIGIT ( Figure 20B ) ability.

[0051] Figure 21A and 21B Shown are Coomasie-stained gels demonstrating the generation of bispecific antibodies TP-83, TP-92, and TP-93.

[0052] Figure 22 Shown are exemplary size exclusion chromatography (SEC) profiles of the bispecific checkpoint antagonists TP-93 and TP-83, illustrating the manufacturability of the molecules after one-step purification.

[0053] Figures 23A-23D We showed that treatment with a bispecific monoclonal antibody (TP-93) increased the expression of T-1β in human PBMCs (donor 333, Figure 23A , Figure 23C ; Donor 287, Figure 23B , Figure 23D ) of IFN-γ production.

[0054] Figures 24A-24D Binding kinetics are shown for anti-TIGIT monoclonal antibodies. DETAILED DESCRIPTION

[0055] Detailed description

[0056] definition

[0057] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the disclosed methods and compositions belong. It must be noted that, as used herein and in the appended claims, the singular forms "a," "an," and "the" include the plural forms unless the context clearly indicates otherwise. Thus, for example, reference to "a peptide" includes "one or more" peptides or "a plurality" of such peptides. Any published patent or patent application disclosure described in this application is expressly incorporated herein by reference for its teachings.

[0058] As used herein, the term "TIGIT" refers to any form of TIGIT and variants thereof that retain at least some TIGIT activity. Unless otherwise indicated, for example by specific reference to human TIGIT, TIGIT includes native sequence TIGIT of all mammalian species (e.g., humans, dogs, cats, horses, and cattle). The following is an exemplary human TIGIT amino acid sequence: MTGTIETTGNISAEKGGSIILQCHLSSTTAQVTQVNWEQQDQLLAICNADLGWHISPSFKDRVAPGPGLGLTLQSLTVNDTGEYFCIYHTYPDGTYTGRIFLEVLESSVAEHGARFQIPLLGAMAATLVVICTAVIVVVALTRKKKALRIHSVEGDLRRKSAGQEEWSPSAPSPPGSCVQAEAAPAGLCGEQRGEDCAELHDYFNVLSYRSLGNCSFFTETG (SEQ ID NO: 182)

[0059] As used herein, the term "PD-1" refers to any form of PD-1 and its variants that retain at least some of the activity of PD-1. Unless otherwise indicated, such as by specific reference to human PD-1, PD-1 includes native sequence PD-1 of all mammalian species (e.g., humans, dogs, cats, horses, and cows). An exemplary human PD-1 amino acid sequence is listed below:

[0060] LDSPDRPWNPPTFSPALLVVTEGDNATFTCSFSNTSESFVLNWYRMSPSNQTDKLAAFPEDRSQPGQDCRFRVTQLPNGRDFHMSVVRARRNDSGTYLCGAISLAPKAQIKESLRAELRVTERRAEVPTAHPSP SPRPAGQFQTLVVGVVGGLLGSLVLLVWVLAVICSRAARGTIGARTGQPLKEDPSAVPVFSVDYGELDFQWREKTPEPPVPCVPEQTEYATIVFPSGMGTSSPARRGSADGPRSAQPLRPEDGHCSWPL(SEQ ID NO:183).

[0061] As used herein, the term "PD-L1" refers to any form of PD-L1 and its variants that retain at least some of the activity of PD-L1. Unless otherwise indicated, for example, by specific reference to human PD-L1, PD-L1 includes native sequence PD-L1 of all mammalian species (e.g., humans, dogs, cats, horses, and cows). An exemplary human PD-L1 amino acid sequence is listed below: FTVTVPKDLYVVEYGSNMTIECKFPVEKQLDLAALIVYWEMEDKNIIQFVHGEEDLKVQHSSYRQRARLLKDQLSLGNAALQITDVKLQDAGVYRCMISYGGADYKRITVKVNAPYNKINQRILVVDPVTSEHELTCQAEGYPKAEVIWTSSDHQVLSGKTTTTNSKREEKLFNVTSTLRINTTTNEIFYCTFRRLDPEENHTAELVIPELPLAHPPNER (SEQ ID NO: 184).

[0062] The term "agonist" refers to a substance that promotes (i.e., induces, causes, enhances, or increases) the biological activity or effect of another molecule. The term agonist includes substances that bind to a receptor (such as antibodies), as well as substances that promote receptor function without binding to it (e.g., by activating related proteins).

[0063] The term "antagonist" or "inhibitor" refers to a substance that prevents, blocks, inhibits, neutralizes or reduces the biological activity or effect of another molecule (such as a receptor).

[0064] As used herein, the term "antibody" refers to a polypeptide or polypeptide complex that specifically recognizes and binds to an antigen through one or more immunoglobulin variable regions. An antibody can be a complete antibody, an antigen-binding fragment, or a single chain thereof. The term "antibody" encompasses a wide variety of polypeptides that can be distinguished biochemically. Those skilled in the art will appreciate that heavy chains are classified into alpha (the first letter of the Greek alphabet), delta (the fourth letter of the Greek alphabet), epsilon (the fifth letter of the Greek alphabet), gamma (the third letter of the Greek alphabet), and mu (the twelfth letter of the Greek alphabet), or α, δ, ε, γ, and μ, among others, with some subclasses (e.g., γ1-γ4). It is the properties of this chain that determine the "class" of the antibody, IgG, IgM, IgA, IgG, or IgE, respectively. Immunoglobulin subclasses (isotypes), for example, IgG1, IgG2, IgG3, IgG4, IgG5, etc., have been well characterized and are known to confer functional specialization. In view of the present disclosure, modified versions of each of these classes and isotypes are readily discernible to those skilled in the art and are therefore within the scope of the present disclosure. While all immunoglobulin classes are within the scope of the present disclosure, the following discussion will generally be directed to the IgG class of immunoglobulin molecules.

[0065] Antibodies disclosed herein include, but are not limited to, polyclonal, monoclonal, multispecific, bispecific, trispecific, human, humanized, primatized, chimeric, and single-chain antibodies. The antibodies disclosed herein can be from any animal origin, including birds and mammals. Preferably, the antibodies are human, mouse, donkey, rabbit, goat, guinea pig, camel, llama, horse, or chicken antibodies. In some embodiments, the variable region may be of condricthoid origin (e.g., from shark).

[0066] The term "antibody fragment" or "antigen-binding fragment" is used with reference to a portion of an antibody, such as F(ab')2, F(ab)2, Fab', Fab, Fv, single-chain Fvs (scFv), single-chain antibodies, disulfide-linked Fvs (sdFv), fragments comprising a VL or VH domain, fragments produced by a Fab expression library, and anti-idiotypic (anti-Id) antibodies. Regardless of the structure, antibody fragments bind to the same antigen recognized by the intact antibody. The term "antibody fragment" includes aptamers, spiegelmers, and diabodies. The term "antibody fragment" also includes any synthetic or genetically engineered protein comprising an immunoglobulin variable region that functions as an antibody by binding to a specific antigen to form a complex.

[0067] "Single-chain variable fragment" or "scFv" refers to a fusion protein of the variable regions of the heavy chain (VH) and light chain (VL) of an immunoglobulin. In some aspects, the regions are connected with a short linker peptide of 10 to about 25 amino acids. The linker can be rich in glycine for flexibility, as well as serine or threonine for solubility, and can connect the N-terminus of VH to the C-terminus of VL, or vice versa. Despite the removal of the constant regions and the introduction of the linker, the protein still retains the specificity of the original immunoglobulin.

[0068] With respect to IgG, a standard immunoglobulin molecule comprises two identical light chain polypeptides of approximately 23,000 daltons and two identical heavy chain polypeptides of 53,000-70,000 daltons. These four chains are typically connected by disulfide bonds in a "Y" configuration, with the light chain starting at the mouth of the "Y" and continuing through the variable region to support the heavy chain.

[0069] Light chains and heavy chains are divided into structural and functional homology. The terms "constant" and "variable" are used functionally. In this regard, it should be understood that the variable domains of the light chain (VL) and heavy chain (VH) chain portions determine antigen recognition and specificity. In contrast, the constant domains of the light chain (CL) and heavy chain (CH1, CH2 or CH3) confer important biological properties, such as secretion, transplacental mobility, Fc receptor binding, complement fixation, etc. By convention, the numbering of the constant region domains in conventional antibodies increases as they become more distant from the antigen binding site or amino terminus of the antibody. In conventional antibodies, the N-terminal portion is the variable region and the C-terminal portion is the constant region; the CH3 and CL domains actually contain the carboxyl termini of the heavy and light chains, respectively.

[0070] As mentioned above, variable region allows antibody selective recognition and specific binding to the epitope on the antigen. That is, the VL domain and VH domain of the antibody, or the subclass of complementary determining region (CDR) combine to form the variable region that limits the three-dimensional antigen binding site. This quaternary antibody structure forms the antigen binding site present at each arm end of Y. More specifically, the antigen binding site is limited by three CDRs (i.e. CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2 and CDR-L3) on each chain of VH and VL chains. In some cases, for example, some immunoglobulin molecules are from camelid species or based on camelid immunoglobulin engineering transformation. Alternatively, immunoglobulin molecules can be composed only of heavy chains, without light chains, or only of light chains, without heavy chains.

[0071] In naturally occurring antibodies, the six CDRs present in each antigen-binding domain are short, non-contiguous sequences of amino acids that are specifically positioned to form the antigen-binding domain when the antibody assumes its three-dimensional configuration in an aqueous environment. The remaining amino acids in the antigen-binding domain, referred to as "framework" regions, exhibit less intermolecular variability. The framework regions largely adopt a β-sheet conformation, and the CDRs form loops that connect and, in some cases, form part of the β-sheet structure. Thus, the framework regions serve to form a scaffold that provides locations for positioning the CDRs in the correct orientation through interchain non-covalent interactions. The antigen-binding domain formed by the positioned CDRs defines a surface that is complementary to an epitope on an immunoreactive antigen. This complementary surface promotes non-covalent binding of the antibody to its cognate epitope. One of ordinary skill in the art can readily identify the amino acids comprising the CDRs and framework regions for any given heavy or light chain variable region because they are precisely defined.

[0072] As used herein, the terms "VH1" and "VH2" refer to immunoglobulin heavy chain variable domains that correspond to two different binding specificities. Similarly, the terms "VL1" and "VL2" refer to light chain variable domains that correspond to two different binding specificities. When used together, it will be understood that the VH1 and VL1 regions define a common binding specificity and the VH2 and VL2 regions define a second binding specificity.

[0073] Light chains are classified as kappa (the tenth letter of the Greek alphabet) or lambda (the eleventh letter of the Greek alphabet) (K, λ). Each heavy chain class can be combined with a kappa or lambda light chain. Typically, the light chain and heavy chain are covalently bound to each other, and when the immunoglobulin is produced by a hybridoma B cell or a genetically engineered host cell, the "tail" portions of the two heavy chains are bonded to each other by covalent disulfide bonds or non-covalent bonds. In the heavy chain, the amino acid sequence extends from the N-terminus at the forked end of the Y configuration to the C-terminus at the bottom of each chain.

[0074] As used herein, the term "light chain constant region" includes an amino acid sequence derived from an antibody light chain. Preferably, the light chain constant region comprises at least one of a constant kappa domain or a constant lambda domain.

[0075] As used herein, the term "heavy chain constant region" includes an amino acid sequence derived from an immunoglobulin heavy chain. A polypeptide comprising a heavy chain constant region comprises at least one of the following: a CH1 domain, a hinge (e.g., upper, middle, and / or lower hinge region) domain, a CH2 domain, a CH3 domain, or a variant or fragment thereof. For example, an antigen-binding polypeptide for use in the present disclosure may comprise a polypeptide chain comprising a CH1 domain; a polypeptide chain comprising a CH1 domain, at least a portion of a hinge domain, and a CH2 domain; a polypeptide chain comprising a CH1 domain and a CH3 domain; a polypeptide chain comprising a CH1 domain, at least a portion of a hinge domain, and a CH3 domain, or a polypeptide chain comprising a CH1 domain, at least a portion of a hinge domain, a CH2 domain, and a CH3 domain. In some embodiments, a polypeptide of the present disclosure comprises a polypeptide chain comprising a CH3 domain. In addition, an antibody for use in the present disclosure may lack at least a portion of a CH2 domain (e.g., all or part of a CH2 domain). It will be appreciated that the heavy chain constant regions may be modified such that they vary in the amino acid sequence of a naturally occurring immunoglobulin molecule.

[0076] The heavy chain constant regions of the antibodies disclosed herein can be derived from different immunoglobulin molecules. For example, the heavy chain constant region of the polypeptide can comprise a CH1 domain derived from an IgG1 molecule and a hinge region derived from an IgG3 molecule. In another example, the heavy chain constant region can comprise a hinge region that is partially derived from an IgG1 molecule and partially derived from an IgG3 molecule. In another example, the heavy chain portion can comprise a chimeric hinge that is partially derived from an IgG1 molecule and partially derived from an IgG4 molecule.

[0077] A "light chain-heavy chain pair" refers to a collection of light and heavy chains that can form dimers through a disulfide bond between the CL domain of the light chain and the CH1 domain of the heavy chain.

[0078] The subunit structures and three-dimensional configurations of the constant regions of the various immunoglobulin classes are well known. As used herein, the term "VH domain" includes the amino-terminal variable domain of an immunoglobulin heavy chain, and the term "CH1 domain" includes the first (most amino-terminal) constant region domain of an immunoglobulin heavy chain. The CH1 domain is adjacent to the VH domain and is amino-terminal to the hinge region of the immunoglobulin heavy chain molecule.

[0079] As used herein, the term "CH2 domain" includes the portion of the heavy chain molecule that extends from about residue 244 to residue 360 ​​of an antibody using a conventional numbering scheme (residues 244 to 360, Kabat numbering system; and residues 231-340, EU numbering system). The CH2 domain is unique in that it is not closely paired with another domain. Instead, two N-linked branched carbohydrate chains are inserted between the two CH2 domains of an intact native IgG molecule. The CH3 domain extends from the CH2 domain to the C-terminus of the IgG molecule and comprises approximately 108 residues.

[0080] As used herein, the term "hinge region" includes the portion of the heavy chain molecule that connects the CH1 domain to the CH2 domain. The hinge region comprises approximately 25 residues and is flexible, thus allowing the two N-terminal antigen-binding regions to move independently. The hinge region can be subdivided into three distinct domains: the upper, middle, and lower hinge domains.

[0081] As used herein, the term "disulfide bond" includes a covalent bond formed between two sulfur atoms. The amino acid cysteine ​​contains a sulfhydryl group that can form a disulfide bond or bridge with a second sulfhydryl group. In most naturally occurring IgG molecules, the CH1 and CL regions are linked by disulfide bonds, and the two heavy chains are linked by two disulfide bonds at positions corresponding to 239 and 242 using the Kabat numbering system (positions 226 or 229, EU numbering system).

[0082] As used herein, a "variant" of an antibody, antibody fragment, or antibody domain refers to an antibody, antibody fragment, or antibody domain that: (1) shares at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence homology with the original antibody, antibody fragment, or antibody domain, and (2) specifically binds to the same target as the original antibody, antibody fragment, or antibody domain.

[0083] It should be understood that where ranges of sequence homology are presented herein, such as, for example, the phrase "about 80% to about 100%", such embodiments include any and all subranges therein, where the lower number can be any integer between 80 and 100.

[0084] As used herein, the phrase "humanized antibody" refers to an antibody derived from a non-human antibody, typically a mouse monoclonal antibody. Alternatively, a humanized antibody can be derived from a chimeric antibody that retains or substantially retains the antigen-binding properties of the parent non-human antibody but exhibits reduced immunogenicity when administered to humans compared to the parent antibody.

[0085] As used herein, the phrase "chimeric antibody" refers to an antibody in which the immunoreactive region or site is obtained or derived from a first species and the constant region (which may be complete, partial, or modified according to the present disclosure) is obtained from a second species. In certain embodiments, the target binding region or site will be from a non-human source (e.g., mouse or primate) and the constant region is human.

[0086] Included within the scope of the multispecific antibodies of the present application are various compositions and methods, including asymmetric IgG-like antibodies (e.g., triomab / cell hybridoma, Trion Pharma / Fresenius Biotech); knobs-into-holes antibodies (Genentech); Cross Mab (Roche); electrostatic matching antibodies (AMGEN); LUZ-Y (Genentech); chain exchange engineered domain (SEED) bodies (EMD Serono; biolonic, Merus); Fab exchanged antibodies (Genmab), symmetrical IgG-like antibodies (e.g., dual targeting (DT)-Ig (GSK / Domantis); two-in-one antibodies (Genentech); cross-linked Mab (Karmanos Cancer Center), mAb 2(F-star); Cov X-body (Cov X / Pfizer); Dual variable domain (DVD)-Ig fusion (Abbott); IgG-like bispecific antibody (Eli Lilly); Ts2Ab (Medimmune / AZ); BsAb (ZymoGenetics); HERCULES (Biogen Idec, TvAb, Roche); scFv / Fc fusion; SCORPION (Emergent BioSolutions / Trubion, ZymoGenetics / BMS); dual affinity retargeting technology (Fc-DART), MacroGenics; bis(scFv)2-Fabs (National Antibody Medical Research Center); F(ab)2 fusion (Medarex / AMGEN); dual-action or Bis-Fab (Genentech); Dock-and-Lock (DNL, ImmunoMedics); Fab-Fv (UCB-Celltech); scFv- and diabody-based antibodies (e.g., bispecific T cell engagers (BiTE, Micromet); tandem diabodies (Tandab, Affimed); DART (MacroGenics); single-chain diabodies; TCR-like antibodies (AIT, Receptor Logics); human serum albumin scFv fusions (Merrimack); COMBODIES (Epigen Biotech); and IgG / non-IgG fusions (e.g., immunocytokines (EMDSerono, Philogen, ImmunGene, ImmunoMedics).

[0087] By "specifically binds" or "is specific for...", it is generally meant that the antibody binds to the epitope through its antigen binding domain, and that this binding requires some complementarity between the antigen binding domain and the epitope. According to this definition, an antibody is said to "specifically bind" to an epitope when it binds to the epitope through its antigen binding domain more easily than it would bind to a random, unrelated epitope. The term "specificity" is used herein to qualify the relative affinity with which an antibody binds to an epitope. For example, antibody "A" can be said to have a higher specificity for a given epitope than antibody "B", or antibody "A" can be said to bind to epitope "C" with higher specificity than to its related epitope "D". In some embodiments, if an antibody or antibody fragment is expressed at 10 -6 M or smaller, 10 -7 M or smaller, 10 -8 M or smaller, 10 -9 M or smaller or 10 -10 The dissociation constant (K d) forms a complex with an antigen, then the antibody or antibody fragment is "specific for the antigen".

[0088] As used herein, the phrase "chimeric antibody" refers to an antibody in which the immunoreactive region or site is obtained or derived from a first species and the constant region (which may be complete, partial, or modified according to the present disclosure) is obtained from a second species. In certain embodiments, the target binding region or site will be from a non-human source (e.g., mouse or primate) and the constant region is human.

[0089] The term "antagonist antibody" refers to an antibody that binds to a target and prevents or reduces the biological effect of the target. In some embodiments, the term can refer to an antibody that prevents the target to which it binds, such as TIGIT, from performing a biological function.

[0090] As used herein, "anti-PD-1 antagonist antibodies" refers to antibodies that are capable of inhibiting the biological activity of PD-1 and / or downstream events mediated by PD-1. Anti-PD-1 antagonist antibodies include antibodies that block, antagonize, inhibit or reduce (to any extent, including significantly) the biological activity of PD-1, including downstream events mediated by PD-1, such as PD-1 binding and downstream signaling, inhibition of T cell proliferation, inhibition of T cell activation, inhibition of IFN secretion, inhibition of IL-2 secretion, inhibition of TNF secretion, induction of IL-10 and inhibition of anti-tumor immune response. For the purposes of the present invention, it will be clearly understood that the term "anti-PD-1 antagonist antibody" (interchangeably referred to as "antagonist PD-1 antibody", "antagonist anti-PD-1 antibody" or "PD-1 antagonist antibody") includes all previously identified terms, titles and functional states and characteristics, whereby PD-1 itself, PD-1 biological activity or the consequences of biological activity are substantially ineffective, reduced or neutralized to any meaningful extent. In some embodiments, the anti-PD-1 antagonist antibody binds to PD-1 and upregulates an anti-tumor immune response.

[0091] As used herein, "anti-PD-L1 antagonist antibody" refers to an antibody that is capable of inhibiting the biological activity of PD-L1 and / or downstream events mediated by PD-L1. Anti-PD-L1 antagonist antibodies include antibodies that block, antagonize, inhibit or reduce (to any extent, including significantly) the biological activity of PD-L1, including downstream events mediated by PD-1, such as PD-1 binding and downstream signaling, inhibition of T cell proliferation, inhibition of T cell activation, inhibition of IFN secretion, inhibition of IL-2 secretion, inhibition of TNF secretion, induction of IL-10 and inhibition of anti-tumor immune response. For the purposes of the present invention, it will be expressly understood that the term "anti-PD-L1 antagonist antibody" includes (interchangeably referred to as "antagonist PD-L1 antibody", "antagonist anti-PD-L1 antibody" or "PD-L1 antagonist antibody") all previously identified terms, titles and functional states and characteristics, whereby PD-L1 itself, PD-L1 biological activity or the consequences of biological activity are substantially ineffective, reduced or neutralized to any meaningful extent. In some embodiments, the anti-PD-L1 antagonist antibody binds to PD-L1 and upregulates an anti-tumor immune response. The phrase "immune checkpoint modulator" refers to a functional class of agents that inhibit or stimulate signaling through immune checkpoints. "Immune checkpoint modulators" include receptors and their associated ligands, which together provide a means of inhibiting or stimulating signaling pathways that would otherwise lead to T cell activation.

[0092] The phrases "immune checkpoint binding antagonist" and "immune checkpoint antagonist" are used interchangeably herein with reference to the class of agents that interfere with (or inhibit) the activity of immune checkpoint regulators, whereby, as a result of binding to a checkpoint regulator or its ligand, signaling through a checkpoint regulator receptor is prevented or inhibited. By inhibiting this signaling, immunosuppression can be reversed, thereby reestablishing or enhancing T cell immunity against cancer cells. Exemplary immune checkpoint antagonists include, but are not limited to, TIGIT and its CD155 ligand, PVR; PD-1 and its ligands, PD-L1 and PD-L2; CTLA-4 and its ligands, B7-1 and B7-2; TIM-3 and its ligand, galectin-9; LAG-3 and its ligands, including liver sinusoidal endothelial cell lectin (LSECtin) and galectin-3; CD122 and its CD122R ligand; CD70, B7H3, B and T lymphocyte attenuator (BTLA), and VISTA. Immune checkpoint regulator antagonists include antibody fragments, peptide inhibitors, dominant-negative peptides, and small-molecule drugs, either in isolated form or as part of a fusion protein or conjugate.

[0093] The phrases "immune checkpoint binding agonists" and "immune checkpoint agonists" are used interchangeably herein with reference to the categories of reagents that stimulate the activity of immune checkpoint regulators, and therefore, as a result of binding to a checkpoint regulator or its ligand, the signal transduction by the checkpoint regulator receptor is stimulated. By stimulating this signal transduction, T cell immunity against cancer cells can be re-established or enhanced. Exemplary immune checkpoint regulator agonists include but are not limited to members of the tumor necrosis factor (TNF) receptor superfamily, such as CD27, CD40, OX40 (CD134), glucocorticoid-induced TNFR family-related proteins (GITR) and 4-1BB (CD137) and their ligands. Other checkpoint regulator agonists belong to the B7-CD28 superfamily, including CD28 and ICOS.

[0094] The phrase "dominant negative protein" or "dominant negative peptide" refers to a protein or peptide derived from a wild-type protein that has been genetically modified by mutation and / or deletion such that the modified protein or peptide interferes with the function of the endogenous wild-type protein from which it is derived.

[0095] The phrase "VEGF binding antagonist" refers to a class of functional agents that bind to VEGF-A or its receptor VEGFR-2, such that, as a result of binding, activation of VEGFR-2 by VEGF-A is blocked or inhibited. As used herein, the term "VEGF binding antagonist" includes antibody fragments, peptide inhibitors, dominant negative peptides, and small molecule drugs, in isolated form or as part of a fusion protein or conjugate.

[0096] The phrase "Tie2 tyrosine kinase receptor binding antagonist" refers to a functional class of agents that bind to the Tie2 tyrosine kinase receptor or one of its ligands, and as a result of binding, the activation of the Tie2 tyrosine kinase receptor or one or more of its ligands (i.e., Ang1, Ang2, Ang3, and Ang4) is blocked or inhibited. As used herein, the term "Tie2 tyrosine kinase receptor binding antagonist" includes antibody fragments, peptide inhibitors, dominant negative peptides, and small molecule drugs, in isolated form or as part of a fusion protein or conjugate.

[0097] The phrase "small molecule drug" refers to a molecular entity, typically organic or organometallic, not a polymer, that has pharmaceutical activity and has a molecular weight of less than about 2 kDa, less than about 1 kDa, less than about 900 Da, less than about 800 Da, or less than about 700 Da. In addition to proteins or nucleic acids, the term also includes most pharmaceutical compounds referred to as "drugs," although small peptides or nucleic acid analogs may be considered small molecule drugs. Examples include chemotherapeutic anticancer drugs and enzyme inhibitors. Small molecule drugs can be obtained synthetically, semisynthetically (i.e., from naturally occurring precursors), or biologically.

[0098] As used herein, the term "recombinant" refers to a polypeptide or polynucleotide that is not naturally occurring and that can be produced by combining polynucleotides or polypeptides in an arrangement that does not normally occur together. The checkpoint regulator antagonists described herein are by definition "recombinant."

[0099] When describing polypeptide domain arrangements with hyphens between the various domains (eg, CH2-CH3), it is understood that the order in which the domains are listed is from amino terminus to carboxyl terminus.

[0100] By "specifically binds" or "is specific for...", it is generally meant that the antibody binds to the epitope through its antigen binding domain, and that this binding requires some complementarity between the antigen binding domain and the epitope. According to this definition, an antibody is said to "specifically bind" an epitope when it binds to that epitope via its antigen binding domain more readily than it would bind to a random, unrelated epitope. The term "specificity" is used herein to qualify the relative affinity with which an antibody binds to a certain epitope. For example, antibody "A" can be said to have a higher specificity for a given epitope than antibody "B", or antibody "A" can be said to bind to epitope "C" with higher specificity than to its related epitope "D".

[0101] The term "immunoconjugate" refers to an antibody fused to an inhibitory peptide or small molecule drug via a covalent bond. The peptide or small molecule drug can be linked to the C-terminus of the constant heavy chain or the N-terminus of the variable light chain and / or heavy chain.

[0102] "Connectors" can be used to connect peptides or small molecule drugs (such as maytansinoids) to checkpoint regulator antagonists in a stable covalent manner. Under conditions where compound or antibody remain active, the connector may be sensitive to acid-induced cutting, light-induced cutting, peptidase-induced cutting, esterase-induced cutting and disulfide bond cutting or substantially tolerate acid-induced cutting, light-induced cutting, peptidase-induced cutting, esterase-induced cutting and disulfide bond cutting. Suitable connectors are well known in the art, and include, for example, disulfide groups, thioether groups, acid-labile groups, light-labile groups, peptidase-labile groups and esterase-labile groups. Connectors also include charged connectors, and its hydrophilic form described herein and known in the art. Immunoconjugates can further include flexible 3-15 amino acid peptides (or spacers) between checkpoint regulator antagonists and peptides and / or small molecule drugs.

[0103] As used herein, the phrase "multispecific inhibitor" refers to a molecule comprising at least two targeting domains with different binding specificities. In some embodiments, the multispecific inhibitor is a polypeptide comprising a scaffold and two or more immunoglobulin antigen binding domains that target different antigens or epitopes. In certain embodiments, the multispecific inhibitor is a bispecific antibody.

[0104] As used herein, the phrase "bispecific checkpoint regulator antagonist" refers to a molecule comprising at least two targeting domains with different binding specificities. Each targeting domain is capable of specifically binding to a target molecule and inhibiting the biological function of the target molecule when binding to the target molecule. In some embodiments, a bispecific checkpoint regulator antagonist is a polymer molecule having two or more peptides. In some embodiments, the targeting domain comprises an antigen binding domain or CDR of an antibody. In some embodiments, the bispecific inhibitor is a bispecific antibody.

[0105] The terms "bispecific antibody" and "bispecific checkpoint regulator antagonist" are used interchangeably herein with reference to antibodies that can specifically bind to two different antigens (or epitopes). In some embodiments, a bispecific antibody is a full-length antibody that binds to one antigen (or epitope) on one of its two binding arms (a pair of HC / LC) and binds to a different antigen (or epitope) on its second arm (a pair of different HC / LC). In these embodiments, the bispecific antibody has two different antigen-binding arms (in specificity and CDR sequences) and is monovalent for each antigen it binds.

[0106] In other embodiments, bispecific antibodies are full-length antibodies that can bind to two different antigens (or epitopes) in each of their two binding arms (two pairs of HC / LC). In these embodiments, the bispecific antibody has two identical antigen-binding arms with the same specificity and the same CDR sequences and is bivalent for each antigen it binds.

[0107] The terms "bispecific antibody" and "bispecific checkpoint regulator antagonist" are used interchangeably herein with reference to molecules comprising three targeting domains with three different binding specificities. Each targeting domain is capable of specifically binding to a target molecule and inhibiting the biological function of the target molecule when bound to the target molecule. In some embodiments, a trispecific checkpoint regulator antagonist is a polymer molecule having two or more peptides. In some embodiments, the targeting domain comprises an antigen binding domain or CDR of an antibody. In some embodiments, a trispecific checkpoint regulator antagonist is a trispecific antibody.

[0108] Exemplary bispecific and trispecific antibodies may include asymmetric IgG-like antibodies (e.g., triomab / cell hybridoma, Trion Pharma / Fresenius Biotech); knobs-into-holes antibodies (Genentech); CrossMAb (Roche); electrostatically matched antibodies (AMGEN); LUZ-Y (Genentech); chain exchange engineered domain (SEED) bodies (EMDSerono; biolonic, Merus); Fab-exchanged antibodies (Genmab), symmetrical IgG-like antibodies (e.g., dual targeting (DT)-Ig (GSK / Domantis); two-in-one antibodies (Genentech); cross-linked MAbs (Karmanos Cancer Center), mAbs 2 (F-star); Cov X-body (Cov X / Pfizer); dual variable domain (DVD)-Ig fusion (Abbott); IgG-like bispecific antibody (Eli Lilly); Ts2Ab (Medimmune / AZ); BsAb (ZymoGenetics); HERCULES (Biogen Idec, TvAb, Roche); scFv / Fc fusion protein; SCORPION (Emergent BioSolutions / Trubion, ZymoGenetics / BMS); dual affinity retargeting technology (Fc-DART), MacroGenics; bis(scFv)2-Fabs (National Antibody Medical Research Center); F(ab)2 fusions (Medarex / AMGEN); dual-action or Bis-Fab (Genentech); Dock-and-Lock (DNL, ImmunoMedics); Fab-Fv (UCB-Celltech); scFv- and diabody-based antibodies (e.g., bispecific T cell engagers (BiTE, Micromet); tandem diabodies (Tandab, Affimed); DART (MacroGenics); single-chain diabodies; TCR-like antibodies (AIT, Receptor Logics); human serum albumin scFv fusions (Merrimack); combodies (Epigen Biotech); and IgG / non-IgG fusions (e.g., immunocytokines (EMDSerono, Philogen, ImmunGene, ImmunoMedics).

[0109] The terms "treat" and "treating" refer to ameliorating one or more symptoms associated with a cell proliferative disorder; preventing or delaying the onset of one or more symptoms of a cell proliferative disorder; and / or lessening the severity or frequency of one or more symptoms of a cell proliferative disorder.

[0110] The phrases "a patient in need thereof," "a patient in need of treatment," or "a subject in need of treatment" include subjects, such as mammalian subjects, who would benefit from administration of a checkpoint regulator antagonist of the disclosure to treat a cell proliferative disorder.

[0111] The terms "therapeutically effective amount," "pharmacologically effective amount," and "physiologically effective amount" are used interchangeably and refer to the amount of a checkpoint modulator antagonist required to provide a threshold level of active antagonist agent in the bloodstream or in a target tissue. The exact amount will depend on many factors, such as the specific active agent, the components and physical characteristics of the composition, the intended patient population, patient considerations, etc., and can be readily determined by one skilled in the art based on the information provided herein or otherwise available in the relevant literature.

[0112] The terms "improve," "increase," or "decrease" as used in this context refer to a value or parameter measured relative to a baseline, e.g., a measurement in the same individual before initiation of a treatment described herein, or a measurement in a control individual (or multiple control individuals) in the absence of a treatment described herein.

[0113] A "control individual" is an individual who has the same cell proliferative disorder as the individual being treated and who is approximately the same age as the individual being treated (to ensure that the disease stages of the treated and control individuals are comparable). The individual being treated (also referred to as a "patient" or "subject") can be a fetus, infant, child, adolescent, or adult with a cell proliferative disorder.

[0114] The term "cell proliferative disorder" refers to a disorder characterized by abnormal cell proliferation. A proliferative disorder does not imply any restriction on the rate of cell growth, but merely indicates a loss of normal controls that influence growth and cell division. Thus, in some embodiments, cells with a proliferative disorder may have the same cell division rate as normal cells, but may not respond to signals that restrict such growth. Included within the scope of "cell proliferative disorders" are neoplasms, cancers, or tumors.

[0115] The term "cancer" refers to any of a variety of malignant neoplasms characterized by cell proliferation that can invade surrounding tissues and / or metastasize to new sites of colonization, and includes leukemias, lymphomas, carcinomas, melanomas, sarcomas, germ cell tumors, and blastomas. Exemplary cancers that can be treated using the methods of the present invention include brain cancer, bladder cancer, breast cancer, cervical cancer, colon cancer, head and neck cancer, kidney cancer, lung cancer, non-small cell lung cancer, mesothelioma, ovarian cancer, prostate cancer, gastric cancer, and uterine cancer, leukemia, and medulloblastoma.

[0116] The term "leukemia" refers to a progressive malignant disease of the hematopoietic organs and is generally characterized by the dysmorphic proliferation and development of leukocytes and their precursors in the blood and bone marrow. Exemplary leukemias include, for example, acute non-lymphocytic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, acute promyelocytic leukemia, adult T-cell leukemia, leukocytic leukemia, leukocytic leukemia, basophilic granulocyte leukemia, stem cell leukemia, bovine leukemia, chronic myeloid leukemia, leukemia cutis, embryonic leukemia, eosinophilic leukemia, Gross leukemia, hairy cell leukemia, hemoblastic leukemia, hemoblastic leukemia, and leukemia. leukemia), histiocytic leukemia, stem cell leukemia, acute monocytic leukemia, leukopenic leukemia, lymphocytic leukemia, lymphoblastic leukemia, lymphocytic leukemia, lymphoblastic leukemia, lymphoblastic leukemia, lymphoblastic leukemia, lymphoid leukemia, lymphosarcoma cell leukemia, mast cell leukemia, megakaryocyte leukemia, microgranulocyte leukemia, monocytic leukemia, myeloblastic leukemia, granulocytic leukemia, myelocytic leukemia, myelomonocytic leukemia, Negley's leukemia, plasma cell leukemia, plasma cell leukemia, promyelocytic leukemia, Rieder cell leukemia, Schilling's leukemia, stem cell leukemia, subleukemic leukemia, and undifferentiated cell leukemia.

[0117] The term "carcinoma" refers to a malignant growth of epithelial cells that tends to infiltrate surrounding tissues and cause metastases. Exemplary carcinomas include, for example, acinar carcinoma, acinous carcinoma, cystic adenoid carcinoma, adenoid cystic carcinoma, adenocarcinoma, adrenocortical carcinoma, alveolar carcinoma, alveolar cell carcinoma, basal cell carcinoma, carcinoma basocellulare, basaloid carcinoma, basosquamous cell carcinoma, bronchioloalveolar carcinoma, bronchiolar carcinoma, bronchogenic carcinoma, medullary carcinoma, cholangiocellular carcinoma, choriocarcinoma, colloid carcinoma, comedo carcinoma, corpus carcinoma, cribriform carcinoma, armor carcinoma, cutaneous carcinoma, cylindrical carcinoma, cylindrical cell carcinoma, ductal carcinoma, scleroderma, embryonal carcinoma, medullary carcinoma, epidermoid carcinoma, adenoid basal cell carcinoma, explant carcinoma, ulcerative carcinoma, scirrhous carcinoma, gelatinous carcinoma, gelatinous carcinoma, carcinoma), giant cell carcinoma, giant cell carcinoma (carcinoma gigantocellulare), adenocarcinoma, granular cell carcinoma, pilomatricoma, hematopoietic carcinoma, hepatocellular carcinoma, Hürthle cell carcinoma, clear cell carcinoma, hypemephroid carcinoma, immature embryonal carcinoma, carcinoma in situ, intraepidermal carcinoma, intraepithelial carcinoma, Kropchel's carcinoma, Kulsitzky cell carcinoma, large cell carcinoma, lenticular carcinoma, carcinoma lenticulare, lipomatous carcinoma, lymphoepithelial carcinoma, medullary carcinoma, medullary carcinoma, melanoma, soft tissue carcinoma, mucinous carcinoma, carcinoma muciparum, carcinoma mucocellulare, mucoepidermoid carcinoma, carcinoma mucosum, mucous carcinoma, myxomatous carcinoma myxomatodes), naspharyngeal carcinoma, oat cell carcinoma, ossifying carcinoma, osteoid carcinoma, papillary carcinoma, portal vein carcinoma, preinvasive carcinoma, prickle cell carcinoma, comedo carcinoma, renal cell carcinoma, reserve cell carcinoma, sarcomatoid carcinoma, schneiderian carcinoma, scirrhous carcinomacarcinoma of the scrotum, signet ring cell carcinoma, simple carcinoma, small cell carcinoma, potato carcinoma, spheroid cell carcinoma, spindle cell carcinoma, cavernous carcinoma, squamous cell carcinoma, squamous cell carcinoma, rope-shaped carcinoma, carcinoma langiectaticum, carcinoma telangiectodes, transitional cell carcinoma, carcinoma tuberosum, tuberous carcinoma, verrucous carcinoma, and villous carcinoma.

[0118] The term "sarcoma" refers to a tumor composed of material such as embryonic connective tissue and usually consists of tightly packed cells embedded in a fibrous or homogeneous substance. Exemplary sarcomas include, e.g., chondrosarcoma, fibrosarcoma, lymphosarcoma, melanosarcoma, myxosarcoma, osteosarcoma, Abemethy's sarcoma, liposarcoma, liposarcoma, alveolar soft part sarcoma, ameloblastic sarcoma, botryoid sarcoma, chloroma, choriocarcinoma, embryonal sarcoma, Wilms' tumor sarcoma, endometrial sarcoma, stromal sarcoma, Ewing's sarcoma, fascial sarcoma, fibroblastic sarcoma, giant cell sarcoma, granulocytic sarcoma, Hodgkin's sarcoma, idiopathic multiple pigmented hemorrhagic sarcoma, B-cell immunoblastic sarcoma, lymphoma (e.g., non-Hodgkin's lymphoma), T-cell immunoblastic sarcoma, Jensen's sarcoma, Kaposi's sarcoma, Kupffer cell sarcoma, angiosarcoma, leukemic sarcoma, malignant mesenchymal sarcoma, parosteal osteosarcoma, reticulum cell sarcoma, Law's sarcoma, serous cystic sarcoma, synovial sarcoma, and capillary angiosarcoma.

[0119] The term "melanoma" refers to a tumor arising from the melanocyte system of the skin and other organs. Melanomas include, for example, acral melanoma, amelanotic melanoma, benign juvenile melanoma, Cloudman melanoma, S91 melanoma, Harding-Passey melanoma, juvenile melanoma, lentigo maligna, malignant melanoma, nodular melanoma submelanomas, and superficial spreading melanoma.

[0120] Other cancers include, for example, Hodgkin's disease, multiple myeloma, neuroblastoma, breast cancer, ovarian cancer, lung cancer, rhabdomyosarcoma, essential thrombocythemia, essential macroglobulinemia, small cell lung tumors, primary brain tumors, gastric cancer, colon cancer, malignant pancreatic insulanoma, malignant carcinoid, premalignant skin lesions, testicular cancer, thyroid cancer, neuroblastoma, esophageal cancer, genitourinary tract cancer, hypercalcemia of malignancy, cervical cancer, endometrial cancer, and adrenocortical carcinoma.

[0121] Checkpoint regulator antagonists

[0122] The present application provides checkpoint regulator antagonists that specifically bind to TIGIT, PD-1, and PD-L1 and inhibit one or more of their corresponding biological functions. In some embodiments, the checkpoint regulator antagonist is an anti-TIGIT antibody or antibody fragment. In some embodiments, the checkpoint regulator antagonist is an anti-PD-1 antibody or antibody fragment. In other embodiments, the checkpoint regulator antagonist is an anti-PD-L1 antibody or antibody fragment. In other embodiments, bispecific or trispecific checkpoint regulator antagonists include multiple specificities (anti-TIGIT, anti-PD-1, and / or anti-PD-L1) for binding to several checkpoint regulators.

[0123] Anti-TIGIT antibodies and anti-TIGIT antibody fragments

[0124] In some embodiments, the TIGIT inhibitor of the present application is an antibody or an antigen-binding portion thereof, comprising: (1) a heavy chain variable region, wherein the heavy chain variable region comprises three complementarity determining regions (HCDRs): HCDR1, HCDR2, and HCDR3, wherein HCDR1 has an amino acid sequence having about 80% to about 100% homology to an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 6, SEQ ID NO: 11, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 20, and SEQ ID NO: 23, wherein HCDR2 has an amino acid sequence having about 80% to about 100% homology to an amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 21, and SEQ ID NO: 24, and wherein HCDR3 has an amino acid sequence having about 80% to about 100% homology to an amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 8, SEQ ID NO: 9 amino acid sequences having about 80% to about 100% homology to the amino acid sequences of SEQ ID NO: 10, SEQ ID NO: 14, SEQ ID NO: 19, SEQ ID NO: 22, and SEQ ID NO: 25;and (2) a light chain variable region, wherein the light chain variable region comprises three complementarity determining regions (LCDRs): LCDR1, LCDR2, and LCDR3, wherein LCDR1 has an amino acid sequence having about 80% to about 100% homology to an amino acid sequence selected from the group consisting of SEQ ID NO: 26, SEQ ID NO: 29, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID NO: 39, SEQ ID NO: 42, and SEQ ID NO: 45, wherein LCDR2 has an amino acid sequence having about 80% to about 100% homology to an amino acid sequence selected from the group consisting of SEQ ID NO: 27, SEQ ID NO: 30, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 40, SEQ ID NO: 43, and SEQ ID NO: 46, wherein LCDR3 has an amino acid sequence having about 80% to about 100% homology to an amino acid sequence selected from the group consisting of SEQ ID NO: 28, SEQ ID NO: 32, SEQ ID NO: 34, SEQ ID NO: 38, SEQ ID NO: 41, SEQ ID NO: 44, and SEQ ID NO: The amino acid sequence of NO: 47 has about 80% to about 100% homology to the amino acid sequence, wherein the antibody or antigen-binding portion thereof specifically binds to human TIGIT.

[0125] In some embodiments, the TIGIT inhibitor of the present application is an antibody or an antigen-binding portion thereof, comprising (1) a heavy chain variable region having an amino acid sequence having about 80% to about 100% homology to an amino acid sequence selected from the group consisting of SEQ ID NO: 107, SEQ ID NO: 109, SEQ ID NO: 111, SEQ ID NO: 113, SEQ ID NO: 115, SEQ ID NO: 117, SEQ ID NO: 119, SEQ ID NO: 121, SEQ ID NO: 123, and SEQ ID NO: 125; and (2) a light chain variable region having an amino acid sequence having about 80% to about 100% homology to an amino acid sequence selected from the group consisting of SEQ ID NO: 108, SEQ ID NO: 110, SEQ ID NO: 112, SEQ ID NO: 114, SEQ ID NO: 116, SEQ ID NO: 118, SEQ ID NO: 120, SEQ ID NO: 122, SEQ ID NO: 124, and SEQ ID NO: 125. The amino acid sequence of NO: 126 has an amino acid sequence with about 80% to about 100% homology, wherein the antibody or antigen-binding portion thereof specifically binds to human TIGIT.

[0126] Anti-PD-1 antibodies and anti-PD-1 antibody fragments

[0127] In some embodiments, the PD-1 inhibitor of the present application is an antibody or an antigen-binding portion thereof, comprising: (1) a heavy chain variable region, wherein the heavy chain variable region comprises three complementarity determining regions (HCDRs): HCDR1, HCDR2, and HCDR3, wherein HCDR1 has an amino acid sequence having about 80% to about 100% homology to an amino acid sequence selected from the group consisting of SEQ ID NO: 48, SEQ ID NO: 51, SEQ ID NO: 54, SEQ ID NO: 56, and SEQ ID NO: 59, wherein HCDR2 has an amino acid sequence having about 80% to about 100% homology to an amino acid sequence selected from the group consisting of SEQ ID NO: 49, SEQ ID NO: 52, SEQ ID NO: 57, and SEQ ID NO: 60, and wherein HCDR3 has an amino acid sequence having about 80% to about 100% homology to an amino acid sequence selected from the group consisting of SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: 55, SEQ ID NO: 58, and SEQ ID NO: NO:61; and (2) a light chain variable region, wherein the light chain variable region comprises three complementarity determining regions (LCDRs): LCDR1, LCDR2, and LCDR3, wherein LCDR1 has an amino acid sequence having about 80% to about 100% homology to an amino acid sequence selected from the group consisting of SEQ ID NO:62, SEQ ID NO:65, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, and SEQ ID NO:73, wherein LCDR2 has an amino acid sequence having about 80% to about 100% homology to an amino acid sequence selected from the group consisting of SEQ ID NO:63, SEQ ID NO:66, SEQ ID NO:71, and SEQ ID NO:74, and wherein LCDR3 has an amino acid sequence having about 80% to about 100% homology to an amino acid sequence selected from the group consisting of SEQ ID NO:64, SEQ ID NO:67, SEQ ID NO:72, and SEQ ID NO:75, wherein the antibody, or antigen-binding portion thereof, specifically binds to human PD-1.

[0128] In some embodiments, the PD-1 inhibitor of the present application is an antibody or an antigen-binding portion thereof, comprising: (1) a heavy chain variable region having an amino acid sequence having about 80% to about 100% homology to an amino acid sequence selected from the group consisting of SEQ ID NO: 127, SEQ ID NO: 129, 131, SEQ ID NO: 133, SEQ ID NO: 135, and SEQ ID NO: 137; and (2) a light chain variable region having an amino acid sequence having about 80% to about 100% homology to an amino acid sequence selected from the group consisting of SEQ ID NO: 128, SEQ ID NO: 130, SEQ ID NO: 132, SEQ ID NO: 134, SEQ ID NO: 136, and SEQ ID NO: 138, wherein the antibody or antigen-binding portion thereof specifically binds to human PD-1.

[0129] Anti-PD-L1 antibodies and anti-PD-L1 antibody fragments

[0130] In some embodiments, the PD-L1 inhibitor of the present application is an antibody or an antigen-binding portion thereof, comprising: (1) a heavy chain variable region, wherein the heavy chain variable region comprises three complementarity determining regions (HCDRs): HCDR1, HCDR2, and HCDR3, wherein HCDR1 has an amino acid sequence having about 80% to about 100% homology to an amino acid sequence selected from the group consisting of SEQ ID NO: 76, SEQ ID NO: 79, SEQ ID NO: 85, and SEQ ID NO: 88, wherein HCDR2 has an amino acid sequence having about 80% to about 100% homology to an amino acid sequence selected from the group consisting of SEQ ID NO: 77, SEQ ID NO: 80, SEQ ID NO: 82, SEQ ID NO: 84, SEQ ID NO: 86, and SEQ ID NO: 89, and wherein HCDR3 has an amino acid sequence having about 80% to about 100% homology to an amino acid sequence selected from the group consisting of SEQ ID NO: 78, SEQ ID NO: 81, SEQ ID NO: 83, SEQ ID NO: 87, and SEQ ID NO: NO:90; and (2) a light chain variable region, wherein the light chain variable region comprises three complementarity determining regions (LCDRs): LCDR1, LCDR2, and LCDR3, wherein LCDR1 has an amino acid sequence having about 80% to about 100% homology to an amino acid sequence selected from the group consisting of SEQ ID NO:91, SEQ ID NO:94, SEQ ID NO:98, SEQ ID NO:101, and SEQ ID NO:104, wherein LCDR2 has an amino acid sequence having about 80% to about 100% homology to an amino acid sequence selected from the group consisting of SEQ ID NO:92, SEQ ID NO:95, SEQ ID NO:99, SEQ ID NO:102, and SEQ ID NO:105, and wherein LCDR3 has an amino acid sequence having about 80% to about 100% homology to an amino acid sequence selected from the group consisting of SEQ ID NO:93, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:100, and SEQ ID NO:101. The amino acid sequence of NO: 106 has an amino acid sequence with about 80% to about 100% homology, wherein the antibody or antigen-binding portion thereof specifically binds to human PD-L1.

[0131] In some embodiments, the PD-L1 inhibitor of the present application is an antibody, or an antigen-binding portion thereof, comprising: (1) a heavy chain variable region having an amino acid sequence with about 80% to about 100% homology to an amino acid sequence selected from the group consisting of SEQ ID NO: 139, SEQ ID NO: 141, SEQ ID NO: 143, SEQ ID NO: 145, SEQ ID NO: 147, SEQ ID NO: 149, SEQ ID NO: 151, and SEQ ID NO: 153; and (2) a light chain variable region having an amino acid sequence with about 80% to about 100% homology to an amino acid sequence selected from the group consisting of SEQ ID NO: 140, SEQ ID NO: 142, SEQ ID NO: 144, SEQ ID NO: 146, SEQ ID NO: 148, SEQ ID NO: 150, SEQ ID NO: 152, and SEQ ID NO: 154, wherein the antibody, or antigen-binding portion thereof, specifically binds to human PD-L1.

[0132] The anti-TIGIT, anti-PD-1 and / or anti-PD-L1 antibodies can be monoclonal antibodies, chimeric antibodies, humanized antibodies, scFv or multispecific antibodies, which contain other binding specificities targeting other TIGIT, PD-1 and / or PD-L1 epitopes or other binding targets as further described below. Figure 4 shows the amino acid sequences corresponding to the CDRs of anti-TIGIT, anti-PD-1 and anti-PD-L1 monoclonal antibodies according to the present application.

[0133] The HCVRs and LCVRs described herein can be linked to a naturally occurring Fc region or a non-naturally occurring or mutated Fc region (e.g., an effector-less or mostly effector-less Fc (e.g., human IgG2 or IgG4)), or alternatively, to an Fc with enhanced binding to one or more activating Fc receptors (FcγRI, FcγRIIa, or FcγRIIIa) to enhance T cell proliferation in the tumor environment. reg consumption.

[0134] Thus, in certain embodiments, the anti-TIGIT, anti-PD-1 and / or anti-PD-L1 HCVRs and LCVRs described herein can be linked to an Fc comprising one or more modifications, typically altering one or more functional properties of the antibody, such as serum half-life, complement fixation, Fc receptor binding and / or antigen-dependent cellular cytotoxicity. In addition, the antibodies described herein can be chemically modified (e.g., one or more chemical moieties can be attached to the antibody) or can be modified to alter its glycosylation, thereby altering one or more functional properties of the antibody. More specifically, in certain embodiments, the antibodies in the present application can include modifications in the Fc region to produce Fc variants having (a) increased or decreased antibody-dependent cell-mediated cytotoxicity (ADCC), (b) increased or decreased complement-mediated cytotoxicity (CDC), (c) increased or decreased affinity for C1q, and / or (d) increased or decreased affinity for Fc receptors relative to the parent Fc. Such Fc region variants will typically comprise at least one amino acid modification in the Fc region. Combining amino acid modifications is considered particularly desirable. For example, a variant Fc region may contain two, three, four, five, etc. substitutions therein, e.g., at a particular Fc region position identified herein.

[0135] For applications where effector functions are to be avoided entirely, for example, when antigen binding alone is sufficient to produce the desired therapeutic benefit and effector functions only result in (or increase the risk of) undesirable side effects, IgG4 antibodies can be used, or antibodies or fragments lacking the Fc region or a substantial portion thereof can be designed, or the Fc can be mutated to completely eliminate glycosylation (e.g., N297A). Alternatively, hybrid constructs of human IgG2 (CH1 domain and hinge region) and human IgG4 (CH2 and CH3 domains) lacking effector functions, lacking the ability to bind FcγRs (e.g., IgG2) and activate complement (e.g., IgG4) can be generated. When using an IgG4 constant domain, it is generally preferred to include the substitution S228P, which mimics the hinge sequence in IgG1 and thereby stabilizes the IgG4 molecule, reducing Fab arm exchange between the therapeutic antibody and endogenous IgG4 in the patient to be treated.

[0136] In certain embodiments, anti-TIGIT, anti-PD-1 or anti-PD-L1 antibodies or fragments thereof can be modified to increase their biological half-life. Various methods can be used, including, for example, increasing the binding affinity of the Fc region to FcRn. In one embodiment, the antibody is changed in the CH1 or CL region to contain a salvage receptor binding epitope of two loops of the CH2 domain taken from the Fc region of IgG, as described in U.S. Patent Nos. 5,869,046 and 6,121,022. The numbering of the residues in the Fc region is the numbering of the EU index of Kabat. The reference residue number is followed by the amino acid substituted by the naturally occurring amino acid, (optionally, a naturally occurring residue is present in front of the position), providing sequence variants disclosed herein. Where multiple amino acids may be present at a given position, for example, if the sequence differs between naturally occurring isoforms, or if multiple mutations can be substituted at the position, they are separated by slashes (e.g., "X / Y / Z").

[0137] Exemplary Fc variants that increase binding to FcRn and / or improve pharmacokinetic properties include substitutions at positions 259, 308, and 434, including, for example, 259I, 308F, 428L, 428M, 434S, 434H, 434F, 434Y, and 434M. Other variants that increase Fc binding to FcRn include: 250E, 250Q, 428L, 428F, 250Q / 428L (Hinton et al., 2004, J. Biol. Chem. 279(8): 6213-6216, Hinton et al., 2006 Journal of Immunology 176:346-356), 256A, 272A, 305A, 307A, 31IA, 312A, 378Q, 380A, 382A, 434A (Shields et al. ( 2001) J.Biol.Chem.276(9):6591-6604), 252F, 252Y, 252W, 254T, 256Q, 256E, 256D, 433 R, 434F, 434Y, 252Y / 254T / 256E, 433K / 434F / 436H (Dall'Acqua et al., (2002) J. Immunol. 169:5171-5180, Dall'Acqua et al., (2006) J. Biol. Chem, 281:23514-23524 and U.S. Pat. No. 8,367,805).

[0138] Modification of certain conserved residues in IgG Fc (1253, H310, Q311, H433, N434), such as the N434A variant (Yeung et al., (2009) J. Immunol. 182: 7663), has been proposed as a means of increasing FcRn affinity, thereby increasing the half-life of the antibody in circulation (WO 98 / 023289). A combined Fc variant comprising M428L and N434S has been shown to increase FcRn binding and increase serum half-life up to fivefold (Zalevsky et al., (2010) Nat. Biotechnol. 28: 157). A combined Fc variant comprising T307A, E380A, and N434A modifications also extended the half-life of IgG1 antibodies (Petkova et al. (2006) Int. Immunol. 18: 1759). In addition, combination Fc variants comprising M252Y-M428L, M428L-N434H, M428L-N434F, M428L-N434Y, M428L-N434A, M428L-N434M and M428L-N434S variants have also been shown to extend half-life (US2006 / 173170). Furthermore, a combination Fc variant comprising M252Y, S254T and T256E has been reported to increase half-life by nearly 4-fold. Dall'Acqua et al., (2006) J. Biol. Chem. 281: 23514.

[0139] Bispecific checkpoint regulator antagonists

[0140] Another aspect of the present application relates to a bispecific checkpoint regulator antagonist comprising: a first targeting domain that specifically binds to a checkpoint regulator and a second targeting domain that specifically binds to a second target. In some embodiments, the second target is selected from vascular endothelial growth factor (VEGF), vascular endothelial growth factor receptor (VEGFR), an immune checkpoint regulator, a Tie2 tyrosine kinase receptor, and a ligand of a Tie2 tyrosine kinase receptor.

[0141] In some embodiments, the second target is also a checkpoint regulator.

[0142] In some embodiments, the first targeting domain comprises an antigen-binding portion of an anti-TIGIT, anti-PD-1, and / or anti-PD-L1 antibody of the present application. In some embodiments, the second targeting domain comprises an antigen-binding portion of another anti-TIGIT, anti-PD-1, and / or anti-PD-L1 antibody of the present application. In some embodiments, the first targeting domain and the second targeting domain each comprise an antigen-binding portion of an anti-TIGIT, anti-PD-1, and / or anti-PD-L1 antibody of the present application, wherein the first targeting domain is different from the second targeting domain.

[0143] In some embodiments, the bispecific checkpoint modulator antagonist comprises a first targeting domain that specifically binds to human TIGIT and a second targeting domain that specifically binds to PD-1 or PD-L1.

[0144] In some embodiments, the bispecific checkpoint regulator antagonist comprises Figure 3B One or more PD-1 specific CDRs may include Figure 3C In some embodiments, the bispecific checkpoint modulator antagonist comprises one or more PD-L1-specific CDRs. Figure 4D -E one or more PD-1 specific variable regions or Figure 4F -H one or more PD-L1-specific variable regions.

[0145] In some embodiments, a bispecific checkpoint regulator antagonist is a full-length antibody that binds to human TIGIT on one of its two binding arms (a pair of HC / LC) and binds to a different antigen (or epitope) on its second arm (a different HC / LC pair). In these embodiments, the bispecific antibody has two different antigen-binding arms (in specificity and CDR sequences) and is monovalent for each antigen it binds.

[0146] In other embodiments, the bispecific checkpoint regulator antagonist is a full-length antibody that can bind to human TIGIT and another antigen in each of its two binding arms (a pair of HC / LC). In these embodiments, the bispecific checkpoint regulator antagonist has two identical antigen-binding arms with the same specificity and the same CDR sequences and is bivalent for each antigen it binds.

[0147] Figures 17A-17N show a variety of different bispecific checkpoint regulator antagonists M1-M14, wherein: (1) VH1 and VL1 regions correspond to anti-PD1, anti-PD-L1 or any other monoclonal antibody variable domains; and (2) VH2 and VL2 regions correspond to anti-TIGIT variable domains. Figures 17A-17D depict embodiments of exemplary bispecific checkpoint regulator antagonists, comprising a homodimer scaffold comprising a double-chain arm with dual binding specificity (anti-TIGIT and anti-PD-1). Figures 17E and 17F depict embodiments of exemplary bispecific checkpoint regulator antagonists, comprising a homodimer scaffold comprising a pair of double-chain arms with a first binding specificity at the N-terminus of the constant region and a pair of double-chain arms with a second binding specificity at the C-terminus of the constant region. Figure 17G-17J depicts an embodiment of an exemplary bispecific checkpoint regulator antagonist, which includes a homodimer scaffold, which is included in a pair of double-chain arms with a first binding specificity at the N-terminus of the constant region and a pair of single-chain Fv (ScFv) fragments with a second binding specificity at the C-terminus of the constant region. Figure 17K-17N depicts an embodiment of an exemplary bispecific checkpoint regulator antagonist, which includes a heterodimer scaffold containing a pair of double-chain arms each having a different binding specificity. In these figures, asterisks represent mutations in immunoglobulin constant regions, which prevent mispairing of a light chain or heavy chain from one binding specificity with a light chain or heavy chain from another binding specificity, as discussed further below.

[0148] Exemplary bispecific checkpoint modulator antagonist sequences are shown in Figure 5. In one embodiment, the bispecific checkpoint modulator antagonist TP-M2T8P5 comprises: (1) a heavy chain variable region having an amino acid sequence about 80% to about 100% homologous to the amino acid sequence in SEQ ID NO: 155; and (2) a variable light chain variable region having an amino acid sequence about 80% to about 100% homologous to the amino acid sequence in SEQ ID NO: 156.

[0149] In another embodiment, the bispecific checkpoint regulator antagonist TP-M4T8P5 comprises: (1) a light chain variable region 2 / heavy chain variable region 1 (VL2 / VH1) having an amino acid sequence with about 80% to about 100% homology to the amino acid sequence in SEQ ID NO: 157; and (2) a heavy chain variable 2 region / light chain variable region 1 (VH2 / VL1) having an amino acid sequence with about 80% to about 100% homology to the amino acid sequence in SEQ ID NO: 158.

[0150] In another embodiment, the bispecific checkpoint regulator inhibitor TP-M6T8P5 comprises: (1) a heavy chain variable region having an amino acid sequence about 80% to about 100% homologous to the amino acid sequence in SEQ ID NO: 159; (2) a light chain variable region 2 / light chain constant region (VL2 / CL) having an amino acid sequence about 80% to about 100% homologous to the amino acid sequence in SEQ ID NO: 160; and (3) a heavy chain variable region 1 / heavy chain constant region 1 (VH1 / CH1) having an amino acid sequence about 80% to about 100% homologous to the amino acid sequence in SEQ ID NO: 161.

[0151] In another embodiment, the bispecific checkpoint regulator inhibitor TP-M6T8L8 comprises: (1) a heavy chain variable region having an amino acid sequence about 80% to about 100% homologous to the amino acid sequence in SEQ ID NO: 162; (2) a light chain variable region 2 / light chain constant region (VL2 / CL) having an amino acid sequence about 80% to about 100% homologous to the amino acid sequence in SEQ ID NO: 163; and (3) a heavy chain variable region 1 / heavy chain constant region 1 (VH1 / CH1) having an amino acid sequence about 80% to about 100% homologous to the amino acid sequence in SEQ ID NO: 164.

[0152] In another embodiment, the bispecific checkpoint regulator inhibitor TP-M8T10P1 (TP-83) comprises: (1) a heavy chain variable region having an amino acid sequence about 80% to about 100% homologous to the amino acid sequence in SEQ ID NO: 165; and (2) a light chain having an amino acid sequence about 80% to about 100% homologous to the amino acid sequence in SEQ ID NO: 166.

[0153] In another embodiment, the bispecific checkpoint regulator inhibitor TP-M9T10P1 (TP-93) comprises: (1) a heavy chain having about 80% to about 100% homology to the amino acid sequence in SEQ ID NO: 167; and (2) a light chain having an amino acid sequence having about 80% to about 100% homology to the amino acid sequence in SEQ ID NO: 168.

[0154] In another embodiment, the bispecific checkpoint regulator inhibitor TP-M9T10P5 comprises: (1) a heavy chain having about 80% to about 100% homology to the amino acid sequence in SEQ ID NO: 169; and (2) a light chain having an amino acid sequence having about 80% to about 100% homology to the amino acid sequence in SEQ ID NO: 170.

[0155] In another embodiment, the bispecific checkpoint regulator inhibitor TP-M10T8P5 (TP-92) comprises: (1) a heavy chain having about 80% to about 100% homology to the amino acid sequence in SEQ ID NO: 171; and (2) a light chain variable region having an amino acid sequence having about 80% to about 100% homology to the amino acid sequence in SEQ ID NO: 172.

[0156] In another embodiment, the bispecific checkpoint regulator inhibitor TP-M10T8L8 comprises an amino acid sequence that is about 80% to about 100% homologous to the amino acid sequence in SEQ ID NO:173.

[0157] In another embodiment, the bispecific checkpoint regulator inhibitor TP-M14T8P5 comprises: (1) a heavy chain variable region 2 / heavy chain constant region 1 (VH2 / CH1) having an amino acid sequence with about 80% to about 100% homology to the amino acid sequence in SEQ ID NO: 174; (2) a variable light chain region 1 / heavy chain constant region 1 (VL1 / CH1) having an amino acid sequence with about 80% to about 100% homology to the amino acid sequence in SEQ ID NO: 175; (3) a light chain variable region 2 / light chain constant region (VL2 / CL) having an amino acid sequence with about 80% to about 100% homology to the amino acid sequence in SEQ ID NO: 176; and (4) a heavy chain variable region 1 / light chain constant region (VH1 / CL) having an amino acid sequence with about 80% to about 100% homology to the amino acid sequence in SEQ ID NO: 177.

[0158] In another embodiment, the bispecific checkpoint regulator inhibitor TP-M14T8L8 comprises: (1) a heavy chain variable region 2 / heavy chain constant region 1 (VH2 / HC1) having an amino acid sequence with about 80% to about 100% homology to the amino acid sequence in SEQ ID NO: 178; (2) a variable light chain region 1 / heavy chain constant region 2 (VL1 / CH2) having an amino acid sequence with about 80% to about 100% homology to the amino acid sequence in SEQ ID NO: 179; (3) a light chain variable region 2 / light chain constant region (VL2 / CL) having an amino acid sequence with about 80% to about 100% homology to the amino acid sequence in SEQ ID NO: 180; and (4) a heavy chain variable region 1 / light chain constant region (VH1 / CL) having an amino acid sequence with about 80% to about 100% homology to the amino acid sequence in SEQ ID NO: 181.

[0159] Tri-specific checkpoint regulator antagonists

[0160] In some embodiments, the trispecific checkpoint regulator antagonist comprises: (1) a first targeting domain having a first binding specificity conferred by one or more anti-TIGIT variable domains; (2) a second targeting conferred by one or more variable regions comprising one or more anti-PD1 variable domains, one or more anti-PD-L1 variable domains, or one or more variable region domains corresponding to any other anti-cancer target, including other checkpoint regulators, as further described herein; and (3) a third targeting domain conferred by one or more peptide sequences (e.g., AMG386) or a variable domain comprising a VEGF binding antagonist, a Tie2 tyrosine kinase receptor antagonist, or a Tie2 tyrosine kinase receptor ligand antagonist, as further described herein.

[0161] Figures 18A-18J Various different trispecific checkpoint regulator antagonists are shown, where: (1) the VH1 and VL1 regions correspond to anti-TIGIT variable domains; (2) the VH2 and VL21 regions correspond to anti-PD1, anti-PD-L1, or any other monoclonal antibody variable domains; and (3) the circular region corresponds to AMG386 or any other biological peptide.

[0162] Homodimers and heterodimers

[0163] One of the challenges of effectively producing bispecific and trispecific checkpoint regulator antagonist formulations involves mispairing of heavy and light chains when co-expressing chains of different binding specificities. Table 1 lists several amino acid substitution options for overcoming mispairing between heavy chains of different binding specificities, which "force" or preferentially promote the correct binding between the desired heavy chains. According to the present disclosure, any method to prevent or reduce mispairing between heavy chains can be used to manufacture bispecific or trispecific checkpoint regulator antagonists.

[0164] The "knobs-into-hole" (KiH) approach relies on modifying the interface between the two CH3 domains, where most interactions occur. Typically, bulky residues are introduced into the CH3 domain of one antibody heavy chain, acting like a key. In the other heavy chain, a "hole" is formed to accommodate these bulky residues, mimicking a lock. The resulting heterodimeric Fc portion can be further stabilized by artificial disulfide bonds.

[0165] Another approach is based on charged residues with ionic interactions or steric complementarity. This involves altering the charge polarity in the CH3 interface so that co-expression of electrostatically matched Fc domains supports favorable attractive interactions and heterodimer formation while retaining the hydrophobic core, while unfavorable repulsive charge interactions inhibit homodimerization. See Table 1. The amino acid numbering in Table 1 follows the Kabat numbering scheme and can be applied to the heavy chain amino acid sequences of the antibodies described herein.

[0166] In another approach, a leucine zipper (LZ) domain can be incorporated into a protein scaffold. Leucine zippers are common three-dimensional structural motifs in proteins and are often found as part of the DNA binding domain in various transcription factors. A single LZ typically contains 4-5 leucine residues spaced approximately 7 residues apart, which form an amphipathic alpha helix with a hydrophobic region extending along one side. In a specific embodiment, the heterodimeric protein scaffold comprises an LZ from a c-jun transcription factor that is associated with an LZ from a c-fos transcription factor. Although c-jun is known to form jun-jun homodimers and c-fos does not form homodimers, the formation of jun-fos heterodimers is much better than that of jun-jun homodimers.

[0167] The leucine zipper domain can be introduced instead of the CH2-CH3 sequence in the protein scaffold, or it can be placed at the carboxyl termini of the two heavy chains in a bispecific or trispecific checkpoint regulator antagonist. In the latter case, a furin cleavage site can be introduced between the carboxyl terminus of CH3 and the amino terminus of the leucine zipper. When the heavy and light chains of the bispecific or trispecific checkpoint regulator antagonist are co-expressed in a suitable mammalian cell expression system, this can promote the cleavage of the furin-mediated leucine zipper after the heterodimerization step (see Wranik et al., J. Biol. Chem., 287 (5): 43331-43339, 2012).

[0168] Table 1

[0169]

[0170] The amino acid numbering in Table 1 follows the Kabat numbering scheme and can be applied to the heavy chain amino acid sequences of the antibodies described herein. The mutations described in Table 1 can be applied to the sequence of any immunoglobulin IgG1 heavy chain (public or otherwise), as well as other immunoglobulin classes and subclasses (or isotypes) therein.

[0171] When the heavy and light chains of a bispecific or trispecific antibody are co-expressed, it is also possible that a light chain of one binding specificity may mispair with a heavy chain having a different binding specificity. Therefore, in certain embodiments, portions of the heavy chain, light chain, or both can be modified relative to the "wild-type" antibody chain from which they are derived to prevent or reduce mispairing of the two heavy chain constant regions with each other, and to prevent or reduce mispairing of the light chain constant region with its heavy chain counterpart.

[0172] The light chain mispairing problem can be solved in several ways. In some embodiments, spatial complementary mutations and / or disulfide bonds can be incorporated into two VL / VH interfaces. In other embodiments, mutations can be incorporated based on ions or electrostatic interactions. In some embodiments, by adopting a first arm having an S183E mutation in the CH1 domain of the heavy chain and an S176K mutation in the CL domain of the light chain, light chain mispairing can be prevented or reduced. The second arm may comprise an S183K mutation in the heavy chain CH1 domain and an S176E mutation in the light chain CL domain. In other embodiments, a "CrossMab" approach is used, in which one arm in a bispecific or trispecific checkpoint regulator antagonist (e.g., Fab) remains unchanged, but in another arm containing other binding specificities, one or more domains in the light chain at the heavy chain: light chain interface cross with one or more domains in the heavy chain at the heavy chain.

[0173] Immunoglobulin domain sequences including specific mutations to prevent mispairing of heavy and light chains are further described in U.S. Patent Application Publication Nos. 2014 / 0243505 and 2013 / 0022601.

[0174] Figures 18G-18J Embodiments of exemplary trispecific checkpoint regulatory antagonists are depicted, where asterisks indicate mutations in the immunoglobulin constant region that prevent mispairing of a light or heavy chain from one binding specificity with a light or heavy chain from another binding specificity.

[0175] Conjugate

[0176] In certain embodiments, the checkpoint regulator antagonist of the present application is chemically conjugated to one or more peptides and / or small molecule drugs. The peptides or small molecule drugs may be the same or different. The peptides or small molecule drugs may be attached to, for example, reduced SH groups and / or carbohydrate side chains. Methods for preparing covalent or non-covalent conjugates of peptides or small molecule drugs with antibodies are known in the art, and any such known methods may be used.

[0177] In some embodiments, peptides or small molecule drugs are connected to the hinge region of the reduced antibody component through disulfide bond formation. Alternatively, heterobifunctional cross-linkers such as N-succinyl 3-(2-pyridyldithio) propionate (SPDP) can be used to connect these agents. General techniques for such conjugation are well known in the art. In some embodiments, peptides or small molecule drugs are conjugated through carbohydrate moieties in the Fc region of antibodies. Carbohydrate groups can be used to increase the loading of the same reagent bound to the thiol group, or carbohydrate moieties can be used to bind different therapeutic agents or diagnostic agents. Methods for conjugating peptide inhibitors or small molecule drugs to antibodies through antibody carbohydrate moieties are well known to those skilled in the art. For example, in one embodiment, the method comprises reacting an antibody component having an oxidized carbohydrate moiety with a carrier polymer having at least one free amine functional group. The reaction produces an initial Schiff base (imine) bond, which can be stabilized by reducing it to a secondary amine to form a final conjugate. Exemplary methods for conjugating small molecule drugs and peptides to antibodies are described in U.S. Patent Application Publication No. 2014 / 0356385.

[0178] Preferably, the checkpoint regulator antagonists of the present disclosure maintain certain desired features and pharmacokinetic properties of antibodies, including desired in vitro and in vivo stability (e.g., long half-life and shelf life stability), effective delivery to desired target cells, increased affinity for binding partners, ideal antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity, and reduced renal clearance or excretion. Therefore, careful attention to the size and need for specific constant region effector functions can be considered in the design of checkpoint regulator antagonists.

[0179] The size range of anti-TIGIT, anti-PD-1 and anti-PD-L1 inhibitors, including monospecific, bispecific and trispecific checkpoint regulator antagonists derived therefrom, can be 50 kD to 300 kD, 50 kD to 250 kD, 60 kD to 250 kD, 80 kDa to 250 kD, 100 kD to 250 kD, 125 kD to 250 kD, 150 kD to 250 kD, 60 kD to 225 kD, 75 kD to 225 kD, 100 kD to 225 kD, 125 kD to 225 kD kD, 150kD to 225kD, 60kD to 200kD, 75kD to 200kD, 100kD to 125kD to 200kD, 150kD to 200kD, 60kD to 150kD, 75kD to 150kD, 100kD to 150kD, 60kD to 125kD, 75kD to 125kD, 75kD to 100kD, or any range encompassed by any combination of integers listed in the above ranges or defined by any combination of integers listed between any of the above ranges.

[0180] Reagent test kit

[0181] The application also provides a kit comprising a checkpoint regulator antagonist of the present application. In some embodiments, the kit comprises one or more anti-TIGIT, anti-PD-1 or anti-PD-L1 antibodies, and bispecific or trispecific checkpoint regulator antagonists thereof. In some embodiments, the kit further comprises additional reagents, including a second antibody for detection and another human antibody as described herein (e.g., a human antibody with complementary activity that binds to an epitope in the TIGIT antigen that is different from the first human antibody). The kit typically includes a label, which includes instructions for the intended use of the contents of the kit. The term label includes any writing or recording material provided on or with the kit, or any other text or recording material provided with the kit.

[0182] Methods of using checkpoint regulator antagonists

[0183] The checkpoint regulator antagonists of the present application, such as anti-TIGIT antibodies, anti-TIGIT antibody fragments, anti-PD-1 antagonists, anti-PD-1 antibody fragments, anti-PD-L1 antibodies, anti-PD-L1 antibody fragments, bispecific checkpoint regulator antagonists and trispecific checkpoint regulator antagonists that specifically bind to TIGIT, PD-1 and / or PD-L1, have many in vitro and in vivo applications, including, for example, enhancing immune responses by blocking signal transduction by TIGIT, PD-1 and / or PD-L1, treating cancer, infectious diseases or autoimmune diseases, and detecting TIGIT, PD-1 and / or PD-L1.

[0184] In some embodiments, the checkpoint regulator antagonist of the present application is applied to cultured cells in vitro or in vitro, or to human subjects (e.g., in vivo) to enhance immunity to various diseases. Therefore, provided herein is a method for changing the immune response of a subject, comprising administering an antibody or its antigen-binding fragment as described herein to the subject so that the immune response in the subject is enhanced, stimulated, or upregulated. Preferred subjects include human patients in need of an enhanced immune response. The method is particularly suitable for treating human patients with conditions that can be treated by enhancing an immune response (e.g., a T cell-mediated immune response). The method is particularly suitable for treating cancer or chronic infection in vivo. For example, an anti-TIGIT, anti-PD-1, or anti-PD-L1 composition can be administered together with the target antigen, or the antigen may already be present in the subject to be treated (e.g., a subject carrying a tumor or a virus) to enhance antigen-specific immunity. When an anti-TIGIT antibody is administered together with another agent, the two can be administered separately or simultaneously.

[0185] In some embodiments, the checkpoint regulator antagonist used in the above method is an anti-TIGIT, anti-PD-1, anti-PD-L1 antibody, a fragment thereof, or a combination thereof. In some embodiments, the checkpoint regulator antagonist is a bispecific or trispecific antibody of the present application.

[0186] In some embodiments, the checkpoint regulator antagonist is an antibody or fragment.In some embodiments, the antibodies described herein are human or humanized antibodies.

[0187] Also included are methods for detecting and / or measuring the presence of human TIGIT, human PD-1, or human PD-L1 in a sample, comprising contacting the sample and a control sample with a human monoclonal antibody or antigen-binding fragment thereof, wherein the human monoclonal antibody or antigen-binding fragment specifically binds to human TIGIT, human PD-1, or human PD-L1 under conditions that allow formation of a complex between the antibody or fragment and human TIGIT, human PD-1, or human PD-L1. The formation of the complex is then detected, wherein the difference in complex formation between the samples compared to the control sample indicates the presence of human TIGIT antigen in the sample. In addition, the anti-TIGIT, anti-PD-1, or anti-PD-L1 antibodies described herein can be used to purify human TIGIT by immunoaffinity purification.

[0188] Taking into account the ability of anti-TIGIT, anti-PD-1 and anti-PD-L1 antibodies to block the inhibition or co-inhibition of T cell responses (e.g., antigen-specific T cell responses), provided herein are methods for stimulating, enhancing or upregulating antigen-specific T cell responses, e.g., anti-tumor T cell responses, using the antibodies described herein in vitro and in vivo. In certain embodiments, CD3 stimulation (e.g., by co-incubation with cells expressing membrane CD3) is also provided, which can be provided while, before or after treatment with anti-TIGIT, anti-PD-1 or anti-PD-L1 antibodies. For example, provided herein is a method for enhancing antigen-specific T cell responses, comprising contacting the T cells with anti-TIGIT, anti-PD-1 or anti-PD-L1 antibodies as described herein and optionally with CD3, so that the antigen-specific T cell response is enhanced, e.g., by removing TIGIT-, PD-1 or PD-L1-mediated inhibitory effects. Antigen-specific T cell responses can be measured using any suitable antigen-specific T cell response indicator. Non-limiting examples of such suitable indicators include increased T cell proliferation in the presence of the antibody, and / or increased cytokine production in the presence of the antibody. In a preferred embodiment, the production of interleukin-2 and / or interferon-γ by antigen-specific T cells is enhanced.

[0189] Further included are methods for enhancing the immune response (e.g., antigen-specific T cell response) of a subject, comprising administering an anti-TIGIT antibody, an anti-PD-1 antibody, an anti-PD-L1 antibody, or a bispecific or trispecific checkpoint regulator antagonist to the subject, such that the immune response (e.g., antigen-specific T cell response) in the subject is enhanced. In a preferred embodiment, the subject is a subject carrying a tumor and the immune response to the tumor is enhanced. The tumor may be a solid tumor or a liquid tumor, such as a hematological malignancy. In certain embodiments, the tumor is an immunogenic tumor. In other embodiments, the tumor is non-immunogenic. In certain embodiments, the tumor is PD-L1 positive. In other embodiments, the tumor is PD-L1 negative. The subject may also be a subject with a virus, wherein the immune response to the virus is enhanced due to the administration of an anti-TIGIT antibody, an anti-PD-1 antibody, an anti-PD-L1 antibody, a bispecific checkpoint regulator antagonist, or a trispecific checkpoint regulator antagonist as described herein.

[0190] In one embodiment, the method for inhibiting the growth of tumor cells in a subject comprises administering to the subject an anti-TIGIT antibody, an anti-PD-1 antibody, an anti-PD-L1 antibody, a bispecific checkpoint regulator antagonist, or a trispecific checkpoint regulator antagonist as described herein, such that the growth of the tumor in the patient is inhibited. Also provided is a method for treating a chronic viral infection in a subject, comprising administering to the subject an anti-TIGIT antibody, an anti-PD-1 antibody, an anti-PD-L1 antibody, a bispecific checkpoint regulator antagonist, or a trispecific checkpoint regulator antagonist as described herein, such that a chronic viral infection is treated in the subject.

[0191] Also included herein are methods for depleting T cells from the tumor microenvironment of a subject having a tumor (e.g., a cancerous tumor). reg A method for stimulating T cells in the tumor microenvironment comprises administering to a subject a therapeutically effective amount of an anti-TIGIT antibody, an anti-PD-1 antibody, an anti-PD-L1 antibody, a bispecific checkpoint regulator antagonist, or a trispecific checkpoint regulator antagonist as described herein. reg Cell-depleted Fc. The Fc can, for example, be one that has effector function or enhanced effector function, such as binding or enhanced binding to one or more activating Fc receptors.

[0192] In a preferred embodiment, T reg Depletion of T cells without significant depletion or suppression of the tumor microenvironment eff cases, and did not significantly deplete or inhibit T cells outside the tumor microenvironment. eff cells and T reg In certain embodiments, the patient is in the T reg T cells eff In some embodiments, anti-TIGIT antibodies or antagonists can deplete T cells in tumors. reg and / or T cells in tumor-infiltrating lymphocytes (TILs) reg For example, in the CT26 tumor model, anti-mouse TIGIT antibodies formatted as mouse IgG2a (which displays effector functions) partially depleted T reg and CD8 + T cells, but does not deplete CD4 + T cells. Effector-conjugate-free anti-TIGIT antibody formatted as mouse IgG1 D265A does not deplete T cells.

[0193] When considering whether to use Fc effector function or effector-free anti-TIGIT antibodies, appropriate consideration must be given to T regs Depletion (can enhance anti-tumor immune response) and CD8 +There is a tradeoff between T cell depletion (which will eliminate some of the cells needed to actually kill tumor cells). regs Depletion of TIGIT might be expected to enhance antitumor activity, but recent studies have demonstrated that TIGIT + Connections on Tregs promote T reg T cell-mediated suppression eff Cell proliferation (Joller et al. (2014) Immunity 40:569), suggesting that blocking TIGIT signaling (e.g., using the antagonist anti-TIGIT antibodies of the present invention) may also enhance anti-tumor activity. Therefore, it may be most effective to use antagonist anti-TIGIT antibodies that lack effector function, which: i) block T reg ii) activate anti-tumor CD8 T cells by blocking TIGIT signaling in the mitochondria and thereby reducing their immunosuppressive activity; iii) activate anti-tumor CD8 T cells by blocking TIGIT inhibition + T cells while avoiding exhaustion of their effector functions; and iii) enhancing DNAM-mediated activation by allowing DNAM to bind to PVR (CD155, TIGIT ligand), which would otherwise bind to TIGIT (and by reducing direct TIGIT-DNAM interactions) (Johnston et al. (2014) Cancer Cell 26: 923). The same applies to the use of anti-PD-1 antibodies, anti-PD-L1 antibodies, bispecific checkpoint regulator antagonists, or trispecific checkpoint regulator antagonists.

[0194] In certain embodiments, an anti-TIGIT antibody, an anti-PD-1 antibody, an anti-PD-L1 antibody, a bispecific checkpoint regulator antagonist, or a trispecific checkpoint regulator antagonist as described herein is administered to a subject as an adjuvant therapy. According to the present application, relative to the current standard of care, treating cancer patients with anti-TIGIT antibodies, anti-PD-1 antibodies, anti-PD-L1 antibodies, bispecific checkpoint regulator antagonists, or trispecific checkpoint regulator antagonists can result in a long-term, lasting response; at least 1, 2, 3, 4, 5, 10 years or more of long-term survival, at least 1, 2, 3, 4, 5, or 10 years or more of recurrence-free survival. In certain embodiments, treating cancer patients with anti-TIGIT antibodies, anti-PD-1 antibodies, anti-PD-L1 antibodies, bispecific checkpoint regulator antagonists, or trispecific checkpoint regulator antagonists can prevent cancer recurrence or delay cancer recurrence, for example, 1, 2, 3, 4, 5, or 10 years or more. Anti-TIGIT, anti-PD-1, and / or anti-PD-L1 therapy can be used as a primary or secondary line of treatment.

[0195] In certain preferred embodiments, the subject suffers from a cell proliferative disease or cancer. Blocking the PVR / binding element-2 (Nectin-2) signaling by TIGIT through anti-TIGIT antibodies can enhance the patient's immune response to cancer cells. Similarly, the blocking provided herein is a method for treating a subject with cancer, comprising administering to the subject anti-TIGIT, anti-PD-1, anti-PD-L1, bispecific checkpoint regulator antagonists or trispecific checkpoint regulator antagonists as described herein, so that the patient is treated, for example, so that the growth of cancerous tumors is inhibited or reduced and / or the tumor regresses. Anti-TIGIT anti-PD-1, anti-PD-L1, bispecific checkpoint regulator antagonists or trispecific checkpoint regulator antagonists as described herein can be used alone to inhibit the growth of cancerous tumors. Alternatively, any of these checkpoint regulator antagonists can be used together with another agent, such as other anti-cancer targets, immunogenic agents, standard cancer therapeutics or other antibodies, as described below.

[0196] Thus, provided herein are methods for treating cancer in a subject, for example, by inhibiting the growth of tumor cells, comprising administering to the subject a therapeutically effective amount of an anti-TIGIT, anti-PD-1, anti-PD-L1, bispecific checkpoint regulator antagonist, or trispecific checkpoint regulator antagonist as described herein. Preferably, the antibody is a human anti-TIGIT, anti-PD-1, or anti-PD-L1 antibody comprising an anti-TIGIT, anti-PD-1, or anti-PD-L1 HCVR and LCVR as described herein, or it may be a chimeric or humanized non-human anti-hu TIGIT, anti-hu PD-1, or anti-PD-L1 antibody, such as a chimeric or humanized anti-TIGIT, anti-PD-1, or anti-PD-L1 antibody that competitively binds to or binds to the same epitope as at least one of the anti-TIGIT, anti-PD-1, or anti-PD-L1 antibodies described herein.

[0197] Cancers whose growth can be inhibited using the antibodies of the present invention include cancers that are generally responsive to immunotherapy. Non-limiting examples of cancers for treatment include: squamous cell carcinoma, small cell lung cancer, non-small cell lung cancer, squamous non-small cell lung cancer (NSCLC), non-NSCLC, glioma, gastrointestinal cancer, renal cancer (e.g., clear cell carcinoma), ovarian cancer, liver cancer, colorectal cancer, endometrial cancer, renal cancer (e.g., renal cell carcinoma (RCC)), prostate cancer (e.g., hormone-refractory prostate cancer), thyroid cancer, neuroblastoma, pancreatic cancer, glioblastoma (glioblastoma multiforme), cervical cancer, gastric cancer, bladder cancer, liver cancer, breast cancer, colon cancer, and head and neck cancer (or carcinoma). tumors of the ovary, stomach, germ cell, pediatric sarcomas, sinonasal natural killer (NK) cells, melanoma (e.g., metastatic malignant melanoma, such as cutaneous or intraocular malignant melanoma), bone, skin, uterine, anal, testicular, fallopian tube, endometrial, cervical, vaginal, vulvar, esophageal, small intestine, endocrine, parathyroid, adrenal, soft tissue sarcomas, urethral, ​​penile, solid childhood tumors, ureteral, renal pelvis, central nervous system (CNS) tumors, primary CNS lymphoma, tumor angiogenesis, spinal axis tumors, brainstem gliomas tumors, pituitary adenomas, Kaposi's sarcoma, epidermoid carcinomas, squamous cell carcinomas, T-cell lymphomas, environmentally induced cancers, including those induced by asbestos, virus-related cancers (e.g., human papillomavirus (HPV)-associated tumors), and hematological malignancies derived from either of the two major blood cell lineages, the myeloid lineage (which produces granulocytes, erythrocytes, platelets, macrophages, and mast cells) or the lymphoid lineage (which produces B, T, NK, and plasma cells), such as all types of leukemias, lymphomas, and myelomas, e.g., acute, chronic, lymphocytic, and / or myelocytic leukemias. disease (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and chronic myeloid leukemia (CML), undifferentiated AML (MO), myeloblastic leukemia (M1), myeloblastic leukemia (M2; with cell maturation), promyelocytic leukemia (M3 or M3 variant [M3V]), myelomonocytic leukemia (M4 or M4 variant with eosinophils [M4E]), monocytic leukemia (M5), erythroleukemia (M6), megakaryoblastic leukemia (M7), isolated granulocytic sarcoma, and chloroma;Lymphomas, such as Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NEIL), B-cell lymphoma, T-cell lymphoma, lymphoplasmacytoid lymphoma, monocytoid B-cell lymphoma, mucosa-associated lymphoid tissue (MALT) lymphoma, systemic anaplastic (e.g., Ki 1+) large cell lymphoma, adult T-cell lymphoma / leukemia, mantle cell lymphoma, angioimmunoblastic T-cell lymphoma, angiocentric lymphoma, intestinal T-cell lymphoma, primary mediastinal B-cell lymphoma, precursor T-lymphoblastic lymphoma, T-lymphocyte; and lymphoma / leukemia (T-Lbly / T-ALL), peripheral T-cell lymphoma, lymphoblastic lymphoma, post-transplant lymphoproliferative disorder, true histiocytic lymphoma, primary central nervous system lymphoma, Primary effusion lymphoma, lymphoblastic lymphoma (LBL), hematopoietic lymphoid neoplasms, acute lymphocytic neoplasms, lymphoblastic leukemia, diffuse large B-cell lymphoma, Burkitt lymphoma, follicular lymphoma, diffuse histiocytic lymphoma (DHL), immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, cutaneous T-cell lymphoma (CTLC) (also known as mycosis fungoides or Sézary syndrome), and Waldenstrom's disease (Waldenstrom's disease). Denstrom's macroglobulinemia; myelomas, such as IgG myeloma, light chain myeloma, nonsecretory myeloma, smoldering myeloma (also called indolent myeloma), solitary plasmacytoma, and multiple myeloma; chronic lymphocytic leukemia (CLL); hairy cell lymphoma; hematopoietic tumors of the myeloid lineage; tumors of mesenchymal origin, including fibrosarcoma and rhabdomyosarcoma; seminoma, teratoma, central and peripheral nerve tumors, including Astrocytomas, schwannomas; tumors of mesenchymal origin, including fibrosarcomas, rhabdomyosarcomas, and osteosarcomas; and other tumors, including melanomas, xeroderma pigmentosum, keratoacanthoma, seminoma, thyroid follicular carcinoma, and teratocarcinoma, hematopoietic tumors of the lymphoid lineage, such as T-cell and B-cell tumors, including but not limited to T-cell diseases such as T-prolymphocytic leukemia (T-PLL), including small cell and brain cell types; large granular lymphocytic leukemia (LGL), preferably T-cell type; a / d T-NHL, hepatosplenic lymphoma; peripheral / post-thymic T-cell lymphoma (polymorphic and immunoblastic subtypes); angiocentric (nasal) T-cell lymphoma; cancer of the head or neck, renal cancer, rectal cancer, thyroid cancer; acute myeloid lymphoma, and any combination of the aforementioned cancers. The methods described herein can also be used to treat metastatic cancers, refractory cancers (e.g., cancers that are refractory to previous immunotherapy, such as with blocking CTLA-4 or PD-1 antibodies), and recurrent cancers.

[0198] Anti-TIGIT, anti-PD-1 antibodies, anti-PD-L1 antibodies, bispecific checkpoint regulator antagonists or trispecific checkpoint regulator antagonists can be administered alone, in combination with another checkpoint regulator antagonist, or simultaneously with another checkpoint regulator antagonist. Anti-TIGIT, anti-PD-1 antibodies, anti-PD-L1 antibodies, bispecific checkpoint regulator antagonists or trispecific checkpoint regulator antagonists can also be administered in combination with an immunogenic agent or administered simultaneously, such as cancer cells, tumor vaccines, purified tumor antigens (including recombinant proteins, peptides and carbohydrate molecules), cells transfected with genes encoding immunostimulatory cytokines, in cancer vaccine strategies (He et al. (2004) J. Immunol. 173: 4919-28) or oncolytic viruses.

[0199] Many experimental strategies for tumor vaccines have been designed. In one of these strategies, vaccines are prepared using autologous or allogeneic tumor cells. Some of these cell vaccines have been shown to be most effective when tumor cells are transduced to express GM-CSF. GM-CSF has been shown to be an effective antigen expression activator for tumor vaccines (Dranoff et al. (1993) Proc. Natl. Acad. Sci. USA 90: 3539-43). Cancer vaccines have been shown to enhance the infiltration of effector T cells into tumors in preclinical models. The main types of cancer vaccines include peptide vaccines, vector-based antigen-specific vaccines, whole cell vaccines, and dendritic cell vaccines. All vaccine-based therapies are designed to deliver single or multiple antigenic epitopes or antigens from whole cells to patients and induce tumor-specific effector T cells. Therefore, vaccine-based therapies may be the most effective way to induce T cell infiltration into tumors.

[0200] Studies of gene expression and large-scale gene expression patterns in various tumors have led to the definition of so-called tumor-specific antigens (Rosenberg, SA (1999) Immunity 10: 281-7). In many cases, these tumor-specific antigens are differentiation antigens expressed in tumors and tumor-producing cells, such as the melanocyte antigen gp100, MAGE antigens, and Trp-2. More importantly, many of these antigens can be shown to be targets of tumor-specific T cells found in the host.

[0201] TIGIT, PD-1 and / or PD-L1 inhibition can be used together with a collection of recombinant proteins and / or peptides expressed in tumors to generate an immune response against these proteins. These proteins are usually seen by the immune system as self-antigens and are therefore tolerated. The tumor antigens include the protein telomerase, which is required for the synthesis of chromosome telomeres and is expressed in more than 85% of human cancers and only in a limited number of somatic tissues (Kim et al. (1994) Science 266: 2011-2013). Tumor antigens can also be "neoantigens" expressed in cancer cells due to somatic mutations that change the protein sequence or produce a fusion protein between two unrelated sequences (i.e., bcr-abl in the Philadelphia chromosome), or from the idiotype of B cell tumors.

[0202] Non-limiting examples of tumor vaccines include sipuleucel-T FDA-approved tumor vaccines for metastatic prostate cancer; tumor cells transfected to express the cytokine granulocyte macrophage colony-stimulating factor (GM-CSF), such as the whole-cell GM-CSF-secreting irradiated allogeneic pancreatic cancer vaccine (GVAX; Johns Hopkins); a peptide vaccine composed of immunogenic peptides derived from breast cancer antigens, neu, legumain, and β-catenin, which, when administered in combination with anti-PD-1 antibodies, prolonged vaccine-induced progression-free survival in mice bearing breast tumors (Karyampudi L. et al. (2014) Cancer Res 74:2974-2985); peptides of melanoma antigens, such as peptides of gp100, MAGE antigens, Trp-2, MARTI, and / or tyrosinase, etc. Other tumor vaccines include proteins from viruses implicated in human cancers, such as human papillomavirus (HPV) (e.g., and ); Hepatitis B virus (such as Engerix-B and Recombivax HB); Hepatitis C virus (HCV), Kaposi's sarcoma-associated herpes sarcoma virus (KSHV). Another tumor-specific antigen that can be used in combination with TIGIT inhibition is purified heat shock proteins (HSPs) isolated from autologous tumor tissue. These heat shock proteins contain fragments from tumor cells, and these HSPs are efficiently delivered to antigen-presenting cells to generate tumor immunity. Talimogenelaherparepvec (T-VEC or ) is an oncolytic virus vaccine approved by the FDA for the treatment of some patients with unresectable, metastatic melanoma.

[0203] Dendritic cells (DCs) are potent antigen-presenting cells that can be used to elicit antigen-specific responses. DCs can be generated in vitro and loaded with a variety of protein and peptide antigens as well as tumor cell extracts (Nestle et al. (1998) Nature Medicine 4: 328-332). DCs can also be genetically transduced to express these tumor antigens. For immunization purposes, DCs have also been directly fused with tumor cells (Kugler et al. (2000) Nature Medicine 6: 332-336). As a vaccination approach, DC immunization can be effectively combined with TIGIT blockade to activate (release) a more effective anti-tumor response.

[0204] TIGIT, PD-1 and / or PD-L1 inhibition can also be combined with standard cancer treatments (such as surgery, radiotherapy and chemotherapy). In particular, TIGIT, PD-1 and / or PD L1 inhibition can be effectively combined with chemotherapy regimens. In these cases, the dose of the chemotherapeutic agent administered may be reduced (Mokyr et al. (1998) Cancer Research 58: 5301-5304). An example of such a combination is the combination of a checkpoint regulator antagonist and dacarbazine for the treatment of melanoma. Another example of such a combination is the combination of a checkpoint regulator antagonist and interleukin-2 (IL-2) for the treatment of melanoma. For example, the scientific principle of combining TIGIT, PD-1 and / or PD-L1 inhibition with chemotherapy to promote cell death is that the result of the cytotoxic effects of most chemotherapy compounds should result in an increase in the level of tumor antigens in the antigen presentation pathway. Other combination therapies that may result in synergy with TIGIT, PD-1 and / or PD-L1 inhibition through cell death are radiation, surgery and hormone deprivation. Each of these approaches creates a source of tumor antigens in the host. Angiogenesis inhibitors can also be used in combination with TIGIT, PD-1, and / or PD-L1 inhibition. Inhibition of angiogenesis leads to tumor cell death, which can feed tumor antigens into host antigen presentation pathways.

[0205] Anti-TIGIT antibodies, anti-PD-1 antibodies, anti-PD-L1 antibodies, bispecific checkpoint regulator antagonists and trispecific checkpoint regulator antagonists described herein can also be used in combination with bispecific antibodies that target effector cells expressing Fcα or Fcγ receptors to tumor cells (see, for example, U.S. Patent Nos. 5,922,845 and 5,837,243). Bispecific antibodies can be used to target two different antigens. For example, anti-Fc receptor / anti-tumor antigen (e.g., Her-2 / neu) bispecific antibodies have been used to target macrophages to tumor sites. This targeting can more effectively activate tumor-specific responses. The T cell arms of these responses will be enhanced by the inhibition of TIGIT, PD-1 and / or PD-L1. Alternatively, antigens can be delivered directly to DCs using bispecific antibodies that bind tumor antigens and dendritic cell-specific cell surface markers.

[0206] Tumors evade host immune surveillance through a variety of mechanisms. Many of these mechanisms can be overcome by inactivating immunosuppressive proteins expressed by tumors. These include TGF-β, IL-10, and Fas ligand. Antibodies to each of these entities can be used in combination with the checkpoint regulator antagonists described herein to offset the effects of immunosuppressants and favor the host's tumor immune response.

[0207] Other antibodies that activate host immune reactivity can be used in combination with the checkpoint regulator antagonists described herein. These include molecules on the surface of dendritic cells that activate DC function and antigen presentation. Anti-CD40 antibodies can effectively replace T cell auxiliary activity (Ridge et al. (1998) Nature 393: 474-478) and can be used in combination with anti-TIGIT antibodies. Activation of antibodies against T cell co-stimulatory molecules such as OX-40 (Weinberg et al. (2000) Immunol 164: 2160-2169), CD137 / 4-1BB (Melero et al. (1997) Nature Medicine 3: 682-685 (1997) and ICOS (Hutloff et al. (1999) Nature 397: 262-266) can also provide increased T cell activation levels. In addition, inhibitors of other immune checkpoint regulators can also be used in combination with checkpoint regulator antagonists as described herein, as further described below.

[0208] Bone marrow transplantation is currently used to treat various hematopoietic tumors. Although graft-versus-host disease (GVHD) is a common consequence of this treatment, TIGIT inhibition could be used to increase the potency of donor-transplanted tumor-specific T cells by reducing the graft-versus-tumor response.

[0209] To stimulate antigen-specific T cells against cancer or viral infection in the presence of anti-TIGIT antibodies, activating and expanding antigen-specific T cells in vitro and adoptively transferring these cells into recipients can increase the frequency and activity of the adoptively transferred T cells.

[0210] Several experimental treatment options involve in vitro activation and expansion of antigen-specific T cells and adoptive transfer of these cells into recipients to stimulate antigen-specific T cells against tumors (Greenberg & Riddell (1999) Science 285: 546-51). These methods can also be used to activate T cells in response to infectious pathogens such as CMV. In vitro activation in the presence of anti-TIGIT antibodies can increase the frequency and activity of adoptively transferred T cells.

[0211] In certain embodiments, the checkpoint regulator antagonists described herein can be administered to subjects with infectious diseases (particularly chronic infections). In this case, similar to its application in cancer, antibody-mediated TIGIT, PD-1 and / or PD-L1 inhibition can be used alone, or used in combination with vaccines as an adjuvant to enhance the immune response to pathogens, toxins and self-antigens. Exemplary pathogens to which this treatment method can be applied include but are not limited to HIV, hepatitis (A, B and C), influenza, herpes, Giardia (Giardia), malaria, Leishmania (Leishmania), Staphylococcus aureus (Staphylococcus aureus) and Pseudomonas aeruginosa (Pseudomonas aeruginosa). TIGIT, PD-1 and / or PD-L1 inhibition are particularly useful for determined infections caused by agents such as HIV, such as HIV agents that present novel or altered antigens during infection. Administration of anti-TIGIT antibodies, anti-PD-1 antibodies, anti-PD-L1 antibodies, bispecific checkpoint regulator antagonists, and trispecific checkpoint regulator antagonists can allow recognition of these antigens as foreign, thereby eliciting appropriate antigen T cell responses.

[0212] Other viral infections that can be treated by the methods described herein include HIV, hepatitis (A, B, or C), herpes virus infections (e.g., VZV, HSV-1, HAV-6, HSV-II, and CMV, Epstein-Barr virus), and infections caused by adenovirus, influenza virus, flavivirus, echovirus, rhinovirus, coxsackievirus, coronavirus, respiratory syncytial virus, mumps virus, rotavirus, measles virus, rubella virus, parvovirus, vaccinia virus, HTLV virus, dengue virus, papillomavirus, molluscum virus, poliovirus, rabies virus, JC virus, arbovirus, or a combination thereof.

[0213] Exemplary pathogenic bacteria or diseases caused by them that can be treated by the methods described herein include Chlamydia, Rickettsia, Mycobacteria, Staphylococci, Streptococci, Pneumonococci, Meningococci and Gonococci, Klebsiella, Proteus, Serratia, Pseudomonas, Legionella, Diphtheria, Salmonella, Bacilli, Cholera, Leptospirosis tetanus, botulism, anthrax, plague, and Lyme disease.

[0214] Exemplary pathogenic fungi that cause infections treatable by the methods described herein include Candida (e.g., albicans, krusei, glabrata, tropicalis, etc.), Cryptococcus neoformans, Aspergillus (e.g., fumigatus, niger, etc.), Mucorales (e.g., mucor, absidia, rhizopus), Sporothrix schenkii, Blastomyces dermatitidis, Paracoccidioides brasiliensis, Coccidioides immitis, and Histoplasma capsulatum.

[0215] Exemplary pathogenic parasites that cause infections treatable by the methods described herein include Entamoeba histolytica, Balantidium coli, Naegleria fowleri, Acanthamoeba sp., Giardia Zambia, Cryptosporidium sp., Pneumocystis carinii, Plasmodium vivax, Babesia microti, Babesia microti, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Nippostrongylus brasiliensis.

[0216] In all of the above approaches, TIGIT, PD-1 and / or PD-L1 inhibition can be combined with other forms of immunotherapy, such as cytokine treatment (e.g., interferon, GM-CSF, G-CSF, IL-2), or bispecific antibody therapy using two different binding specificities to provide enhanced presentation of tumor antigens.

[0217] Anti-TIGIT antibodies, anti-PD-1 antibodies, anti-PD-L1 antibodies, bispecific checkpoint regulator antagonists and trispecific checkpoint regulator antagonists described herein can be used to enhance antigen-specific immune responses by co-administering one or more of these antibodies with target antigens (e.g., vaccines). Therefore, provided herein is a method for enhancing the immune response of a subject to an antigen, comprising administering to the subject: (i) an antigen, and (ii) an anti-TIGIT antibody, an anti-PD-1 antibody, an anti-PD-L1 antibody, a bispecific checkpoint regulator antagonist, a trispecific checkpoint regulator antagonist, or a combination thereof, thereby enhancing the immune response to the antigen in the subject. The antigen can be, for example, a tumor antigen, a viral antigen, a bacterial antigen, or an antigen from a pathogen. Non-limiting examples of such antigens include those discussed in the above section, such as tumor antigens (or tumor vaccines), or antigens from viruses, bacteria, or other pathogens as described above.

[0218] In certain embodiments, peptides or fusion proteins comprising epitopes bound by anti-TIGIT antibodies, anti-PD-1 antibodies, anti-PD-L1 antibodies, bispecific checkpoint regulator antagonists, or trispecific checkpoint regulator antagonists may be used as vaccines instead of or in addition to checkpoint regulator antagonists.

[0219] Suitable routes for in vivo and in vitro administration of the antibody compositions described herein (e.g., human monoclonal antibodies, multispecific antibodies or antagonists and immunoconjugates) are well known in the art and can be selected by one of ordinary skill in the art. For example, the antibody compositions can be administered by injection (e.g., intravenously or subcutaneously). The appropriate dosage of the molecule used depends on the age and weight of the subject and the concentration and / or formulation of the antibody composition.

[0220] Combination therapy

[0221] On the other hand, the present application provides a combination therapy for enhancing antigen-specific T cell responses in a subject. In one embodiment, the method comprises contacting T cells with an anti-TIGIT antibody, an anti-PD-1 antibody, an anti-PD-L1 antibody, an antibody fragment thereof, a bispecific checkpoint regulator antagonist, or a trispecific checkpoint regulator antagonist, and with a second antibody, antibody fragment, antagonist or drug combination, so that the antigen-specific T cell response or apoptosis pathway is enhanced. For example, in some embodiments, the first antibody or antibody fragment specifically binds to TIGIT and the second antibody or antibody fragment specifically binds to PD-1 or PD-L1. In some embodiments, the second antibody or antibody fragment comprises Figure 3B In some embodiments, the second antibody or antibody fragment comprises one or more anti-PD-1 CDRs. Figure 4D -One or more anti-PD-1 variable regions of E.

[0222] In a related aspect, a method of reducing or depleting regulatory T cells in a tumor in a subject in need thereof comprises administering an effective amount of an antibody or antibody fragment in combination with a second antibody, antibody fragment, antagonist, or drug such that the number of regulatory T cells in the subject is reduced.

[0223] In some embodiments, the subject has a cell proliferative disorder or cancer as described herein.

[0224] In other embodiments, the subject has a chronic viral infection, inflammatory disease, or autoimmune disease as described herein.

[0225] Providing two different signals to T-cells is a widely accepted model for lymphocyte activation of resting T lymphocytes by antigen presenting cells (APCs). This model further provides self-non-self discrimination and immune tolerance. The initial signal or antigen-specific signal is transduced by the T cell receptor (TCR) after recognizing foreign antigenic peptides presented in the context of the major histocompatibility complex (MHC). The secondary or co-stimulatory signal is delivered to T cells by co-stimulatory molecules expressed on antigen presenting cells (APCs) and induces T cells to promote clonal expansion, cytokine secretion and effector function. In the absence of co-stimulation, T cells may become refractory to antigen stimulation, which leads to a tolerogenic response to exogenous or endogenous antigens.

[0226] In the dual-signal model, T cells receive positive co-stimulatory signals and negative co-inhibitory signals. Regulating these positive and negative signals is crucial for maximizing the host's protective immune response while maintaining immune tolerance and preventing autoimmunity. Negative signals appear to be necessary for inducing T cell tolerance, while positive signals promote T cell activation. Both co-stimulatory and co-inhibitory signals are provided to T cells exposed to antigens, and the interaction between co-stimulatory and co-inhibitory signals is essential for controlling the amplitude of the immune response. In addition, when the infection or immune challenge is cleared, worsens, or persists, the signals provided to T cells change, and these changes strongly affect the responding T cells and reshape the immune response.

[0227] The mechanism of co-stimulation has therapeutic significance because manipulation of co-stimulatory signals has been shown to provide a means of enhancing or terminating cell-based immune responses. Recently, it has been found that T cell dysfunction or anergy can occur in conjunction with induced and sustained expression of immune checkpoint regulators such as programmed death 1 polypeptide (PD-1) and its ligands PD-L1 and PD-L2. PD-L1 is overexpressed in many cancers and is often associated with poor prognosis (Thompson RH et al., Cancer Res 2006, 66(7): 3381). In addition, compared with T lymphocytes in normal tissues and peripheral blood T lymphocytes, most tumor-infiltrating T lymphocytes predominantly express PD-1, suggesting that upregulation of PD-1 on tumor-reactive T cells can lead to impaired anti-tumor immune responses (Blood 2009 114(8): 1537). This may be due to the utilization of PD-L1 signaling mediated by the interaction between PD-L1-expressing tumor cells and PD-1-expressing T cells, resulting in the attenuation of T cell activation and evasion of immune surveillance. Inhibition of PD-L1 / PD-1 interaction provides a way to enhance T cell immunity, including CD8 +T cell-mediated killing of cancer cells and tumors. Similar enhancement of T cell immunity has been observed by inhibiting the binding of PD-L1 to its binding partner B7-1. Therefore, therapeutic targeting of PD-1 and other immune checkpoint regulators is an area of ​​great interest.

[0228] Combining inhibition of TIGIT, PD-1, and / or PD-L1 signaling with other signaling pathways that are dysregulated in tumor cells may offer a means to enhance therapeutic efficacy. In recent years, numerous immune checkpoint regulators in the form of receptors and their ligands have been identified. An important family of membrane-bound ligands that bind to co-stimulatory or co-inhibitory receptors is the B7 family, which includes CTLA-4 and its ligands, B7-1 and B7-2; PD-1 and its ligands, PD-L1 (B7-H1) and PD-L2 (B7-DC); B7-H2 (ICOS-L), B7-H3, B7-H4, B7-H5 (VISTA), and B7-H6. Additional immune checkpoint antagonists include, but are not limited to, TIM-3 and its ligand, galectin-9; LAG-3 and its ligands, including liver sinusoidal endothelial cell lectin (LSECtin) and galectin-3; CD122 and its CD122R ligand; CD70, B7H3, B and T lymphocyte attenuator (BTLA), and VISTA (Le Mercier et al. (2015) Front. Immunol., (6), Article 418). In addition, many checkpoint regulator antagonists have been identified and tested in various clinical and preclinical models and / or approved by the FDA (Kyi et al., FEBS Letters, 588: 368-376 (2014)). The concept of inhibitory receptor blockade, also known as immune checkpoint blockade, has been validated by, for example, the FDA-approved PD-1 inhibitors, nivolumab and pembrolizumab, and the anti-CTLA-4 antibody, ipipimumab for metastatic melanoma.

[0229] Immune checkpoint antagonists regulate or interfere with the activity of immune checkpoint regulator, so that as a result of being combined with checkpoint regulator or its ligand, blocking or suppressing the signal transduction by checkpoint regulator receptor.By suppressing this signal transduction, immunosuppression can be reversed, so that the T cell immunity against cancer cells can be re-established or enhanced.On the contrary, immune checkpoint agonists (for example, costimulatory molecules) stimulate the activity of immune checkpoint regulator, so as a result of being combined with checkpoint regulator or its ligand, stimulate the signal transduction by checkpoint regulator receptor.By stimulating this signal transduction, the T cell immunity against cancer cells can be re-established or enhanced.

[0230] Thus, in one embodiment, a method for stimulating an immune response in a subject comprises administering to the subject an anti-TIGIT antibody, anti-PD-1 antibody, anti-PD-L1 antibody, antibody fragments thereof (e.g., anti-TIGIT HCVR and / or LCVR) or a bispecific checkpoint regulator antagonist, or a trispecific checkpoint regulator antagonist as described herein, in combination with another immune checkpoint regulator as described above, such that an immune response is stimulated in the subject, e.g., inhibiting tumor growth or stimulating an antiviral response.

[0231] In one embodiment, according to the present application's anti-TIGIT antibodies, anti-PD-1 antibodies, anti-PD-L1 antibodies, antibody fragments thereof, bispecific checkpoint regulator antagonists, or trispecific checkpoint regulator antagonists are administered in combination with another immune checkpoint regulator, as a separate antibody or in a multispecific antibody comprising binding specificities for a variety of products. In general, the anti-TIGIT antibodies, anti-PD-1 antibodies, anti-PD-L1 antibodies, bispecific checkpoint regulator antagonists, or trispecific checkpoint regulator antagonists described herein can be combined with the following substances to stimulate an immune response, wherein the substance is (i) an antagonist of an IgSF family protein, a B7 family, or a TNF family that inhibits T cell activation, or a cytokine antagonist (e.g., IL-6, IL-10, TGF-β, VEGF, or other immunosuppressive cytokines) that inhibits T cell activation and / or (ii) an agonist of a stimulatory receptor of the IgSF family, B7 family, or TNF family, or an agonist of a cytokine that stimulates T cell activation, for stimulating an immune response.

[0232] In one embodiment, an anti-TIGIT antibody, or its HCVR and / or LCVR fragment, is administered to a subject in combination with an anti-PD-1 antibody or a PD-1 antagonist. In another embodiment, an anti-TIGIT antibody, or its HCVR and / or LCVR fragment, is administered to a subject in combination with an anti-PD-L1 antibody or a PD-L1 antagonist. In another embodiment, an anti-TIGIT antibody, or its HCVR and / or LCVR fragment, is administered to a subject in combination with an anti-CTLA-4 antibody or a CTLA-4 antagonist.

[0233] In certain embodiments, only subjects with cancers that exhibit high expression of ligands for immune checkpoint regulators are selected for combined treatment with the anti-TIGIT, anti-PD-1 and / or anti-PD-L1 antibodies, fragments thereof, or any bispecific or trispecific antagonists of the present application. For example, in one embodiment, subjects with cancers that exhibit high expression of PVR (CD155) and / or Nectin-2 (CD112) and / or low expression of PD-L1 may be selected for monotherapy with the anti-TIGIT antibodies, fragments thereof, or TIGIT antagonists of the present application, or in combination with PD-1 antagonists or other immune checkpoint regulators.

[0234] The anti-TIGIT antibody, anti-PD-1 antibody, anti-PD-L1 antibody can be administered separately from a second antibody, antibody fragment, or antagonist, or a multispecific antibody or antagonist comprising at least one binding specificity for TIGIT and a second binding specificity for another target product can be administered. In addition, the anti-TIGIT, anti-PD-1 antibody, anti-PD-L1 antibody, or bispecific or trispecific antagonist according to the present application can be co-administered with one or more additional agents, for example, an antibody, antagonist, or drug in an amount effective to stimulate an immune response and / or programmed cell death, to further enhance, stimulate, or upregulate the subject's immune response and / or apoptosis.

[0235] In some embodiments, anti-TIGIT, anti-PD-1 or anti-PD-L1 antibodies or fragments thereof are administered after treatment with different immune checkpoint regulator antagonists. For example, in one embodiment, anti-TIGIT, anti-PD-1 or anti-PD-L1 antibodies can be administered only after treatment with a PD-1 / PD-L1 antagonist has failed, resulting in an incomplete therapeutic response, or existing tumor recurrence or recurrence (or "PD-1 failure"). In some embodiments, cancers that exhibit such failure can be screened for expression of, for example, PVR and / or Nectin-2, and only those cancers with high levels of expression are treated with the anti-TIGIT, anti-PD-1 or anti-PD-L1 antibodies, fragments or antagonists of the present application.

[0236] In a specific embodiment, an anti-TIGIT, anti-PD-1 or anti-PD-L1 antibody or fragment is administered in combination with a PD-1, PD-L1, PD-L2 or TIGIT antagonist.

[0237] Other anti-PD-1 antibodies include but are not limited to nivolumab (BMS-936558, MDX-1106, OPDIVO TM), a humanized immunoglobulin G4 (IgG4) mAb (Bristol-Myers Squibb); pembrolizumab (MK-3475, lambrolizumab, KEYTRUDA TM ) (Merck); pidilizumab (CT-011) (Medivation); and AMP-224 (Merck). Anti-PD-1 antibodies are commercially available, for example, from ABCAM (AB137132), BIOLEGEND TM (EH12.2H7, RMP1-14) and AFFYMETRIX EBIOSCIENCE (J105, J116, MIH4). Anti-PD-1 antibodies also include Figure 3B one or more anti-PD-1 CDRs, or Figure 4D -E one or more anti-PD-1 variable region antibodies or antibody fragments.

[0238] Other anti-PD-L1 antibodies include atezolizumab (MPDL3280A, RG7446), a fully human IgG4 mAb (Genentech / Roche); BMS-936559 (MDX-1105), a fully human IgG4 mAb (Bristol-Myers Squibb); MEDI4736, a humanized IgG antibody (Medimmune / AstraZeneca); and MSB0010718C, a fully human IgG4 mAb (Merck, EMD Serono).

[0239] Exemplary anti-CTLA-4 antibodies for use in accordance with the methods of the present invention include ipilimumab, trevilizumab, and tremelimumab. Exemplary anti-CTLA-4 dominant negative proteins include the humanized fusion proteins abatacept (Orencia), which includes the Fc region of IgG1 fused to the CTLA-4 ECD, and belatacept (Orencia). ), a second-generation, higher-affinity CTLA-4-Ig variant with two amino acid substitutions in the CTLA-4 ECD relative to abatacept.

[0240] In certain embodiments, the immune checkpoint regulator antagonist is a dominant negative protein of an immune checkpoint regulator. In a specific embodiment, the dominant negative protein comprises an extracellular domain derived from a member of the group consisting of PD-L1, PD-L2, PD-1, B7-1, B7-2, B7H3, CTLA-4, LAG-3, TIM-3, TIGIT, BTLA, VISTA, CD70, and a combination thereof. In certain specific embodiments, these extracellular domains are fused to the immunoglobulin constant region or Fc receptor in the currently described antibodies. Such mutants can bind to endogenous receptors to form a complex with a signal transduction defect. In certain embodiments, the extracellular domain is fused to an immunoglobulin constant region or Fc fragment or to a monomer in an oligomeric protein complex.

[0241] In certain embodiments, the dominant negative PD-L1 antagonist comprises the extracellular domain of PD-L1, PD-L2 or PD-1. In another embodiment, a dominant negative PD-1 antagonist is used that has a mutation so that it can no longer bind to PD-L1. An exemplary dominant negative protein is AMP-224 (co-developed by GlaxoSmith Kline and Amplimmune), which is a recombinant fusion protein comprising the extracellular domain of PD-L2 and the Fc region of human IgG.

[0242] Exemplary immune checkpoint regulator agonists include, but are not limited to, tumor necrosis factor (TNF) receptor superfamily members, such as CD27, CD40, OX40, GITR and 4-1BB (CD137) and its ligands, or B7-CD28 superfamily members, including CD28 and ICOS (CD278). Other checkpoint regulator agonists include CD2, CDS, ICAM-1, LFA-1 (CD11a / CD18), CD30, BAFFR, HVEM, CD7, LIGHT, NKG2C, SLAMF7, NKp80, CD160, B7-H3, CD83 ligands. Immune checkpoint agonists may include antibodies or soluble fusion protein agonists comprising one or more costimulatory domains. Agonist antibodies include, but are not limited to, anti-CD40 monoclonal antibodies, such as CP-870,893, lucatumumab, and dacetuzumab; anti-CD137 monoclonal antibodies, such as BMS-663513urelumab and PF-05082566; anti-OX40 monoclonal antibodies; anti-GITR monoclonal antibodies, such as TRX518; anti-CD27 monoclonal antibodies, such as CDX-1127; and anti-ICOS monoclonal antibodies.

[0243] Exemplary GITR agonists include, for example, GITR fusion proteins and anti-GITR antibodies (e.g., bivalent anti-GITR antibodies), such as those described in U.S. Patent Nos. 6,111,090 and 8,586,023; European Patent No. 090505B1, and U.S. Patent PCT Publication Nos. WO 2010 / 003118 and 2011 / 090754. Anti-GITR antibodies are described in, for example, U.S. Patent Nos. 7,025,962, 7,618,632, 7,812,135, 8,388,967, and 8,591,886; European Patent Nos. 1947183B1 and 1866339; PCT Publication Nos. WO2011 / 028683, WO2013 / 039954, WO2005 / 007190, WO2007 / 133822, WO2005 / 055808, WO99 / 40196, WO2001 / 03720, WO99 / 20758, WO2006 / 083289, WO 2005 / 115451, WO2011 / 051726. An exemplary anti-GITR antibody is TRX518.

[0244] Another family of membrane-bound ligands that bind to co-stimulatory or co-inhibitory receptors are the TNF family molecules that bind to cognate TNF receptor family members, including CD40 and CD40L, OX-40, OX-40L, CD70, CD27L, CD30, CD30L, 4-1BBL, CD137 / 4-1BB, TRAIL / Apo2-L, TRAILR1 / DR4, TRAILR2 / DR5, TRAILR3, TRAILR4, OPG, RANK, RANKL, TWEAKR / Fn14, TWEAK, BAFFR, EDR, XEDAR, TACI, APRIL, BCMA, LTβR, LIGHT, DcR3, HVEM, VEGI / TL1A, TRAMP / DR3, EDAR, EDA1, XEDAR, EDA2, TNFR1, lymphotoxin alpha / TNFγ, TNFR2, TNFα, LTβR, lymphotoxin alpha 1(32, FAS, FASL, RELT, DR6, TROY, NGFR (see, e.g., Tansey, MG et al. (2009) Drug Discovery Today, 14(23-24): 1082-1088).

[0245] Immune checkpoint agonists or co-stimulatory molecules include cell surface molecules other than antigen receptors or their ligands required for an effective immune response and include, but are not limited to: MHC class I molecules, TNF receptor proteins, immunoglobulin-like proteins, cytokine receptors, integrins, signal transducing lymphocyte activation molecules (SLAM proteins), activated NK cell receptors, BTLA, Toll ligand receptors, OX40, CD2, CD7, CD27, CD28, CD30, CD40, CDS, ICAM-1, LFA-1 (CD11a / CD18), 4-1BB (CD137), B7-H3, CDS, ICAM-1, ICOS (CD278), GITR, BAFFR, LI GHT, HVEM(LIGHTR), KIRDS2, SLAMF7, NKp80(KLRF1), NKp44, NKp30, NKp46, CD19, CD4, CD8α, CD8β, IL2Rβ, IL2Rγ, IL7Rα , ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, NKG2D, NKG2C, TNFR2, TRANCE / RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRT AM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, ​​LAT, GADS, SLP-76, PAG / Cbp, CD19a and ligands that specifically bind to CD83.

[0246] In one aspect, T cell responses can be stimulated by a combination of an anti-TIGIT, anti-PD-1 or anti-PD-L1 monoclonal antibody of the invention and one or more of the following: (i) an antagonist of a protein that inhibits T cell activation (e.g., an immune checkpoint inhibitor), such as CTLA-4, PD-1, PD-L1, PD-L2, LAG-3, TIM-3, galectin-9, CEACAM-1, BTLA, CD69, galectin-1, CD113, GPR56, or a combination thereof. , VISTA, 2B4, CD48, GARP, PD-1H, LAIR1, TIM-1, CD96 and TIM-4, and (ii) agonists of proteins that stimulate T cell activation, such as B7-1, B7-2, CD28, 4-1BB (CD137), 4-1BBL, ICOS, CD40, ICOS-L, OX40, OX40L, GITR, GITRL, CD70, CD27, CD40, DR3 and CD28H.

[0247] Exemplary agents that modulate one of the above proteins and that can be combined with anti-TIGIT antibodies (such as those described herein for the treatment of cancer) include: YERVOY™ / ipilimumab or tremelimumab (directed to CTLA-4), galiximab (directed to B7.1), OPDIVO TM / nivolumab / BMS-936558 (targeting PD-1), pidilizumab / CT-011 (targeting PD-1), KEYTRUDA TM / pembrolizumab / MK-3475 (targeting PD-1), AMP224 (targeting B7-DC / PD-L2), BMS-936559 (targeting B7-H1), MPDL3280A (to B7-H1), MEDI-570 (targeting ICOS), AMG557 (targeting B7H2), MGA271 (targeting B7H3), IMP321 (targeting LAG-3), urelumab / BMS-663513, and PF- 05082566 (targeting CD137 / 4-1BB), CDX-1127 (targeting CD27), MEDI-6383 and MEDI-6469 (targeting OX40), RG-7888 (targeting OX40L), Atacicept (targeting TACI), CP-870893 (targeting CD40), Rucamorumab (targeting CD40), Daclizumab (targeting CD40), and Muromonab-CD3 (targeting CD3).

[0248] Other molecules that can be combined with the checkpoint regulator antagonists described herein for the treatment of cancer include antagonists of inhibitory receptors on NK cells or agonists of receptors on activating NK cells. For example, antagonist anti-TIGIT, anti-PD-1 and / or anti-PD-L1 antibodies can be combined with antagonists of KIR (e.g., lirilumab), CSF-1R antagonists (such as RG7155).

[0249] Tumors evade host immune surveillance through a variety of mechanisms. Many of these mechanisms can be overcome by inactivating immunosuppressive proteins expressed by tumors. These include TGF-β, IL-10, and Fas ligand. Antibodies to each of these entities can be used in combination with the checkpoint regulator antagonists described herein to offset the effects of immunosuppressants and favor the host's tumor immune response.

[0250] Other antibodies that activate host immune reactivity can be used in combination with the checkpoint regulator antagonists described herein. These include molecules on the surface of dendritic cells that activate DC function and antigen presentation. Anti-CD40 antibodies can effectively replace T cell helper activity and can be used in combination with the checkpoint regulator antagonists described herein. Antibodies to activated T cell co-stimulatory molecules such as OX-40, CD137 / 4-1BB and ICOS can also be provided for increasing T cell activation levels.

[0251] In certain embodiments, the checkpoint regulator antagonists described herein can be co-administered with one or more other therapeutic agents, such as anticancer agents, radiotoxic agents, or immunosuppressants. Such co-administration can address problems caused by the development of resistance to the drug, changes in the antigenicity of tumor cells (which render the antibody unreactive), and toxicity (by administering lower doses of one or more agents).

[0252] Checkpoint regulator antagonists described herein can be connected to a medicament (as an immune complex) or can be administered separately from a medicament. In the latter case (separate administration), the antibody can be administered before, after, or simultaneously with the medicament, or can be co-administered with other known therapies, such as anticancer therapies (such as radiation). Checkpoint regulator antagonists as described herein can be co-administered with one or more anticancer agents to provide an anticancer agent that operates in concert with two different mechanisms, thereby producing a cytotoxic effect in human cancer cells.

[0253] The checkpoint regulator antagonists described herein can be used in combination with an anti-cancer agent, such as an alkylating agent, an anthracycline, an antimetabolite, an antidote, an interferon, a polyclonal or monoclonal antibody, an EGFR inhibitor, a HER2 inhibitor, a histone deacetylase inhibitor, a hormone, a mitotic inhibitor, a phosphatidylinositol-3-kinase (PI3K) inhibitor, an Akt inhibitor, a mammalian target of rapamycin (mTOR) inhibitor, a proteasome inhibitor, a poly (ADP-ribose) polymerase (PARP) inhibitor, a Ras / MAPK pathway inhibitor, a centrosome declustering agent, a multikinase inhibitor, a serine / threonine kinase inhibitor, a tyrosine kinase inhibitor, a VEGF / VEGFR inhibitor, a taxane or taxane derivative, an aromatase inhibitor, an anthracycline, a microtubule-targeting drug, a topoisomerase poison drug, a molecular target or enzyme inhibitor (e.g., a kinase or protein methyltransferase), a cytidine analog, or a combination thereof.

[0254] Exemplary alkylating agents include, but are not limited to, cyclophosphamide (Cytoxan; Neosar); chlorambucil (Leukeran); melphalan (Alkeran); carmustine (BiCNU); busulfan (Busulfex); lomustine (CeeNU); dacarbazine (DTIC-Dome); oxaliplatin (Eloxatin); carmustine (Gliadel); ifosfamide (Ifex), mechlorethamine (Mustargen); busulfan (Myleran); carboplatin (Paraplatin); cisplatin (CDDP; Platinol); temozolomide (Temodar); thiotepa (Thioplex); bendamustine (Treanda); or streptozotocin (Zanosar).

[0255] Exemplary anthracyclines include, but are not limited to, doxorubicin (Adriamycin); liposomal doxorubicin (Doxil); mitoxantrone (Novantrone); bleomycin (Blenoxane); daunorubicin (Cerubidine); liposomal daunorubicin (DaunoXome); actinomycin (Cosmegen); epirubicin (Ellence); idarubicin (Idamycin); plicamycin (Mithracin); mitomycin (Mutamycin); pentostatin (Nipent); or valrubicin (Valstar).

[0256] Exemplary antimetabolites include, but are not limited to, fluorouracil (Adrucil); fluorouracil capecitabine (Xeloda); hydroxyurea (Hydrea); mercaptopurine (Purinethol); pemetrexed (Alimta); fludarabine (Fludara); nelarabine (Arranon); cladribine (Cladribine); Novaplus; clofarabine (Clolar); cytarabine (Cytosar-U); decitabine (Dacogen); liposomal cytarabine (DepoCyt); hydroxyurea (Droxia); pralatrexate (Folotyn); floxuridine (FUDR); gemcitabine (Gemzar); cladribine (Leustatin); fludarabine (Oforta); methotrexate (MTX; Rheumatrex); methotrexate (Trexall), thioguanine (Tabloid); TS-1 or cytarabine (Tarabine PFS).

[0257] Exemplary antidotes include, but are not limited to, Ethyol or Mesnex.

[0258] Exemplary interferons include, but are not limited to, interferon alpha-2b (Intron A) or interferon alpha-2a (Roferon-A).

[0259] Exemplary polyclonal or monoclonal antibodies include, but are not limited to, trastuzumab (Herceptin); ofatumumab (Arzerra); bevacizumab (Avastin); rituximab (Rituxan); cetuximab (Erbitux); panitumumab (Vectibix); tositumomab / iodine-131 tositumomab (Bexxar); alemtuzumab (Campath); ibritumomab (Zevalin; In-111; Y-90Zevalin), gemtuzumab tuzumab (Mylotarg); eculizumab (Soliris) ordenosumab.

[0260] Exemplary EGFR inhibitors include, but are not limited to, gefitinib (Iressa); lapatinib (Tykerb); cetuximab (Erbitux); erlotinib (Tarceva), panitumumab (Vectibix); PKI-166; canertinib (CI-1033); matuzumab (Emd7200), or EKB-569.

[0261] Exemplary HER2 inhibitors include, but are not limited to, trastuzumab (Herceptin); lapatinib (Tykerb); or AC-480.

[0262] Exemplary histone deacetylase inhibitors include, but are not limited to, vorinostat (Zolinza), valproic acid, romidepsin, entinostat, abexinostat, gvinostat, and moxidectinstat.

[0263] Exemplary hormones include, but are not limited to, tamoxifen (Soltamox; Nolvadex); raloxifene (Evista); megestrol acetate (Megace); leuprorelin (Lupron; Lupron Depot; Eligard; Viadur); fulvestrant (Faslodex); letrozole (Femara); triptorelin (Trelstar LA; Trelstar Depot); exemestane (Aromasin); goserelin (Zoladex); bicalutamide (Casodex); anastrozole (Arimidex); fluoxymesterone (Androxy; Halotestin); medroxyprogesterone (Provera; Depo-Provera); estramustine (Emcyt); flutamide (Eulexin); toremifene (Fareston); degarelix (Firmagon); nilutamide (Nilandron); abrelix (Plenaxis); or testolactone (Teslac).

[0264] Exemplary mitotic inhibitors include, but are not limited to, paclitaxel (Taxol; Onxol; Abraxane); docetaxel (Taxotere); vincristine (Oncovin; Vincasar PFS); vinblastine (Velban); etoposide (Toposar; Etopophos; VePesid); teniposide (Vumon); ixabepilone (Ixempra); nocodazole; epothilone; vinorelbine (Navelbine); camptothecin (CPT); irinotecan (Camptosar); topotecan (Hycamtin); amsacrine or lamellarin D (LAM-D).

[0265] Exemplary phosphatidyl-inositol-3 kinase (PI3K) inhibitors include the irreversible PI3K inhibitor wortmannin, the wortmannin derivative desmethoxypyridine LY294002, a reversible PI3K inhibitor; BKM120 (Buparlisib), Idelalisib (a PI3Kδ inhibitor); duvelisib (IPI-145, an inhibitor of PI3Kδ and γ); alpelisib (BYL719) (an α-specific PI3K inhibitor); TGR 1202 (formerly known as RP5264) (an oral PI3Kδ inhibitor); and copanlisib (BAY80-6946) (a PI3Kα, δ isoform-dominant inhibitor).

[0266] Exemplary Akt inhibitors include, but are not limited to, miltefosine, AZD5363, GDC-0068, MK2206, perifosine, RX-0201, PBI-05204, GSK2141795, and SR13668.

[0267] Exemplary MTOR inhibitors include, but are not limited to, everolimus (Afinitor) or temsirolimus (Torisel); rapamune, ridaforolimus; deforolimus (AP23573); AZD8055 (AstraZeneca), OSI-027 (OSI), INK-128, BEZ235, PI-103, Torin1, PP242, PP30, Ku-0063794, WAY-600, WYE-687, WYE-354, and CC-223.

[0268] Exemplary proteasome inhibitors include, but are not limited to, bortezomib (PS-341), ixazomib (MLN2238), MLN 9708, delanzomib (CEP-18770), carfilzomib (PR-171), YU101, oprozomib (ONX-0912), marizomib (NPI-0052), and disufiram.

[0269] Exemplary PARP inhibitors include, but are not limited to, olaparib, iparib, velaparib, BMN-673, BSI-201, AG014699, ABT-888, GPI21016, MK4827, INO-1001, CEP-9722, PJ-34, Tiq-A, Phen, PF-01367338, and combinations thereof.

[0270] Exemplary Ras / MAPK pathway inhibitors include, but are not limited to, trametinib, selumetinib, cobimetinib, CI-1040, PD0325901, AS703026, RO4987655, RO5068760, AZD6244, GSK1120212, TAK-733, U0126, MEK162, and GDC-0973.

[0271] Exemplary centrosome declustering agents include, but are not limited to, griseofulvin; noscapine, noscapine derivatives, such as brominated noscapine (e.g., 9-bromobenzcapine), reduced bromoscapine (RBN), N-(3-bromobenzyl) noscapine, aminocarbazepine, and water-soluble derivatives thereof; CW069; the phenanthrene-derived poly (ADP-ribose) polymerase inhibitor PJ-34; N2-(3-pyridylmethyl)-5-nitro-2-furamide, N2-(2-thienylmethyl)-5-nitro-2-furamide, and N2-benzyl-5-nitro-2-furamide.

[0272] Exemplary multi-kinase inhibitors include, but are not limited to, regorafenib; sorafenib (Nexavar); sunitinib (Sutent); BIBW 2992; E7080; ZD6474; PKC-412; motesanib; or AP24534.

[0273] Exemplary serine / threonine kinase inhibitors include, but are not limited to, ruboxistaurin; eril / easudil hydrochloride; flavonoid antineoplastic agents; seliciclib (CYC202; Roscovitrine); SNS-032 (BMS-387032); PKC412; bryostatin; KAI-9803; SF1126; VX-680; AZD1152; Arry-142886 (AZD-6244); SCIO-469; GW681323; CC-401; CEP-1347 or PD 332991.

[0274] Exemplary tyrosine kinase inhibitors include, but are not limited to, erlotinib (Tarceva); gefitinib (Iressa); imatinib (Gleevec); sorafenib (Nexavar); sunitinib (Sutent); trastuzumab (Herceptin); bevacizumab (Avastin); rituximab (Rituxan); lapatinib (Tykerb); cetuximab (Erbitux); panitumumab (Vectibix); everolimus (Afinitor); alemtuzumab (Campath); gemtuzumab (Mylizumab); otarg); temsirolimus (Torisel); pazopanib (Votrient); dasatinib (Sprycel); nilotinib (Tasigna); vatalanib (Ptk787; ZK222584); CEP-701; SU5614; MLN518; XL999; VX-322; AZD0530; BMS-354825; SKI-606CP-690; AG-490; WHI-P154; WHI-P131; AC-220; or AMG888.

[0275] Exemplary VEGF / VEGFR inhibitors include, but are not limited to, bevacizumab (Avastin); sorafenib (Nexavar); sunitinib (Sutent); ranibizumab; pegaptanib; or vandetinib.

[0276] Exemplary microtubule-targeting drugs include, but are not limited to, paclitaxel; docetaxel; vincristin; vinblastine; nocodazole; epothilones and navelbine.

[0277] Exemplary topoisomerase poison drugs include, but are not limited to, teniposide, etoposide, doxorubicin, camptothecin, daunorubicin, actinomycin D, mitoxantrone, amsacrine, epirubicin, and idarubicin.

[0278] Exemplary taxanes or taxane derivatives include, but are not limited to, paclitaxel and docetaxel.

[0279] Exemplary general chemotherapeutic agents, anti-tumor agents, anti-proliferative agents include, but are not limited to: Hexalen; Accutane; Amnesteem; Claravis; Sotret; Vesanoid; Azacitidine; Bortezomib; Elspar; Levamisole; Lysodren; Procarbazine; Pegaspargase;

[0015] The following agents were used: in the presence of aspirin (incaspar); denileukin-toxin conjugate (Ontak); porphyrin (Photofrin); aldesleukin (Proleukin); lenalidomide (Revlimid); bexarotene (Targretin); thalidomide (Thalomid); temsirolimus (Torisel); arsenic trioxide (Trisenox); verteporfin (Visudyne); mimosine (Leucenol); (1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyrimidine-1 M potassium oxophosphonate); or lovastatin.

[0280] In certain embodiments, the anti-TIGIT antibodies or anti-TIGIT antibody fragments described herein can be combined with one or more angiogenesis inhibitors. Angiogenesis, the development of new blood vessels from existing blood vessels, is crucial for tumor growth and metastasis. Angiogenesis inhibition presents a potentially valuable strategy for treating diseases (such as cancer) in which progression (e.g., metastasis) depends on the formation of new blood vessels. Two important angiogenesis pathways include the vascular endothelial growth factor (VEGF) pathway and the Tie2 pathway. The main VEGF pathway is mediated by the transmembrane tyrosine kinase VEGF-R2. Various isoforms of VEGF, particularly VEGF-A, bind to VEGF-R2, leading to dimerization and activation through phosphorylation of various downstream tyrosine kinases. The Tie2 pathway is another angiogenesis pathway for which therapeutic antibodies and small molecule drugs have been developed. The Tie2 tyrosine kinase receptor activates angiogenesis in response to the binding of one of its angiopoietin (Ang) ligands (i.e., Ang1, Ang2, Ang3 (mouse) and Ang4). Inhibition of angiogenesis leads to tumor cell death, which can feed tumor antigens into the host antigen presentation pathway.

[0281] In some embodiments, an anti-TIGIT antibody or its HCVR and / or LCVR fragment is administered to a subject in combination with one or more VEGF binding antagonists and / or one or more Tie2 receptor binding antagonists. The VEGF binding antagonist binds to VEGF-A or its receptor VEGFR-2, thereby blocking or inhibiting the activation of VEGFR-2 by VEGF-A due to binding. The Tie2 receptor binding antagonist binds to the Tie2 tyrosine kinase receptor or one of its angiopoietin (Ang) ligands (i.e., Ang-1, Ang-2, Ang-3, and Ang-4), thereby blocking or inhibiting the activation of the Tie2 receptor by one or more of its ligands due to binding.

[0282] A preferred VEGF antibody antagonist is bevacizumab (AVASTIN TM ), a humanized antibody. Bevacizumab comprises mutated human IgG1 framework regions and antigen-binding complementarity-determining regions from the murine anti-hVEGF monoclonal antibody A.4.6.1, which blocks the binding of human VEGF-A to VEGFR-2. Approximately 93% of bevacizumab's amino acid sequence (including most of the framework regions) is derived from human IgG1, with approximately 7% derived from the murine antibody A4.6.1. Bevacizumab has a molecular weight of approximately 149,000 daltons and is glycosylated.

[0283] Other anti-VEGF antibodies include ranibizumab (trade name Lucentis) TM), a monoclonal antibody fragment derived from the same parent murine antibody as bevacizumab; the G6 or B20 series antibodies (e.g., G6-23, G6-31, B20-4.1) described in U.S. Publication Nos. 2006 / 0280747, 2007 / 0141065, and / or 2007 / 0020267, and U.S. Patent Nos. 7,060,269, 6,884,879, 6,582,959, 6,703,020, 6,054,297; antibodies described in U.S. Patent Application Publication Nos. US2007 / 059312, US2006 / 009360, US2005 / 0186208, U.S.2003 / 0206899, US2003 / 0190317, and US2003 / 0203409.

[0284] An exemplary dominant negative anti-VEGF antagonist is Aflibercept, a recombinant fusion protein comprising the VEGF-A binding portion from the extracellular domains of human VEGF receptors 1 and 2 fused to the Fc portion of human IgG1. Aflibercept serves as a soluble receptor decoy for VEGF-A.

[0285] An exemplary anti-VEGFR-2 antagonist is the humanized IgG1 monoclonal antibody Ramucirumab, which binds to the extracellular domain of VEGFR-2, thereby blocking its interaction with VEGF-A.

[0286] Exemplary small molecule antagonists of the VEGF pathway include multikinase inhibitors of VEGFR-2, including sunitinib, sorafenib, selumetinib, pazonib, and nintinib.

[0287] The Tie2 receptor binding antagonist binds to the Tie2 tyrosine kinase receptor or one of its angiopoietin (Ang) ligands (i.e., Ang-1, Ang-2, Ang-3, and Ang-4), thereby blocking or inhibiting the activation of the Tie2 receptor by one or more of its ligands. In one embodiment, the Tie2 receptor binding antagonist is an inhibitory peptide. In a specific embodiment, the inhibitory peptide comprises the amino acid sequence of SEQ ID NO: 185, i.e., AQQEECEWDPWTCEHMGSGSATGGSGSTASSGSGSATHQEECEWDPWTCEHMLE. In another embodiment, the Tie2 receptor binding antagonist comprises the peptide of SEQ ID NO: 93 fused to an Fc fragment, i.e.,

[0288] DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV

[0289] DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS

[0290] KAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP

[0291] VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGGAQ

[0292] QEECEWDPWTCEHMGSGSATGGSGSTASSGSGSATHQEECEWDPWTCEHMLE (SEQ ID NO: 186).

[0293] Other peptide inhibitors of Tie2 activation (including Ang-2 inhibitors) include: A-11 (Compugen), which comprises the amino acid sequence ETFLSTNKLENQ (SEQ ID NO: 187); CVX-060 peptide (Pfizer); CVX-037 peptide (Pfizer); and CGEN-25017 (Compugen). Additional peptide inhibitors of Tie2 activation are described in U.S. Patent No. 7,138,370.

[0294] Antibody inhibitors of Tie2 activation (and / or angiopoietin-2) include: AMG-780 (Amgen), MEDI-3617 (MedImmune / AstraZeneca), DX-2240 (Dyax / Sanofi-Aventis), REGN-910 (Sanofi / Regeneron), RG7594 (Roche), LC06 (Roche), TAvi6 (Roche), AT-006 (Roche / Affitech). Additional Tie2 receptor binding antibody antagonists and antibody binding sequences derived therefrom are described in U.S. Patent Nos. 7,521,053, 7,658,924, and 8,030,025 and U.S. Patent Application Publication Nos. 2013 / 0078248, 2013 / 0259859, and 2015 / 0197578.

[0295] Tie2 binding antagonists also include: small molecule inhibitors, CGI-1842 (CGI Pharmaceuticals), LP-590 (Locus Pharmaceuticals), ACTB-1003 (Act Biotech / Bayer AG), CEP-11981 (Cephalon / Teva), MGCD265 (Methyl), Regorafenib (Bayer), Cabozantinib / XL-184 / BMS-907351 (Exelixis), Foretnib (Exelixis), MGCD-265 (MethylGene).

[0296] In certain embodiments, a checkpoint regulator antagonist described herein is administered at a subtherapeutic dose, another anti-immune checkpoint regulator antibody or antagonist is administered at a subtherapeutic dose, an angiogenesis antagonist is administered at a subtherapeutic dose, or any antagonist in a combination thereof is each administered at a subtherapeutic dose.

[0297] In certain embodiments, TIGIT, PD-1 and / or PD-L1 inhibition is combined with standard cancer treatments (e.g., surgery, radiotherapy, and chemotherapy). TIGIT, PD-1 and / or PD-L1 inhibition can be effectively combined with chemotherapy regimens. In these cases, the dose of the chemotherapeutic agent administered may be reduced. An example of such a combination is the combination of anti-TIGIT, anti-PD-1 or anti-PD-L1 antibodies with decarbazine for the treatment of melanoma. Another example of such a combination is the combination of anti-TIGIT, anti-PD-1 or anti-PD-L1 antibodies with interleukin-2 (IL-2) for the treatment of melanoma. It is believed that combining TIGIT, PD-1 and / or PD-L1 inhibition with chemotherapy can enhance apoptosis and increase tumor antigen presentation for cytotoxic immunity. Other synergistic combination therapies include TIGIT, PD-1 and / or PD-L1 inhibition by cell death when used in combination with radiation, surgery or hormone deprivation. Each of these regimens produces a source of tumor antigens in the host.

[0298] In certain embodiments, the checkpoint regulator antagonists described herein can also be used for multispecific antagonists, or used in combination with bispecific antibodies that target effector cells expressing Fcα or Fcγ receptors to tumor cells (see, e.g., U.S. Patents 5,922,845 and 5,837,243). Bispecific antibodies can be used to target two different antigens. For example, anti-Fc receptor / anti-tumor antigen (e.g., Her-2 / neu) bispecific antibodies have been used to target macrophages to cancer cells or tumors. This targeting can more effectively activate tumor-specific responses. The T cell arms of these responses will be enhanced by the inhibition of TIGIT, PD-1 and / or PD-L1. Alternatively, antigens can be delivered directly to DCs using bispecific antibodies that bind tumor antigens and dendritic cell-specific cell surface markers.

[0299] Nucleic acids and host cells for expressing checkpoint regulator antagonists

[0300] In another aspect, the present application provides nucleic acids encoding the checkpoint regulator antagonists of the present application, and expression vectors comprising such nucleic acids. In some embodiments, the nucleic acid encodes the HCVR and / or LCVR fragments of the antibodies or fragments described in the embodiments herein, or any other antibodies and antibody fragments described herein.

[0301] The DNA encoding the antigen binding site in the monoclonal antibody can be isolated and sequenced from the hybridoma cells using conventional methods (e.g., by using oligonucleotide probes that can specifically bind to the genes encoding the heavy and light chains of the monoclonal antibody). Alternatively, the amino acid sequence of the immunoglobulin of interest can be determined by direct protein sequencing, and a suitable encoding nucleotide sequence can be designed based on a universal codon table. In other cases, the nucleotide and amino acid sequences of the antigen binding site or other immunoglobulin sequences (including constant regions, hinge regions, etc.) can be obtained from sources well known in the art.

[0302] Expression vectors encoding specific monospecific, bispecific or trispecific checkpoint regulator antagonists can be used to synthesize the checkpoint regulator antagonists disclosed herein in cells cultured in vitro, or they can be directly administered to patients to express the checkpoint regulator antagonists in vivo or in vitro. As used herein, "expression vector" refers to a viral or non-viral vector that includes one or more polypeptide chains encoding a monospecific, bispecific or trispecific checkpoint regulator antagonist of the present disclosure, in a form suitable for expression from a polynucleotide in a host cell for antibody preparation purposes or for direct administration as a therapeutic agent.

[0303] When a nucleic acid sequence is in a functional relationship with another nucleic acid sequence, the former is "operably linked" to the latter. For example, if the DNA of the presequence or signal peptide is expressed as a preprotein that participates in the secretion of the polypeptide, the DNA of the presequence or signal peptide is operably linked to the DNA of the polypeptide; if a promoter or enhancer affects the transcription of the sequence, the promoter or enhancer is operably linked to the coding sequence; or if the ribosome binding site is positioned to facilitate translation, the nucleic acid binding site is operably linked to the coding sequence. Generally, "operably linked" means that the DNA sequences being linked are continuous, and in the case of signal peptides, continuous and in reading phase. However, enhancers do not have to be continuous. Connection is accomplished by connecting at convenient restriction sites. If such sites do not exist, synthetic oligonucleotide adapters or joints can be used according to conventional practice.

[0304] The nucleic acid sequence used to express the checkpoint regulator antagonist typically includes an amino-terminal signal peptide sequence removed from the mature protein. Since the signal peptide sequence can affect the expression level, the polynucleotide can encode any of a variety of different N-terminal signal peptide sequences. Those skilled in the art will understand that the design of the expression vector may depend on factors such as the choice of host cell to be transformed and the desired protein expression level.

[0305] The above-mentioned "regulatory sequence" refers to the DNA sequence necessary for expressing an operably linked coding sequence in one or more host organisms. The term "regulatory sequence" is intended to include promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Regulatory sequences include those that direct the constitutive expression of the nucleotide sequence in many types of host cells, or those that direct the expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). Expression vectors typically contain sequences for transcription termination and may additionally contain one or more elements that positively affect mRNA stability.

[0306] The expression vector contains one or more transcriptional regulatory elements, including promoters and / or enhancers, that direct the expression of the checkpoint regulator antagonist. Promoters include DNA sequences that initiate transcription at a fixed position relative to the transcription start site. Promoters contain the core elements required for the basic interaction between RNA polymerase and transcription factors and can operate in conjunction with other upstream elements and response elements.

[0307] As used herein, the term "promoter" should be taken in its broadest sense and includes transcriptional regulatory elements (TREs) from genomic genes or chimeric TREs therefrom, including TATA boxes or initiator elements for precise transcription initiation, with or without additional TREs (i.e., upstream activating sequences, transcription factor binding sites, enhancers, and silencers), which regulate the activation or repression of genes operably linked thereto in response to development and / or external stimuli, as well as trans-acting regulatory proteins or nucleic acids. A promoter may comprise a genomic fragment, or it may contain a chimera of one or more TREs combined together.

[0308] Preferred promoters are promoters that can direct high-level expression in target target cells. Promoters can include constitutive promoters (e.g., HCMV, SV40, elongation factor-1α (EF-1α)) or those that show preferential expression in specific target cell types. An enhancer generally refers to a DNA sequence that acts away from the transcription start site and can be 5' or 3' of the transcription unit. In addition, enhancers can be within introns and within coding sequences. They are generally between 10 and 300 bp in length, and they act in cis. The function of an enhancer is to increase and / or regulate the transcription of nearby promoters. Preferred enhancers are enhancers that direct high-level expression in antibody-producing cells. Cell or tissue-specific transcriptional regulatory elements (TREs) can be introduced into expression vectors to limit expression to desired cell types. Pol III promoters (H1 or U6) are particularly suitable for expressing shRNAs expressed by siRNAs. Expression vectors can be designed to promote the expression of checkpoint regulator antagonists in one or more cell types.

[0309] In certain embodiments, one or more expression vectors can be engineered to simultaneously express a checkpoint regulator antagonist and one or more siRNAs targeting the Tie2 pathway, the VEGF pathway, or an immune checkpoint regulator.

[0310] siRNA is double-stranded RNA, and it can be engineered to induce gene silencing after the sequence-specific transcription of mRNA.The siRNA produced by synthesis structurally simulates the type of siRNA that normally processes in cell by Dicer enzyme.When being expressed by expression vector, expression vector is engineered to be processed into the short double-stranded hairpin sample RNA (shRNA) of targeting siRNA in cell with transcription.Can use well-known algorithm design synthetic siRNA and shRNA, and use conventional DNA / RNA synthesizer to synthesize.

[0311] In order to co-express a single chain of a checkpoint regulator antagonist, suitable splicing donor and splicing acceptor sequences can be introduced to express two products. Alternatively, an internal ribosome binding sequence (IRES) or a 2A peptide sequence can be used to express multiple products from a promoter. IRES provides a structure that a ribosome can bind to and does not need to be located at the 5' end of the mRNA. Therefore, it can guide the ribosome to initiate translation at the second start codon within the mRNA, thereby allowing more than one polypeptide to be produced from a single mRNA. The 2A peptide comprises a short sequence that mediates the co-translational self-cleavage of the upstream and downstream peptides from the 2A site, allowing two different proteins to be produced from a single transcript in equimolar amounts. CHYSEL is a non-limiting example of a 2A peptide that causes the eukaryotic ribosome of the translation to release the growing polypeptide chain, the synthesis of which does not need to dissociate from the mRNA. The ribosome continues to translate, thereby producing a second polypeptide.

[0312] Expression vectors can include viral vectors or non-viral vectors. Viral vectors can be derived from adeno-associated virus (AAV), adenovirus, herpes virus, vaccinia virus, poliovirus, poxvirus, retrovirus (including lentivirus, such as HIV-1 and HIV-2), Sindbis and other RNA viruses, alphavirus, astrovirus, coronavirus, orthomyxovirus, papovavirus, paramyxovirus, parvovirus, picornavirus, togavirus, etc. Non-viral vectors are simply "naked" expression vectors that are not packaged with virus-derived components (such as capsid and / or envelope).

[0313] In some cases, these vectors can be engineered to target certain diseases or cell populations by using targeting features inherent to or engineered into viral vectors. Specific cells can be "targeted" for both delivery of polynucleotides and expression. Thus, in this context, the term "targeting" can be based on the use of endogenous or heterologous binding agents in the form of capsids, envelope proteins, antibodies for delivery to specific cells, the use of tissue-specific regulatory elements that limit expression to a specific subset of cells, or both.

[0314] In some embodiments, expression of the antibody chain is under the control of a regulatory element such as a tissue-specific or ubiquitous promoter. In some embodiments, a ubiquitous promoter such as the CMV promoter, the CMV-chicken β-actin hybrid (CAG) promoter, a tissue-specific or tumor-specific promoter is used to control expression of a specific antibody heavy or light chain or single chain derivative thereof.

[0315] Non-viral expression vectors can be used for non-viral gene transfer, either by direct injection of naked DNA or by encapsulating polynucleotides encoding checkpoint regulator antagonists in liposomes, microparticles, microcapsules, virus-like particles, or red blood cell ghosts. Such compositions can be further linked to targeting domains by chemical conjugation to facilitate targeted delivery and / or delivery of nucleic acids into desired target cells. In addition, plasmid vectors can be incubated with synthetic gene transfer molecules such as polymeric DNA-binding cations such as polylysine, protamine, and albumin, and linked to cell targeting ligands such as non-sialomycin, insulin, galactose, lactose, or transferrin.

[0316] Alternatively, naked DNA can be used. The uptake efficiency of naked DNA can be improved by compaction or by using biodegradable latex beads. This delivery can be further improved by treating the beads to increase hydrophobicity and thereby promote the destruction of endosomes and release of DNA into the cytoplasm.

[0317] Methods for producing monospecific or multispecific antibodies

[0318] In another aspect, the present application provides a host cell transformed with an anti-TIGIT, anti-PD-1 and / or anti-PD-L1 HCVR and / or LCVR encoding nucleic acid or expression vector. The host cell can be a bacterial or eukaryotic cell capable of expressing an anti-TIGIT, anti-PD-1 and / or anti-PD-L1 HCVR and / or LCVR encoding nucleic acid or expression vector or any other co-administered antibody or antagonist described herein.

[0319] In another aspect, a method for producing a checkpoint regulator antagonist comprises culturing host cells transformed with one or more anti-TIGIT, anti-PD-1 and / or anti-PD-L1 HCVR and / or LCVR encoding nucleic acids or expression vectors under conditions that allow for the production of antibodies or fragments, and purifying the antibodies from the cells.

[0320] In another aspect, the present application provides a method for producing antibodies, comprising: culturing cells that transiently or stably express one or more constructs encoding one or more polypeptide chains in the antibody; and purifying the antibody from the cultured cells. Any cell capable of producing functional antibodies can be used. In a preferred embodiment, the antibody-expressing cells are of eukaryotic or mammalian origin, preferably human cells. Cells from various tissue cell types can be used to express antibodies. In other embodiments, the cells are yeast cells, insect cells, or bacterial cells. Preferably, the antibody-producing cells are stably transformed with a vector expressing the antibody.

[0321] One or more expression vectors encoding the antibody heavy or light chain can be introduced into the cell by any conventional method, for example, by naked DNA technology, cationic lipid-mediated transfection, polymer-mediated transfection, peptide-mediated transfection, viral-mediated infection, physical or chemical reagents or treatment, electroporation, etc. In addition, the cell can be transfected with one or more expression vectors for expressing the antibody together with a selectable marker that promotes the selection of stably transformed clones expressing the antibody. The antibodies produced by these cells can be collected and / or purified according to techniques known in the art, for example, by centrifugation, chromatography, etc.

[0322] Examples of selectable markers suitable for use in mammalian cells include: dihydrofolate reductase (DHFR), thymidine kinase, neomycin, the neomycin analog G418, hydromycin, and puromycin. When such a selectable marker is successfully transferred into a mammalian host cell, the transformed mammalian host cell can survive if placed under selective pressure. There are two different classes of selectivity systems that are widely used. The first class is based on the metabolism of the cell and uses mutant cell lines that lack the ability to grow independently of a supplemented medium. Two examples are CHO DHFR - Cell and mouse LTK - Cells. These cells lack the ability to grow without supplemented nutrients such as thymidine or hypoxanthine. Because these cells lack certain genes necessary for the complete nucleotide synthesis pathway, they cannot survive unless the missing nucleotides are provided in a supplemented medium. An alternative to supplementing the medium is to introduce the intact DHFR or TK gene into cells lacking the corresponding gene, thereby changing their growth requirements. Individual cells that have not been transformed with the DHFR or TK gene will not survive in non-supplemented medium.

[0323] The second category is dominant selection, which refers to selection schemes used in any cell type and does not require the use of mutant cell lines. These schemes typically use drugs to prevent the growth of host cells. Those cells with the new gene will express proteins that convey drug resistance and will survive the selection. Examples of this type of dominant selection are the use of the drugs neomycin, mycophenolic acid, or hygromycin. These three examples use bacterial genes under the control of eukaryotic cells to convey tolerance to the appropriate drugs G418 or neomycin (Geneticin), xgpt (mycophenolic acid), or hygromycin, respectively. Others include the neomycin analog G418 and puromycin.

[0324] Exemplary antibody-expressing cells include human Jurkat, human embryonic kidney (HEK) 293, Chinese hamster ovary (CHO) cells, mouse WEHI fibrosarcoma cells, and single-cell protozoan species, such as Leishmania tarentolae. Additionally, primary cells immortalized by c-myc or other immortalizing agents can be used to produce stably transformed antibody-producing cell lines.

[0325] In one embodiment, the cell line comprises a stably transformed Leishmania cell line, such as Leishmania. Leishmania is well known to provide a robust, rapidly growing single-cell host for high-level expression of eukaryotic proteins that exhibit mammalian-type glycosylation patterns. Commercially available Leishmania eukaryotic expression kits are available (JenaBioscience GmbH, Jena, Germany).

[0326] In some embodiments, the cell line expresses at least 1 mg, at least 2 mg, at least 5 mg, at least 10 mg, at least 20 mg, at least 50 mg, or at least 100 mg of antibody per liter of culture.

[0327] In any suitable culture medium such as RPMI, DMEM and AIM After culture and maintenance, the antibodies in the present application can be separated from the antibody expressing cells. Conventional protein purification methods (such as affinity purification, chromatography, etc.) can be used to purify antibodies, including the use of protein A or protein-G immunoaffinity purification. In some embodiments, the antibodies are engineered to be secreted into the culture supernatant to be separated therefrom.

[0328] Pharmaceutical compositions and methods of treatment

[0329] Another aspect of the present application relates to pharmaceutical compositions and methods for treating cell proliferative disorders (such as cancer, chronic infection or immunocompromised disease states). In one embodiment, the pharmaceutical composition includes the checkpoint regulator antagonist of the present application. In some embodiments, the checkpoint regulator antagonist includes anti-TIGIT antibodies, anti-PD-1 antibodies, anti-PD-L1 antibodies, bispecific checkpoint regulator antagonists, trispecific checkpoint regulator antagonists or its antigen binding fragment as described herein, which are formulated together with a pharmaceutically acceptable carrier. Such a composition may include one or more different antibodies, one or more multispecific antibodies, one or more immunoconjugates or a combination thereof as described herein.

[0330] As described above, the methods of using the pharmaceutical compositions described herein comprise administering to a subject in need thereof an effective amount of a pharmaceutical composition according to the present disclosure.

[0331] Any suitable route or mode of administration can be used to provide a therapeutically or prophylactically effective dose of an antibody or antagonist to a patient. Exemplary routes or modes of administration include parenteral (e.g., intravenous, intraarterial, intramuscular, subcutaneous, intratumoral), oral, topical (nasal, transdermal, intradermal, or intraocular), mucosal (e.g., nasal, sublingual, oral, rectal, vaginal) inhalation, intralymphatic, intraspinal, intracranial, intraperitoneal, intratracheal, intravesical, intrathecal, intestinal, intrapulmonary, intralymphatic, intravascular, intraorbital, intracapsular, and transurethral, ​​as well as local delivery by catheter or stent.

[0332] Pharmaceutical compositions comprising antibodies or antagonists according to the present disclosure can be formulated in any pharmaceutically acceptable carrier or excipient. As used herein, the term "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic agents, and absorption delaying agents that are physiologically compatible. Pharmaceutical compositions can include suitable solid or gel phase carriers or excipients. Exemplary carriers or excipients include, but are not limited to, calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycol. Exemplary pharmaceutically acceptable carriers include one or more of water, saline, phosphate buffered saline, dextrose, glycerol, ethanol, and the like, and combinations thereof. In many cases, it is preferred to include an isotonic agent, such as a sugar, a polyol such as mannitol, sorbitol, or sodium chloride in the composition. Pharmaceutically acceptable carriers can further include a small amount of auxiliary substances, such as a wetting agent or emulsifier, a preservative, or a buffer, which increases the shelf life or effectiveness of the therapeutic agent.

[0333] Checkpoint regulator antagonists can be introduced into pharmaceutical compositions suitable for parenteral administration. Suitable buffers include but are not limited to sodium succinate, sodium citrate, sodium phosphate or potassium phosphate. Sodium chloride can be used to change the toxicity of solutions with a concentration of 0-300mM (optimally 150mM for liquid dosage forms). Cryoprotectants can be included for lyophilized dosage forms, mainly 0-10% sucrose (optimally 0.5-1.0%). Other suitable cryoprotectants include trehalose and lactose. Fillers can be included for lyophilized dosage forms, mainly 1-10% mannitol (optimally 2-4%). ​​Stabilizers can be used for liquid and lyophilized dosage forms, mainly 1-50mM L-methionine (optimally 5-10mM). Other suitable fillers include glycine, arginine, and can include 0-0.05% polysorbate-80 (optimally 0.005-0.01%). Additional surfactants include but are not limited to polysorbate 20 and BRIJ surfactants.

[0334] Therapeutic checkpoint regulator antagonist formulations can be lyophilized and stored as a sterile powder, preferably under vacuum, and then reconstituted in bacteriostatic water (containing, for example, benzyl alcohol preservative) or in sterile water before injection. The pharmaceutical composition can be formulated for parenteral administration by injection, for example, by bolus injection or continuous infusion.

[0335] The therapeutic agent in the pharmaceutical composition can be formulated in a "therapeutically effective amount" or a "prophylactically effective amount." A "therapeutically effective amount" refers to an amount effective to achieve the desired therapeutic outcome at the dosage and time period necessary. The therapeutically effective amount of the recombinant vector can vary depending on the condition to be treated, the severity and course of the condition, the mode of administration, whether the antibody or agent is being administered for preventive or therapeutic purposes, the bioavailability of the particular agent, the ability of the checkpoint regulator antagonist to elicit a desired response in the individual, previous therapy, the patient's age, weight, and sex, the patient's clinical history and response to the antibody, the type of checkpoint regulator antagonist used, the considerations of the attending physician, and the like. A therapeutically effective amount is also an amount in which any toxic or deleterious effects of the recombinant vector outweigh the beneficial effects of the treatment. A "prophylactically effective amount" refers to an amount effective to achieve the desired prophylactic outcome at the dosage and time period necessary.

[0336] Preferably, the polypeptide domains in the checkpoint regulator antagonists are derived from the same host to which they will be administered, so as to reduce the inflammatory response to the administered therapeutic agent.

[0337] The checkpoint regulator antagonist is suitably administered to the patient at one time or over a series of treatments and can be administered to the patient at any time from diagnosis. The checkpoint regulator antagonist can be administered as a monotherapy or in combination with other drugs or therapies useful for treating the disease.

[0338] As a general suggestion, a therapeutically or prophylactically effective amount of a checkpoint regulator antagonist will be administered in the range of about 1 ng / kg body weight / day to about 100 mg / kg body weight / day, whether by one or more administrations.In a specific embodiment, each checkpoint regulator antagonist is administered in a range of about 1 ng / kg body weight / day to about 10 mg / kg body weight / day, about 1 ng / kg body weight / day to about 1 mg / kg body weight / day, about 1 ng / kg body weight / day to about 100 μg / kg body weight / day, about 1 ng / kg body weight / day to about 10 μg / kg body weight / day, about 1 ng / kg body weight / day to about 1 μg / kg body weight / day, about 1 ng / kg body weight / day to about 100 ng / kg body weight / day, about 1 ng / kg body weight / day to about 10 ng / kg body weight / day, about 10 ng / kg body weight / day to about 100 mg / kg body weight / day, about 10 ng / kg body weight / day to about 10 mg / kg body weight / day, about 10 ng / kg body weight / day to about 1 mg / kg body weight / day, about 10 ng / kg body weight / day to about 100 μg / kg body weight / day, about 10 ng / kg body weight / day to about 10 μg / kg body weight / day, about 10 ng / kg body weight / day to about 1 μg / kg body weight / day, 10 ng / kg body weight / day to about 100 ng / kg body weight / day, about 100 ng / kg body weight / day to about 100 mg / kg body weight / day, about 100 ng / kg body weight / day to about 10 mg / kg body weight / day, about 100 ng / kg body weight / day to about 1 mg / kg body weight / day, about 10 0ng / kg body weight / day to about 100μg / kg body weight / day, about 100ng / kg body weight / day to about 10μg / kg body weight / day, about 100ng / kg body weight / day to about 1μg / kg body weight / day, about 1μg / kg body weight / day to about 100mg / kg body weight / day, about 1μg / kg body weight / day to about 10mg / kg body weight / day, about 1μg / kg body weight about 1mg / kg body weight / day, about 1μg / kg body weight / day to about 100μg / kg body weight / day, about 1μg / kg body weight / day to about 10μg / kg body weight / day, about 10μg / kg body weight / day to about 100mg / kg body weight / day, about 10μg / kg body weight / day kg body weight / day to about 10 mg / kg body weight / day, about 10 μg / kg body weight / day to about 1 mg / kg body weight / day, about 10 μg / kg body weight / day to about 100 μg / kg body weight / day, about 100 μg / kg body weight / day to about 100 mg / kg body weight / day, about 100 μg / kg body weight / day to about 10 mg / kg body weight / day, about 100 μg / kg body weight / day to about 10 mg / kg body weight / day, about 100 μg / kg body weight / day to about 1 mg / kg body weight / day, about 1 mg / kg body weight / day to about 100 mg / kg body weight / day, about 1 mg / kg body weight / day to about 10 mg / kg body weight / day, about 10 mg / kg body weight / day to about 100 mg / kg body weight / day.

[0339] In other embodiments, the checkpoint regulator antagonist is administered at a dose of 500 μg to 20 g every three days, or 25 mg / kg body weight every three days.

[0340] In other embodiments, each checkpoint regulator antagonist is administered in a range of about 10 ng to about 100 ng per subject, about 10 ng to about 1 μg per subject, about 10 ng to about 10 μg per subject, about 10 ng to about 100 μg per subject, about 10 ng to about 100 μg per subject, about 10 ng to about 1 mg per subject, about 10 ng to about 10 mg per subject, about 10 ng to about 10 mg per separate administration, about 10 ng to about 100 mg per single administration, about 10 ng to about 1000 mg per injection, about 10 ng to about 10,000 mg per subject, about 100 ng to about 1 μg per subject. , about 100 ng to about 10 μg is administered per subject, about 100 ng to about 100 μg is administered per subject, about 100 ng to about 1 mg is administered per subject, about 100 ng to about 10 mg is administered per subject, about 100 ng to about 100 mg is administered per subject, about 100 ng to about 1000 mg is administered per injection, about 100 ng to about 10,000 mg is administered per subject, about 1 μg to about 10 μg is used per subject, about 1 μg to about 100 μg is administered per subject, about 1 μg to about 100 μg is administered per subject, about 1 μg to about 10 mg is administered per subject, about 1 μg to about 100 mg is administered per subject, 1 μg to about 100 mg is administered per subject , about 1 μg to about 1000 mg per injection, about 1 μg to about 10,000 mg per subject, about 10 μg to about 100 μg per subject, about 10 μg to about 1 mg per subject, about 10 μg to about 10 mg per subject, about 10 μg to about 100 mg per subject, about 10 μg to about 1000 mg per injection, about 10 μg to about 10,000 mg per subject, about 100 μg to about 1 mg per subject, about 100 μg to about 10 mg per subject, about 100 μg to about 1000 mg per injection g, about 100 μg to about 10,000 mg per subject, about 1 mg to about 10 mg per subject, about 1 mg to about 100 mg per subject, about 1 mg to about 1000 mg per injection, about 1 mg to about 10,000 mg per subject, about 10 mg to about 100 mg per injection, about 10 mg to about 10,000 mg per subject, about 100 mg to about 1000 mg per injection, about 10 mg to about 10,000 mg per subject, about 100 mg to about 10,000 mg per injection, about 100 mg to about 10,000 mg per subject, and about 1000 mg to about 10,000 mg per subject. Checkpoint regulator antagonists can be administered daily every 2, 3, 4, 5, 6, or 7 days or every 1, 2, 3, or 4 weeks.

[0341] In other embodiments, the amount of the checkpoint regulator antagonist can be administered at a dose of about 0.0006 mg / day, 0.001 mg / day, 0.003 mg / day, 0.006 mg / day, 0.01 mg / day, 0.03 mg / day, 0.06 mg / day, 0.1 mg / day, 0.3 mg / day, 0.6 mg / day, 1 mg / day, 3 mg / day, 6 mg / day, 10 mg / day, 30 mg / day, 60 mg / day, 100 mg / day, 300 mg / day, 600 mg / day, 1000 mg / day, 2000 mg / day, 5000 mg / day or 10,000 mg / day. As expected, the dosage will depend on the patient's condition, size, age, and condition.

[0342] In certain embodiments, the coding sequence of the checkpoint regulator antagonist is introduced into a suitable expression vector (e.g., a viral or non-viral vector) for expressing an effective amount of the checkpoint regulator antagonist in a patient suffering from a cell proliferative disorder. In certain embodiments comprising administering, for example, one or more recombinant AAV (rAAV) viruses, the pharmaceutical composition may include rAAV in an amount comprising at least 10 10 , at least 10 11 , at least 10 12 , at least 10 13 , or at least 10 14 genome copies (GC) or recombinant virus particles per kilogram, or any range thereof. In certain embodiments, the pharmaceutical composition comprises an effective amount of a recombinant virus, such as rAAV, in an amount comprising at least 10 11 , at least 10 12 , at least 10 13 , at least 10 14 , at least 10 15 genome copies or recombinant viral particles per subject, or any range thereof.

[0343] Doses can be tested in several art-accepted animal models applicable to any particular cell proliferative disorder.

[0344] Delivery methodologies can also include the use of polycationic condensed DNA linked or not to killed viruses, ligand-linked DNA, liposomes, eukaryotic cell delivery vector cells, deposition of photopolymerizable hydrogel materials, use of handheld gene transfer particle guns, ionizing radiation, nuclear charge neutralization or fusion with cell membranes, particle-mediated gene transfer, and the like.

[0345] The present invention is further illustrated by the following examples, which should not be construed as limiting.The contents of all references, patents and published patent applications, as well as the figures and tables cited throughout this application are incorporated herein by reference.

[0346] Example

[0347] Example 1: Production of monoclonal antibodies

[0348] The monoclonal antibodies (mAbs) of the present invention are generated and screened using techniques well known in the art, see, for example, Harlow and Lane (1988) Antibodies, A Laboratory Manual, Cold Spring Harbor Press, New York. Antigen-specific hybridoma monoclonal antibodies are cloned, sequenced, and engineered using techniques well known in the art, see, for example, Lo. BKC Methods in Molecular Biology. TM , Volume 248 2004 Antibody Engineering (Methods in Molecular Biology TM .Volume 248 2004.Antibody Engineering).

[0349] Example 2: TIGIT Adhesive Screening Assay

[0350] The membranes were coated with 1 μg / ml TIGIT-His protein overnight at 4°C and blocked with 1% BSA in PBS for 1 hour at room temperature. The membranes were then incubated with 50 μl of hybridoma supernatant for 1 hour at room temperature. Mouse IgG was detected with anti-mouse IgG HRP for 30 minutes. TMB substrate was then added and the reaction was terminated by the addition of 2N HSO. Wells with an OD value at least 5 times that of background were selected as positive binders.

[0351] Example 3: TIGIT Blocker Screening Assay

[0352] 3 × 10 4 TIGIT+CHO-K1 cells were incubated in 50 μl of hybridoma supernatant for 20 minutes, and then human PVR human Fc tag fusion protein was added to a final concentration of 0.6 μg / ml; after incubation at 4°C for 30 minutes, the cells were washed with FACS buffer (0.5% BSA, 2mM EMTA in PBS), and then the cells were incubated with 1 μg / ml PE-labeled anti-human Fc antibody at 4°C for 20 minutes. The cells were then washed with FACS buffer and resuspended in 7-amino-actinomycin D (7AAD) solution and then analyzed using the iQue intellicyt system. Wells that completely blocked the binding of TIGIT and PVR (Fc tag) were selected as blockers. In the first screening, 18 blockers were identified from 65 binders. In the second screening, 17 blockers were identified from 30 binders. Figure 1 Exemplary results of competition assays with various mouse anti-TIGIT monoclonal antibodies are shown.

[0353] Example 4: Anti-TIGIT Monoclonal Antibody Blocking / IC50 Determination

[0354] CHO-K1 cells stably expressing human TIGIT were washed with FACS buffer (0.5% BSA, 2 mM EMTA in PBS) and cultured at 10 ^ 6 cells / ml. Biotinylated hPVR-mIg (catalog number: 555-030, Ancell) was added to the resuspended cells at 1 μg / ml; mixed well; 20,000 of these CHO-K1 cells (containing human CD155 / PVR protein) in 20 μl FACS buffer were added to a 96-well round-bottom plate without incubation; 20 μl of 2-fold serial dilutions of anti-human TIGIT monoclonal antibody were added to the cells and incubated at 4°C for 30 minutes. The cells were washed twice and then stained with PE streptavidin (BioLegend) for 20 minutes at 4°C. The cells were then washed, resuspended in 30 μl of 7AAD solution, and 35 μl of 10% neutral buffered formalin solution was added. The cells were then incubated for 15 minutes. Flow cytometry was performed and the IC50 was calculated using the iQueintellicyt system. Table 2 shows the IC50s of various anti-hu TIGIT monoclonal antibodies. Table 3 shows the binding constants of several anti-hu TIGIT monoclonal antibodies.

[0355] Table 2

[0356]

[0357]

[0358] Table 3

[0359]

[0360] Example 5: Anti-TIGIT Monoclonal Antibody Binding Assay

[0361] Figure 6Binding of anti-TIGIT mouse monoclonal antibodies to cells expressing full-length human TIGIT (hu TIGIT) is shown. Briefly, serial dilutions of anti-TIGIT monoclonal antibodies were added to CHO-K1 cells (20,000 cells / well) overexpressing human or canine (cyno) TIGIT. The mixture was incubated at 4°C for 20 minutes and washed three times. The mixture was stained with a secondary antibody (PE-labeled F(ab')2-goat anti-human IgG Fc (ThermoH10104)) at 4°C for 20 minutes. The cells were washed and resuspended in 7AAD solution and fixed with 10% neutral buffered formalin solution for 15 minutes before analysis with the iQue Intellicyt system.

[0362] Example 6: Anti-TIGIT monoclonal antibodies block the interaction between huTIGIT and its ligand

[0363] The ability of anti-TIGIT monoclonal antibodies to block the interaction between huTIGIT and its ligand, human PVR (CD155), was evaluated using the cell-based blocking assay described in Example 4. The results of this assay are shown in Figure 7 middle.

[0364] Example 7: Human T cell assay using PBMC from normal donors and PVR signaling from pre-coated PVR-mIgG

[0365] Two human T cell assays were performed to demonstrate the functionality of anti-TIGIT antibodies. Briefly, normal healthy human PBMCs were activated for 5 to 7 days with SEB (Toxin Technology, catalog number: BT202) or anti-CD3 + anti-CD28 in 6-well plates with PBMCs expressing high levels of TIGIT. 96-well flat-bottom plates were coated overnight at 4°C with hu PVR / CD155 mouse IgG2a Fc tag (ACROBiosystems).

[0366] To measure IFN-γ production, 100,000 cells were plated into pre-coated wells and restimulated with 0.5 μg / ml Staphylococcal enterotoxin B (SEB). 66 μg / ml of anti-TIGIT monoclonal antibody or isotype control antibody (Ab) was added. After 3 to 5 days, IFN-γ was detected in the supernatant by ELISA. Figure 8 Anti-TIGIT monoclonal antibodies were shown to induce IFN-γ production from human PBMCs.

[0367] To determine T cell proliferation, 100,000 cells labeled with CellTrace Far Red were plated into pre-coated wells and restimulated with 0.5ug / ml SEB. 66ug / ml of anti-TIGIT or isotype-matched control antibody was added to wells coated with human CD155 / PVR. The total volume per well was 200μl. The plates were incubated at 37°C. 4 or 5 days after stimulation, PBMC cells were stained with FITC-labeled anti-human CD3 Ab (BioLegend) and analyzed using the iQue intellicyt system. The T cell proliferation index was calculated based on the decrease in the MFI (mean fluorescence intensity) of the CellTrace Far Red signal on gated CD3+ T cells. Figure 9 As shown, the results of this assay showed that anti-TIGIT monoclonal antibodies induced T cell proliferation.

[0368] Example 8: Binding of anti-TIGIT monoclonal antibodies to hu TIGIT and cyno-hu TIGIT

[0369] Figure 10A Binding of anti-TIGIT monoclonal antibodies to hu TIGIT and cyno-hu TIGIT using the binding assay described in Example 5 is shown. Figure 10B Inhibition of antibody binding to huTIGIT and cyno-hu TIGIT by anti-TIGIT monoclonal antibodies was shown using the blocking assay described in Example 4.

[0370] Example 9: PD-1 binder screening assay

[0371] Wells were coated with 1 μg / ml of huPD-1-His protein overnight at 4°C and blocked with 1% BSA in PBS for 1 hour at room temperature. The wells were then incubated with 50 μl of hybridoma supernatant for 1 hour at room temperature. Mouse IgG was detected by incubating the wells with anti-mouse IgG HRP for 30 minutes, adding TMB substrate, and stopping the reaction with 2N sulfuric acid. Wells with an OD450 value at least 5 times background were selected as positive binders.

[0372] Example 10: PD-1 Blocker Screening Assay

[0373] 3×10 4Each huPD1+CHO-K1 cell was incubated in 50 μl of hybridoma supernatant at 4 ° C for 20 minutes, and then human PD-L1 human Fc tag fusion protein was added to a final concentration of 0.6 μg / ml. After incubation at 4 ° C for 30 minutes, the cells were washed with FACS buffer (0.5% BSA, 2mM EMTA in PBS) and then incubated with 1 μg / ml PE-labeled anti-human Fc antibody at 4 ° C for 20 minutes. The cells were then washed with FACS buffer and resuspended in 7AAD solution before analysis using the iQue intellicyt system. The wells that completely blocked the binding of PD-1 and PD-L1 (Fc tag) were selected as blockers.

[0374] Example 11: Anti-PD-1 Monoclonal Antibody Blocking / IC 50 Determination

[0375] Blocking assays were performed to calculate the IC 50 of the selected anti-PD-1 antibodies. Briefly, 2- or 3-fold serial dilutions of anti-human PD-1 monoclonal antibodies or bispecific Abs were prepared (highest Ab concentration: 128 nM; triplicates for each monoclonal antibody). CHO-K1 cells transfected with human or canine PD-1 were washed with FACS buffer (0.5% BSA 2 mM EDTA in PBS) and incubated for 10 min. 6 The cells were resuspended at a concentration of 1 μg / ml. FITC-labeled human PD-L1-Fc protein was added to human or canine PD-1 transfected CHO-K1 cells at a final concentration of 7 μg / ml and mixed thoroughly. Without incubation, 2000 of these CHO-K1 cells (with PD-L1 protein) in 20 μl FACS buffer were immediately added to a 96-well round-bottom culture plate, and 20 μl or 2- or 3-fold serial dilutions of anti-human PD-1 monoclonal antibody were immediately added to the cells and incubated at 4 ° C for 30 minutes. The cells were then washed and resuspended in 30 μl of 7AAD solution; then 35 μl of 10% neutral buffered formalin solution was added and incubated for 15 minutes before analysis using the iQue intellicyt system. Figure 11A 、 12A and 12B show results demonstrating the ability of several anti-PD-1 monoclonal antibodies to block the interaction between human PD-1 and human PD-L1. Figure 11B The ability of anti-PD-1 monoclonal antibodies to block the interaction between cyno huPD-1 and cyno PD-L1 was demonstrated.

[0376] Example 12: Anti-PD-1 Antibody / Kinetic Analysis by Biolayer Interferometry

[0377] Biointerferometry was performed using the Octet RED96 system (ForteBio Octet RED96 system) to characterize the binding kinetics of the antibody to the His-tagged human PD-1 protein. 20 nM of antibody was loaded onto the anti-human IgG capture biosensor. The binding of the analyte (His-tagged human PD-1 protein) was observed by placing the biosensor in a well containing 2 or 3-fold serial dilutions of the analyte (the highest concentration was 72 nM) for 5 minutes. Dissociation was measured after the biosensor was transferred to the kinetic buffer alone, and the interferometry signal was monitored for 10 minutes. The observed on and off rates (Ka and Kd) were fitted using a 1:1 binding global fitting model containing at least 5 test concentrations, and the equilibrium binding constant K was then calculated. D . Figure 13A -C shows the PD-01 monoclonal antibody ( Figure 13A ), PD-02 monoclonal antibody ( Figure 13B ) and benchmark (BM) anti-PD-1 mAb ( Figure 13C ) binding affinity.

[0378] Example 13: Enhanced IFN-γ Production Using Anti-PD-1 Monoclonal Antibodies Alone or in Combination with Anti-TIGIT Monoclonal Antibodies

[0379] To demonstrate the ability of anti-PD-1 antibodies to induce IFN-γ production, 100,000 normal healthy human PBMCs were activated with SEB (Toxin Technologies). H358 cancer cell lines were added to provide PD-L1 ligand signaling. 10 μg / ml of anti-PD-1 monoclonal antibody or isotype control antibody was added. After 3 days, IFN-γ in the supernatant was measured by ELISA. Figure 14 Enhancement of IFN-γ production by human PBMCs by the depicted anti-PD-1 monoclonal antibodies is shown. Figure 15 and 16B The combination of anti-TIGIT (T-08) and anti-PD-1 (PD-01) monoclonal antibodies was shown to further increase IFN-γ production from human PBMCs relative to the levels of anti-PD-1 antibody alone.

[0380] Example 14: Enhanced T cell proliferation using anti-PD-1 monoclonal antibodies alone or in combination with anti-TIGIT monoclonal antibodies

[0381] To evaluate the ability of anti-PD-1 antibodies to induce T cell proliferation, an assay similar to that described in Example 7 was performed except that the H358 cancer cell line was added to provide a PD-L1 ligand signal. Figure 16A and 16B showed increased proliferation of human T cells by a combination of anti-TIGIT and anti-PD-1 monoclonal antibodies.

[0382] Example 15: Screening assay for selecting bispecific antibodies

[0383] Figure 19A -D shows the method for identifying cells that can block PD-1 binding ( Figure 19A 、 Figure 19B ) and TIGIT ( Figure 19C 、 Figure 19D These screening assays employed the IC50 blocking assays described in Examples 6 and 11. Antibody constructs that demonstrated effective binding are shown in FIG17 .

[0384] Example 16: Expression and functional evaluation of bispecific antibodies

[0385] The blocking assay in Example 11 was used to calculate the IC50s for three exemplary bispecific checkpoint modulator antagonists, TP-83, TP-92, and TP-93. Figure 20A -B shows that these bispecific checkpoint regulator antagonists block the binding of PD-L1 to PD-1 ( Figure 20A ) and blocks the ability of PVR to bind to TIGIT ( Figure 20B ). These figures further show that blocking the binding of PD-L1 to PD-1 ( Figure 20A ) and the calculated IC50 for blocking the binding of PVR to TIGIT ( Figure 20B ). FIG21 shows a Coomasie-stained gel demonstrating the production of bispecific antibodies TP-83, TP-92, and TP-93.

[0386] Example 17: Exemplary Size Exclusion Chromatography (SEC) Profiles of Bispecific Checkpoint Modulator Antagonists

[0387] Figure 22 An exemplary SEC profile of an exemplary bispecific checkpoint regulator antagonist after one-step purification is shown. Briefly, 20 μg of sample (TP-93 or TP-83) was loaded onto a Zenix SEC-300 column (3 μm, 7.8×300mm). The mobile phase (150mM sodium phosphate, pH 7.0) was delivered at a flow rate of 0.80mL / min. UV absorbance was monitored at 280nm. The main peak represents the desired product (86% for TP-93 and 74% for TP-83). The secondary peak represents incorrectly aggregated or assembled products. This analysis emphasizes the manufacturability of the bispecific checkpoint regulator antagonist according to the present application.

[0388] Example 18: Increasing upregulation of IFN-γ production by bispecific checkpoint regulator antagonists

[0389] To evaluate the ability of a bispecific checkpoint regulator antagonist (TP-93) to induce T cell proliferation compared to monospecific anti-TIGIT (T-08) and anti-PD-1 (PD-01) monoclonal antibodies, a CMV antigen-specific recall assay was performed. Briefly, PBMCs (donor 333 and donor 287) from pre-screened CMV antigen reactivity of individual donors were purchased from Astarte Biologics. Cell lysates from CMV-infected cells (used as CMV antigens) were also purchased from Astarte Biologics. 1) For IFN-g production: 250,000 PBMCs were plated and antigen-specifically stimulated by adding 0.1 μg / ml of CMV Ag, which stimulates CMV-reactive T cells. SHP-77 cells were co-cultured with PBMCs to provide an immune function suppressive environment. IgG4 control, anti-TIGIT Ab, anti-PD-1 Ab, anti-TIGIT Ab plus anti-PD-1 Ab, and bispecific Ab were added to each plate, respectively. After 5 days, the supernatant was checked for IFN-γ production by ELISA. 2) For T cell proliferation, 250,000 PBMCs were plated and activated with 0.1 μg / ml CMV Ag for 2 days and then labeled with CellTrace Far Red. 100,000 labeled PBMCs were then re-plated and restimulated with 1 μg / ml CMV Ag. 128nM IgG4 control, anti-TIGIT Ab, anti-PD-1Ab, anti-TIGIT Ab plus anti-PD-1 Ab, or bispecific Ab were added to each plate, respectively. The total volume per well was 200 μl. The plates were incubated at 37°C. 5 days after stimulation, PBMC cells were stained with PE-labeled anti-human CD4 Ab (BioLegend) and analyzed by the iQueintellicyt system. The T cell proliferation index was calculated based on the reduction in the mean fluorescence intensity (MFI) of the CellTrace Far Red signal on gated CD4+ T cells. 3) T cell surface expression of TIGIT and PD-1 was detected by FACS on day 5 using APC-labeled anti-human CD3, PE-labeled anti-TIGIT, and FITC-labeled anti-PD-1 antibodies (data not shown).

[0390] Figure 23A and 23B We showed that the bispecific checkpoint regulator antagonist TP-93 showed better efficacy than monospecific anti-TIGIT (T-08) and anti-PD-1 (PD-01) mAbs alone or using two different human PBMC cell populations (donor 333, Figure 23A ; Donor 287, Figure 23B ) combined with monospecific anti-TIGIT and anti-PD-1 antibodies to increase IFN-γ production to a greater extent. Figure 23C and 23D We show that the bispecific checkpoint regulator antagonist TP-93 is more effective than monospecific anti-TIGIT (T-08) and anti-PD-1 (PD-01) antibodies alone or using two different human PBMC cell populations (donor 333, Figure 23C ; Donor 287, Figure 23D ) showed a higher T cell proliferation index in combination with monospecific anti-TIGIT and anti-PD-1 antibodies.

[0391] Example 19: Anti-TIGIT Antibody / Kinetic Analysis by Biolayer Interferometry

[0392] Octet RED96 system (ForteBio) was used to perform bio-interferometry to characterize the binding kinetics of antibodies against human TIGIT mouse IgG2a fusion protein (Acrobio). 40 nM antibody was loaded onto the anti-human IgG capture biosensor. The binding of the analyte (human TIGIT mouse IgG2a fusion protein) was observed by placing the biosensor in a hole containing 3-fold serial dilutions of the analyte (maximum concentration of 50 nM) for 5 minutes and the dissociation was measured after the biosensor was transferred to the kinetic buffer alone, and the interference measurement signal was monitored for 10 minutes. The observed on and off rates (Ka and Kd) were fitted using a 1:1 combined overall fitting model comprising at least 4 test concentrations, and the equilibrium binding constant KD was then calculated. Figures 24A-24C Shown are the binding kinetics of antibodies T-08, T-10, and a benchmark (BM) anti-TIGIT monoclonal antibody.

[0393] The above description is intended to teach one skilled in the art how to implement the present invention and is not intended to detail all such obvious modifications and variations that would become apparent to one skilled in the art upon reading the specification. However, all such obvious modifications and variations are intended to be included within the scope of the present invention as defined by the following claims. The claims are intended to cover the claimed components and steps in any order that effectively achieve their intended purpose unless the context specifically indicates otherwise. Sequence Listing <110> GENSUN BIOPHARMA INC. <120> Checkpoint regulator antagonists <130> 2022-002 US <150> US 15 / 858,963 <151> 2017-12-29 <160> 192 <170> PatentIn version 3.5 <210> 1 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Synthetic: HCDR1; TIGIT <400> 1 Ser Asp Tyr Ala Trp Asn 1 5 <210> 2 <211> 16 <212> PRT <213> Artificial sequence <220> <223> Synthetic: HCDR2; TIGIT <400> 2 Tyr Ile Ser Tyr Ser Gly Ser Thr Gly Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 3 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic: HCDR3; TIGIT <400> 3 Arg Met Ile Gly Tyr Ala Met Asp Tyr 1 5 <210> 4 <211> 17 <212> PRT <213> Artificial sequence <220> <223> Synthetic: HCDR2; TIGIT <400> 4 Tyr Ile Thr Tyr Ser Gly Gly Ser Thr Ser Tyr Asn Pro Ser Leu Lys 1 5 10 15 Ser <210> 5 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic: HCDR3; TIGIT <400> 5 Arg Gln Ile Gly Leu Gly Phe Thr Tyr 1 5 <210> 6 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Synthetic: HCDR1; TIGIT <400> 6 Asp His Thr Ile His 1 5 <210> 7 <211> 17 <212> PRT <213> Artificial sequence <220> <223> Synthetic: HCDR2; TIGIT <400> 7 Tyr Phe Tyr Pro Arg Asp Gly Ser Thr Lys Tyr Asn Glu Lys Phe Lys 1 5 10 15 Gly <210> 8 <211> 8 <212> PRT <213> Artificial sequence <220> <223> Synthetic: HCDR3; TIGIT <400> 8 Gly Met Leu Arg Trp Phe Ala Asp 1 5 <210> 9 <211> 17 <212> PRT <213> Artificial sequence <220> <223> Synthetic: HCDR2; TIGIT <400> 9 Tyr Ile Tyr Pro Arg Asp Gly Ser Ser Lys Tyr Asn Val Lys Phe Lys 1 5 10 15 Gly <210> 10 <211> 8 <212> PRT <213> Artificial sequence <220> <223> Synthetic: HCDR3; TIGIT <400> 10 Gly Met Leu Arg Trp Phe Ala Tyr 1 5 <210> 11 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Synthetic: HCDR1; TIGIT <400> 11 Asp Gln Ala Ile His 1 5 <210> 12 <211> 17 <212> PRT <213> Artificial sequence <220> <223> Synthetic: HCDR2; TIGIT <400> 12 Tyr Ile Tyr Pro Arg Asp Gly Ser Thr Lys Tyr Asn Glu Thr Phe Lys 1 5 10 15 Gly <210> 13 <211> 16 <212> PRT <213> Artificial sequence <220> <223> Synthetic: HCDR2; TIGIT <400> 13 Tyr Ile Thr Tyr Ser Gly Ser Thr Ser Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 14 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic: HCDR3; TIGIT <400> 14 Arg Gln Val Gly Leu Gly Phe Ala Tyr 1 5 <210> 15 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Synthetic: HCDR1; TIGIT <400> 15 Ser Asp Ser Ala Trp Asn 1 5 <210> 16 <211> 16 <212> PRT <213> Artificial sequence <220> <223> Synthetic: HCDR2; TIGIT <400> 16 Tyr Ile Thr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Arg Ser 1 5 10 15 <210> 17 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Synthetic: HCDR1; TIGIT <400> 17 Asn Tyr Gly Met Asn 1 5 <210> 18 <211> 17 <212> PRT <213> Artificial sequence <220> <223> Synthetic: HCDR2; TIGIT <400> 18 Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe Lys 1 5 10 15 Gly <210> 19 <211> 12 <212> PRT <213> Artificial sequence <220> <223> Synthetic: HCDR3; TIGIT <400> 19 Ala Pro Pro Tyr Gly Tyr Asp Val Arg Phe Ala Tyr 1 5 10 <210> 20 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Synthetic: HCDR1; TIGIT <400> 20 Thr Phe Ala Met Gly Val Gly 1 5 <210> twenty one <211> 16 <212> PRT <213> Artificial sequence <220> <223> Synthetic: HCDR2; TIGIT <400> twenty one His Ile Trp Trp Asp Asp Asp Lys Tyr Tyr Asn Pro Ala Leu Lys Ser 1 5 10 15 <210> twenty two <211> 11 <212> PRT <213> Artificial sequence <220> <223> Synthetic: HCDR3; TIGIT <400> twenty two Met Asp Tyr Ser Tyr Phe Ala Trp Phe Ala Tyr 1 5 10 <210> twenty three <211> 5 <212> PRT <213> Artificial sequence <220> <223> Synthetic: HCDR1; TIGIT <400> twenty three Ser Tyr Tyr Met His 1 5 <210> twenty four <211> 16 <212> PRT <213> Artificial sequence <220> <223> Synthetic: HCDR2; TIGIT <400> twenty four Ile Asn Pro Ser Gly Gly Arg Thr Ser Tyr Ala Gln Met Phe Gln Gly 1 5 10 15 <210> 25 <211> 13 <212> PRT <213> Artificial sequence <220> <223> Synthetic: HCDR3; TIGIT <400> 25 Asp Arg Glu Glu Gln Trp Pro Val Gly Gly Phe Asp Tyr 1 5 10 <210> 26 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Synthetic: LCDR1; TIGIT <400> 26 Lys Ala Ser Gln Asp Val Ser Thr Val Val Ala 1 5 10 <210> 27 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Synthetic: LCDR2; TIGIT <400> 27 Ser Ala Ser Tyr Arg Tyr Thr 1 5 <210> 28 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic: LCDR3; TIGIT <400> 28 Gln Gln His Tyr Ser Thr Pro Trp Thr 1 5 <210> 29 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Synthetic: LCDR1; TIGIT <400> 29 Lys Ala Ser Gln Asp Leu Ser Thr Ala Val Ala 1 5 10 <210> 30 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Synthetic: LCDR2; TIGIT <400> 30 Ser Ser Ser Tyr Arg Tyr Thr 1 5 <210> 31 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Synthetic: LCDR1; TIGIT <400> 31 Lys Ala Ser Gln Asp Val Ser Thr Thr Val Ala 1 5 10 <210> 32 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic: LCDR3; TIGIT <400> 32 Gln Gln His Tyr Ser Thr Pro Leu Thr 1 5 <210> 33 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Synthetic: LCDR1; TIGIT <400> 33 Lys Ala Ser Gln Asp Val Phe Thr Ala Val Ala 1 5 10 <210> 34 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic: LCDR3; TIGIT <400> 34 Gln Gln His Tyr Ser Ile Pro Leu Thr 1 5 <210> 35 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Synthetic: LCDR1; TIGIT <400> 35 Lys Ala Ser Gln Asp Val Ser Thr Ala Val Ala 1 5 10 <210> 36 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Synthetic: LCDR2; TIGIT <400> 36 Ser Ala Ser Tyr His Tyr Thr 1 5 <210> 37 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Synthetic: LCDR2; TIGIT <400> 37 Ser Ala Ser Tyr Arg Phe Thr 1 5 <210> 38 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic: LCDR3; TIGIT <400> 38 Gln His His Tyr Ser Thr Pro Trp Thr 1 5 <210> 39 <211> 16 <212> PRT <213> Artificial sequence <220> <223> Synthetic: LCDR1; TIGIT <400> 39 Arg Ser Ser Gln Ser Ile Val His Ser Asn Gly Asn Thr Tyr Leu Glu 1 5 10 15 <210> 40 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Synthetic: LCDR2; TIGIT <400> 40 Lys Val Ser Asp Arg Phe Ser 1 5 <210> 41 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic: LCDR3; TIGIT <400> 41 Phe Gln Gly Ser His Val Pro Trp Thr 1 5 <210> 42 <211> 14 <212> PRT <213> Artificial sequence <220> <223> Synthetic: LCDR1; TIGIT <400> 42 Arg Ser Ser Thr Gly Ala Val Thr Thr Ser Asn Tyr Ala Asn 1 5 10 <210> 43 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Synthetic: LCDR2; TIGIT <400> 43 Gly Thr Asn Asn Arg Ala Pro 1 5 <210> 44 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic: LCDR3; TIGIT <400> 44 Ala Leu Trp Tyr Ser Asn His Trp Val 1 5 <210> 45 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Synthetic: LCDR1; TIGIT <400> 45 Arg Ala Ser Gln Ser Ile Arg Arg Tyr Leu Asn 1 5 10 <210> 46 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Synthetic: LCDR2; TIGIT <400> 46 Ser Ala Ser Asn Leu Gln Ser 1 5 <210> 47 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic: LCDR3; TIGIT <400> 47 Gln Gln Ser Tyr Ile Ile Pro Pro Thr 1 5 <210> 48 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Synthetic: HCDR1; PD-1 <400> 48 Asn Phe Leu Met Ser 1 5 <210> 49 <211> 17 <212> PRT <213> Artificial sequence <220> <223> Synthetic: HCDR2; PD-1 <400> 49 Thr Ile Ser Gly Gly Gly Arg Asp Thr Tyr Tyr Val Asp Ser Val Lys 1 5 10 15 Gly <210> 50 <211> 8 <212> PRT <213> Artificial sequence <220> <223> Synthetic: HCDR3; PD-1 <400> 50 Arg Thr Thr Tyr Ser Met Asp Tyr 1 5 <210> 51 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Synthetic: HCDR1; PD-1 <400> 51 Asn Ser Tyr Leu Tyr 1 5 <210> 52 <211> 17 <212> PRT <213> Artificial sequence <220> <223> Synthetic: HCDR2; PD-1 <400> 52 Gly Ile Asn Pro Ser Asn Gly Gly Thr Asn Phe Asn Glu Lys Phe Lys 1 5 10 15 Thr <210> 53 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Synthetic: HCDR3; PD-1 <400> 53 Arg Asp Tyr Asn Tyr Asp Gly Gly Phe Asp Ser 1 5 10 <210> 54 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Synthetic: HCDR1; PD-1 <400> 54 Asn Ser Tyr Ile Tyr 1 5 <210> 55 <211> 12 <212> PRT <213> Artificial sequence <220> <223> Synthetic: HCDR3; PD-1 <400> 55 Arg Arg Asp Tyr Arg Tyr Asp Gly Gly Phe Asp Ser 1 5 10 <210> 56 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Synthetic: HCDR1; PD-1 <400> 56 Thr Tyr Tyr Ile Tyr 1 5 <210> 57 <211> 17 <212> PRT <213> Artificial sequence <220> <223> Synthetic: HCDR2; PD-1 <400> 57 Gly Ile Asn Pro Gly Asn Gly Gly Thr Asn Phe Asn Glu Lys Phe Lys 1 5 10 15 Ile <210> 58 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Synthetic: HCDR3; PD-1 <400> 58 Arg Tyr His Gly Tyr Asp Gly Gly Leu Asp Tyr 1 5 10 <210> 59 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Synthetic: HCDR1; PD-1 <400> 59 Ser Tyr Tyr Ile His 1 5 <210> 60 <211> 17 <212> PRT <213> Artificial sequence <220> <223> Synthetic: HCDR2; PD-1 <400> 60 Trp Ile Phe Pro Gly Ser Gly Asn Ser Lys Tyr Asn Glu Asn Phe Lys 1 5 10 15 Gly <210> 61 <211> 13 <212> PRT <213> Artificial sequence <220> <223> Synthetic: HCDR3; PD-1 <400> 61 Ser Asp Tyr Gly Ser Ser Pro Tyr Tyr Tyr Phe Asp Tyr 1 5 10 <210> 62 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Synthetic: LCDR1; PD-1 <400> 62 Leu Ala Ser Gln Thr Ile Gly Thr Trp Leu Ala 1 5 10 <210> 63 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Synthetic: LCDR2; PD-1 <400> 63 Ala Ala Thr Ser Leu Ala Asp 1 5 <210> 64 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic: LCDR3; PD-1 <400> 64 Gln Gln Phe Tyr Ser Ile Pro Trp Thr 1 5 <210> 65 <211> 12 <212> PRT <213> Artificial sequence <220> <223> Synthetic: LCDR1; PD-1 <400> 65 Arg Ala Ser Ser Thr Leu Tyr Ser Asn Tyr Leu His 1 5 10 <210> 66 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Synthetic: LCDR2; PD-1 <400> 66 Arg Ala Ser Phe Leu Ala Ser 1 5 <210> 67 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic: LCDR3; PD-1 <400> 67 Gln Gln Gly Ser Ser Ile Pro Leu Thr 1 5 <210> 68 <211> 12 <212> PRT <213> Artificial sequence <220> <223> Synthetic: LCDR1; PD-1 <400> 68 Ser Ala Ser Ser Ser Leu Tyr Ser Ser Tyr Leu His 1 5 10 <210> 69 <211> 12 <212> PRT <213> Artificial sequence <220> <223> Synthetic: LCDR1; PD-1 <400> 69 Arg Ala Ser Ser Ser Leu Tyr Ser Asn Tyr Leu His 1 5 10 <210> 70 <211> 15 <212> PRT <213> Artificial sequence <220> <223> Synthetic: LCDR1; PD-1 <400> 70 Arg Ala Ser Lys Ser Val Ser Thr Ser Gly Phe Ser Tyr Ile His 1 5 10 15 <210> 71 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Synthetic: LCDR2; PD-1 <400> 71 Leu Ala Ser Asn Leu Glu Ser 1 5 <210> 72 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic: LCDR3; PD-1 <400> 72 Gln His Thr Trp Glu Leu Pro Asn Thr 1 5 <210> 73 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Synthetic: LCDR1; PD-1 <400> 73 Lys Ala Ser Gln Asn Val Gly Thr Asn Val Ala 1 5 10 <210> 74 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Synthetic: LCDR2; PD-1 <400> 74 Ser Ala Ser Tyr Arg Tyr Ser 1 5 <210> 75 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic: LCDR3; PD-1 <400> 75 Gln Gln Tyr Tyr Ser Tyr Pro Tyr Thr 1 5 <210> 76 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Synthetic: HCDR1; PD-L1 <400> 76 Asn Tyr Trp Met His 1 5 <210> 77 <211> 17 <212> PRT <213> Artificial sequence <220> <223> Synthetic: HCDR2; PD-L1 <400> 77 Met Ile His Pro Asn Thr Asn Asn Tyr Asn Tyr Asn Glu Lys Phe Lys 1 5 10 15 Ser <210> 78 <211> 12 <212> PRT <213> Artificial sequence <220> <223> Synthetic: HCDR3; PD-L1 <400> 78 Ser Asp Tyr Gly Ser Ser Pro Tyr Tyr Phe Asp Tyr 1 5 10 <210> 79 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Synthetic: HCDR1; PD-L1 <400> 79 Ser Tyr Trp Met His 1 5 <210> 80 <211> 17 <212> PRT <213> Artificial sequence <220> <223> Synthetic: HCDR2; PD-L1 <400> 80 Met Ile His Pro Asn Val Gly Ser Thr Asn Tyr Asn Glu Lys Phe Lys 1 5 10 15 Ser <210> 81 <211> 12 <212> PRT <213> Artificial sequence <220> <223> Synthetic: HCDR3; PD-L1 <400> 81 Ser Arg Tyr Gly Ser Ser Pro Tyr Tyr Phe Asp Tyr 1 5 10 <210> 82 <211> 17 <212> PRT <213> Artificial sequence <220> <223> Synthetic: HCDR2; PD-L1 <400> 82 Met Ile His Pro Asn Ser Gly Gly Asn Asn Tyr Asn Glu Lys Phe Lys 1 5 10 15 Ser <210> 83 <211> 12 <212> PRT <213> Artificial sequence <220> <223> Synthetic: HCDR3; PD-L1 <400> 83 Ser Trp Tyr Gly Ser Ser Pro Tyr Tyr Phe Asp Tyr 1 5 10 <210> 84 <211> 17 <212> PRT <213> Artificial sequence <220> <223> Synthetic: HCDR2; PD-L1 <400> 84 Met Ile His Pro Thr Gly Val Ser Thr Asp Tyr Asn Glu Lys Phe Lys 1 5 10 15 Ser <210> 85 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Synthetic: HCDR1; PD-L1 <400> 85 Ser Asp Tyr Ala Trp Asn 1 5 <210> 86 <211> 16 <212> PRT <213> Artificial sequence <220> <223> Synthetic: HCDR2; PD-L1 <400> 86 Tyr Ile Ser Asp Ser Gly Ser Thr Ser Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 87 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Synthetic: HCDR3; PD-L1 <400> 87 Ser Phe Leu Arg Leu Arg Ser Tyr Phe Asp His 1 5 10 <210> 88 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Synthetic: HCDR1; PD-L1 <400> 88 Ser Tyr Gly Ile Asn 1 5 <210> 89 <211> 17 <212> PRT <213> Artificial sequence <220> <223> Synthetic: LCDR1; PD-L1 <400> 89 Cys Ile Tyr Ile Gly Asn Asp Tyr Thr Asn Tyr Asn Glu Lys Phe Lys 1 5 10 15 Gly <210> 90 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic: LCDR2; PD-L1 <400> 90 Ala Tyr Tyr Gly Ser Arg Val Asp Tyr 1 5 <210> 91 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Synthetic: LCDR1; PD-L1 <400> 91 Arg Ala Ser Gln Asp Ile Asp Asn Tyr Leu Asn 1 5 10 <210> 92 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Synthetic: LCDR2; PD-L1 <400> 92 Tyr Thr Ser Arg Leu His Ser 1 5 <210> 93 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic: LCDR3; PD-L1 <400> 93 Gln Gln Gly Tyr Thr Leu Pro Trp Thr 1 5 <210> 94 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Synthetic: LCDR1; PD-L1 <400> 94 Arg Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn 1 5 10 <210> 95 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Synthetic: LCDR2; PD-L1 <400> 95 Tyr Thr Ser Arg Leu Gln Ser 1 5 <210> 96 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic: LCDR3; PD-L1 <400> 96 Gln Gln Gly Asn Thr Leu Pro Trp Thr 1 5 <210> 97 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic: LCDR3; PD-L1 <400> 97 Gln Gln Gly Asp Thr Leu Pro Trp Thr 1 5 <210> 98 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Synthetic: LCDR1; PD-L1 <400> 98 Lys Ala Ser Gln Asp Val Asn Val Ala Val Ala 1 5 10 <210> 99 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Synthetic: LCDR2; PD-L1 <400> 99 Trp Ala Ser Thr Arg His Ile 1 5 <210> 100 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic: LCDR3; PD-L1 <400> 100 Gln Gln His Tyr Ser Thr Pro Tyr Thr 1 5 <210> 101 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Synthetic: LCDR1; PD-L1 <400> 101 Lys Ala Ser Gln Asp Ile Asn Lys Tyr Ile Ala 1 5 10 <210> 102 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Synthetic: LCDR2; PD-L1 <400> 102 Tyr Thr Ser Thr Leu Gln Pro 1 5 <210> 103 <211> 8 <212> PRT <213> Artificial sequence <220> <223> Synthetic: LCDR3; PD-L1 <400> 103 Leu Gln Tyr Asp Asn Leu Tyr Thr 1 5 <210> 104 <211> 8 <212> PRT <213> Artificial sequence <220> <223> Synthetic: LCDR1; PD-L1 <400> 104 Gln Ser Ile Ser Asp Tyr Leu His 1 5 <210> 105 <211> 8 <212> PRT <213> Artificial sequence <220> <223> Synthetic: LCDR2; PD-L1 <400> 105 Cys Ala Ser Gln Ser Ile Ser Gly 1 5 <210> 106 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic: LCDR3; PD-L1 <400> 106 Gln Asn Gly His Ser Phe Pro Tyr Thr 1 5 <210> 107 <211> 118 <212> PRT <213> artificial sequence <220> <223> Synthesis: HCVR; TIGIT <400> 107 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Tyr Ser Ile Thr Ser Asp 20 25 30 Tyr Ala Trp Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp 35 40 45 Ile Gly Tyr Ile Ser Tyr Ser Gly Ser Thr Gly Tyr Asn Pro Ser Leu 50 55 60 Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser 65 70 75 80 Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Arg Met Ile Gly Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Watch Val Thr Val Watch Watch 115 <210> 108 <211> 115 <212> PRT <213> artificial sequence <220> <223> Synthetic: LCVR; TIGIT <400> 108 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Thr Val 20 25 30 Val Ala Trp His Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ser Ala Ser Tyr Arg Tyr Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Gln 85 90 95 Gln His Tyr Ser Thr Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu 100 105 110 Ile Lys Arg 115 <210> 109 <211> 118 <212> PRT <213> Artificial sequence <220> <223> Synthetic: HCVR; TIGIT <400> 109 Gln Val Lys Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Thr Gly Tyr Ser Ile Thr Ser Asp 20 25 30 Tyr Ala Trp Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp 35 40 45 Ile Gly Tyr Ile Thr Tyr Ser Gly Gly Thr Ser Tyr Asn Pro Ser Leu 50 55 60 Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser 65 70 75 80 Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Ser Cys 85 90 95 Ala Arg Arg Gln Ile Gly Leu Gly Phe Thr Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ala 115 <210> 110 <211> 114 <212> PRT <213> artificial sequence <220> <223> Synthesis: LCVR; TIGIT <400> 110 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Pro Cys Lys Ala Ser Gln Asp Leu Ser Thr Ala 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ser Ser Ser Tyr Arg Tyr Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Gln 85 90 95 Gln His Tyr Ser Thr Pro Trp Thr Phe Gly Glu Gly Thr Lys Leu Glu 100 105 110 Ile Lys <210> 111 <211> 118 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: HCVR; TIGIT <400> 111 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Thr Val Lys Ile Ser Cys Lys Val Ser Gly Tyr Thr Phe Thr Asp His 20 25 30 Thr Ile His Trp Val Gln Gln Ala Pro Gly Lys Gly Leu Glu Trp Met 35 40 45 Gly Tyr Phe Tyr Pro Arg Asp Gly Ser Thr Lys Tyr Asn Glu Lys Phe 50 55 60 Lys Gly Arg Val Thr Ile Thr Ala Asp Thr Ser Thr Asp Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Thr Gly Met Leu Arg Trp Phe Ala Asp Trp Gly Gln Gly Thr Leu 100 105 110 Ile Thr Val Ser Val Ala 115 <210> 112 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: LCVR; TIGIT <400> 112 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Thr Thr 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ser Ala Ser Tyr Arg Tyr Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Ser Thr Pro Leu 85 90 95 Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 100 105 <210> 113 <211> 117 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: HCVR; TIGIT <400> 113 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Thr Val Lys Ile Ser Cys Lys Val Ser Gly Tyr Thr Phe Thr Asp His 20 25 30 Thr Ile His Trp Val Gln Gln Ala Pro Gly Lys Gly Leu Glu Trp Met 35 40 45 Gly Tyr Ile Tyr Pro Arg Asp Gly Ser Ser Lys Tyr Asn Val Lys Phe 50 55 60 Lys Gly Arg Val Thr Ile Thr Ala Asp Thr Ser Thr Asp Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Thr Gly Met Leu Arg Trp Phe Ala Tyr Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser 115 <210> 114 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: LCVR; TIGIT <400> 114 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Val Phe Thr Ala 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ser Ala Ser Tyr Arg Tyr Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln His Tyr Ser Ile Pro Leu 85 90 95 Thr Phe Gly Ala Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 115 <211> 117 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: HCVR; TIGIT <400> 115 Glu Val Gln Leu Lys Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Thr Val Lys Ile Ser Cys Lys Val Ser Gly Tyr Thr Phe Thr Asp Gln 20 25 30 Ala Ile His Trp Val Gln Gln Ala Pro Gly Lys Gly Leu Glu Trp Met 35 40 45 Gly Tyr Ile Tyr Pro Arg Asp Gly Ser Thr Lys Tyr Asn Glu Thr Phe 50 55 60 Lys Gly Arg Val Thr Ile Thr Ala Asp Thr Ser Thr Asp Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Phe Cys 85 90 95 Ala Arg Gly Met Leu Arg Trp Phe Ala Tyr Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser 115 <210> 116 <211> 107 <212> PRT <213> artificial sequence <220> <223> Synthesis: LCVR; TIGIT <400> 116 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Thr Ala 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ser Ala Ser Tyr Arg Tyr Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Ser Thr Pro Leu 85 90 95 Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 100 105 <210> 117 <211> 118 <212> PRT <213> artificial sequence <220> <223> Synthesis: HCVR; TIGIT <400> 117 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Val Ser Ser Asp 20 25 30 Tyr Ala Trp Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp 35 40 45 Ile Gly Tyr Ile Thr Tyr Ser Gly Ser Thr Ser Tyr Asn Pro Ser Leu 50 55 60 Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser 65 70 75 80 Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Arg Gln Val Gly Leu Gly Phe Ala Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ala 115 <210> 118 <211> 107 <212> PRT <213> artificial sequence <220> <223> Synthesis: LCVR; TIGIT <400> 118 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Thr Ala 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ser Ala Ser Tyr His Tyr Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Ser Thr Pro Trp 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 119 <211> 118 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: HCVR; TIGIT <400> 119 Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Asp 1 5 10 15 Thr Leu Ser Leu Thr Cys Ala Val Ser Gly Tyr Ser Ile Thr Ser Asp 20 25 30 Ser Ala Trp Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp 35 40 45 Ile Gly Tyr Ile Thr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu 50 55 60 Arg Ser Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Phe Ser 65 70 75 80 Leu Lys Leu Ser Ser Val Thr Ala Val Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Thr Arg Arg Gln Val Gly Leu Gly Phe Ala Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ala 115 <210> 120 <211> 107 <212> PRT <213> artificial sequence <220> <223> Synthesis: LCVR; TIGIT <400> 120 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Thr Ala 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ser Ala Ser Tyr Arg Phe Thr Gly Ala Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Gly Ile Tyr Tyr Cys Gln His His Tyr Ser Thr Pro Trp 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Phe Lys 100 105 <210> 121 <211> 121 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: HCVR; TIGIT <400> 121 Gln Val Gln Leu Val Gln Ser Gly Ser Glu Leu Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Gly Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe 50 55 60[[ID= / / ]] Lys Gly Arg Phe Val Phe Ser Leu Asp Thr Ser Val Ser Thr Ala Tyr 65 70 75 80 Leu Gln Ile Ser Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ala Pro Pro Tyr Gly Tyr Asp Val Arg Phe Ala Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 122 <211> 112 <212> PRT <213> artificial sequence <220> <223> Synthesis: LCVR; TIGIT <400> 122 Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile Val His Ser 20 25 30 Asn Gly Asn Thr Tyr Leu Glu Trp Phe Gln Gln Arg Pro Gly Gln Ser 35 40 45 Pro Arg Val Leu Ile Tyr Lys Val Ser Asp Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Phe Gln Gly 85 90 95 Ser His Val Pro Trp Thr Phe Gly Arg Gly Thr Lys Leu Glu Ile Lys 100 105 110 <210> 123 <211> 121 <212> PRT <213> Synthetic sequence <220> <223> Synthetic: HCVR; TIGIT <400> 123 Gln Val Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Phe 20 25 30 Ala Met Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala His Ile Trp Trp Asp Asp Asp Lys Tyr Tyr Asn Pro Ala 50 55 60 Leu Lys Ser Arg Leu Thr Ile Thr Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Met Asp Tyr Ser Tyr Phe Ala Trp Phe Ala Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 124 <211> 109 <212> PRT <213> Synthetic sequence <220> <223> Synthetic: LCVR; TIGIT <400> 124 Gln Ala Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly 1 5 10 15 Thr Val Thr Leu Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Thr Ser 20 25 30 Asn Tyr Ala Asn Trp Val Gln Gln Lys Pro Gly Gln Leu Phe Arg Gly 35 40 45 Leu Ile Gly Gly Thr Asn Asn Arg Ala Pro Trp Val Pro Ala Arg Phe 50 55 60 Ser Gly Ser Leu Ile Gly Asp Lys Ala Ala Leu Thr Leu Ser Gly Val 65 70 75 80 Gln Pro Glu Asp Glu Ala Glu Tyr Phe Cys Ala Leu Trp Tyr Ser Asn 85 90 95 His Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 125 <211> 122 <212> PRT <213> Synthetic sequence <220> <223> Synthetic: HCVR; TIGIT <400> 125 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Gly Gly Arg Thr Ser Tyr Ala Gln Met Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Arg Glu Glu Gln Trp Pro Val Gly Gly Phe Asp Tyr Trp 100 105 110 Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 126 <211> 108 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: LCVR; TIGIT <400> 126 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Arg Arg Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ser Ala Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ile Ile Pro Pro 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Arg Arg 100 105 <210> 127 <211> 117 <212> PRT <213> artificial sequence <220> <223> Synthesis: HCVR; PD-1 <400> 127 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Phe 20 25 30 Leu Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Thr Ile Ser Gly Gly Gly Arg Asp Thr Tyr Tyr Val Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys Arg Thr Thr Tyr Ser Met Asp Tyr Trp Gly Gln Gly Thr Ser 100 105 110 Val Thr Val Ser Ser 115 <210> 128 <211> 107 <212> PRT <213> artificial sequence <220> <223> Synthesis: LCVR; PD-1 <400> 128 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Leu Ala Ser Gln Thr Ile Gly Thr Trp 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ala Ala Thr Ser Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Phe Tyr Ser Ile Pro Trp 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 129 <211> 120 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: HCVR; PD-1 <400> 129 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Asp Tyr Thr Phe Thr Asn Ser 20 25 30 Tyr Leu Tyr Trp Leu Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Asn Pro Ser Asn Gly Gly Thr Asn Phe Asn Glu Lys Phe 50 55 60 Lys Thr Arg Thr Thr Ser Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Val Val Tyr Tyr Cys 85 90 95 Thr Arg Arg Asp Tyr Asn Tyr Asp Gly Gly Phe Asp Ser Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 130 <211> 108 <212> PRT <213> artificial sequence <220> <223> Synthesis: LCVR; PD-1 <400> 130 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Phe Thr Cys Arg Ala Ser Ser Thr Leu Tyr Ser Asn 20 25 30 Tyr Leu His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Arg Ala Ser Phe Leu Ala Ser Gly Val Pro Ser Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln 65 70 75 80 Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Ser Ser Ile Pro 85 90 95 Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 <210> 131 <211> 120 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: HCVR; PD-1 <400> 131 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Asp Tyr Thr Phe Thr Asn Ser 20 25 30 Tyr Ile Tyr Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Asn Pro Ser Asn Gly Gly Thr Asn Phe Asn Glu Lys Phe 50 55 60 Lys Thr Arg Val Thr Ser Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Val Val Tyr Tyr Cys 85 90 95 Ala Arg Arg Asp Tyr Arg Tyr Asp Gly Gly Phe Asp Ser Trp Gly Gln 100 105 110 Gly Thr Thr Leu Thr Val Ser Ser 115 120 <210> 132 <211> 108 <212> PRT <213> artificial sequence <220> <223> Synthesis: LCVR; PD-1 <400> 132 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Leu Tyr Ser Ser 20 25 30 Tyr Leu His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Arg Ala Ser Phe Leu Ala Ser Gly Val Pro Ser Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln 65 70 75 80 Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Ser Ser Ile Pro 85 90 95 Leu Thr Phe Gly Ala Gly Thr Lys Leu Asp Leu Lys 100 105 <210> 133 <211> 120 <212> PRT <213> artificial sequence <220> <223> Synthesis: HCVR; PD-1 <400> 133 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Asp Tyr Thr Phe Thr Asn Ser 20 25 30 Tyr Ile Tyr Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Asn Pro Ser Asn Gly Gly Thr Asn Phe Asn Glu Lys Phe 50 55 60 Lys Thr Arg Val Thr Ser Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Val Val Tyr Tyr Cys 85 90 95 Ala Arg Arg Asp Tyr Asn Tyr Asp Gly Gly Phe Asp Ser Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 134 <211> 108 <212> PRT <213> artificial sequence <220> <223> Synthesis: LCVR; PD-1 <400> 134 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Phe Thr Cys Arg Ala Ser Ser Ser Leu Tyr Ser Asn 20 25 30 Tyr Leu His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Arg Ala Ser Phe Leu Ala Ser Gly Val Pro Ser Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln 65 70 75 80 Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Ser Ser Ile Pro 85 90 95 Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 <210> 135 <211> 120 <212> PRT <213> artificial sequence <220> <223> Synthesis: HCVR; PD-1 <400> 135 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr 20 25 30 Tyr Ile Tyr Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Asn Pro Gly Asn Gly Gly Thr Asn Phe Asn Glu Lys Phe 50 55 60 Lys Ile Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Arg Tyr His Gly Tyr Asp Gly Gly Leu Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 136 <211> 111 <212> PRT <213> Synthetic sequence <220> <223> Synthetic: LCVR; PD-1 <400> 136 Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Pro Gly 1 5 10 15 Gln Arg Ala Thr Ile Thr Cys Arg Ala Ser Lys Ser Val Ser Thr Ser 20 25 30 Gly Phe Ser Tyr Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro 35 40 45 Lys Leu Leu Ile Tyr Leu Ala Ser Asn Leu Glu Ser Gly Val Pro Ala 50 55 60 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn 65 70 75 80 Pro Val Glu Ala Asn Asp Thr Ala Asn Tyr Tyr Cys Gln His Thr Trp 85 90 95 Glu Leu Pro Asn Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 110 <210> 137 <211> 117 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: HCVR; PD-1 <400> 137 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 35 40 45 Gly Trp Ile Phe Pro Gly Ser Gly Asn Ser Lys Tyr Asn Glu Asn Phe 50 55 60 Lys Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Phe Cys 85 90 95 Ala Ser Glu Thr Tyr Asp Tyr Gly Asp Tyr Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser 115 <210> 138 <211> 107 <212> PRT <213> artificial sequence <220> <223> Synthesis: LCVR; PD-1 <400> 138 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Asn 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Ser Leu Ile 35 40 45 Tyr Ser Ala Ser Tyr Arg Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Tyr Tyr Ser Tyr Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 139 <211> 121 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: HCVR; PD-L1 <400> 139 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Trp Met His Trp Met Lys Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Met Ile His Pro Asn Thr Asn Asn Tyr Asn Tyr Asn Glu Lys Phe<B 50 55 60 Lys Ser Arg Val Thr Ser Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Val Val Tyr Tyr Cys 85 90 95 Ala Arg Ser Asp Tyr Gly Ser Ser Pro Tyr Tyr Phe Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 140 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: LCVR; PD-L1 <400> 140 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Asp Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Lys Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Gly Tyr Thr Leu Pro Trp 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 <210> 141 <211> 121 <212> PRT <213> artificial sequence <220> <223> Synthesis: HCVR; PD-L1 <400> 141 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Met Ile His Pro Asn Val Gly Ser Thr Asn Tyr Asn Glu Lys Phe 50 55 60 Lys Ser Lys Ala Thr Met Thr Arg Asp Lys Ser Ser Ser Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ser Arg Tyr Gly Ser Ser Pro Tyr Tyr Phe Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 142 <211> 107 <212> PRT <213> artificial sequence <220> <223> Synthesis: LCVR; PD-L1 <400> 142 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr Ser Arg Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Trp 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 <210> 143 <211> 121 <212> PRT <213> artificial sequence <220> <223> Synthesis: HCVR; PD-L1 <400> 143 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Met Ile His Pro Asn Ser Gly Gly Asn Asn Tyr Asn Glu Lys Phe 50 55 60 Lys Ser Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ser Trp Tyr Gly Ser Ser Pro Tyr Tyr Phe Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 144 <211> 107 <212> PRT <213> artificial sequence <220> <223> Synthesis: LCVR; PD-L1 <400> 144 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Trp 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 <210> 145 <211> 121 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: HCVR; PD-L1 <400> 145 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Met Ile His Pro Thr Gly Val Ser Thr Asp Tyr Asn Glu Lys Phe 50 55 60 Lys Ser Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ser Asp Tyr Gly Ser Ser Pro Tyr Tyr Phe Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 146 <211> 107 <212> PRT <213> artificial sequence <220> <223> Synthesis: LCVR; PD-L1 <400> 146 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Lys Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Gly Asp Thr Leu Pro Trp 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 <210> 147 <211> 120 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: HCVR; PD-L1 <400> 147 Asp Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 1 5 10 15 Ser Leu Ser Leu Thr Cys Thr Val Thr Gly Tyr Ser Ile Thr Ser Asp 20 25 30 Tyr Ala Trp Asn Trp Ile Arg Gln Phe Pro Gly Asn Lys Leu Glu Trp 35 40 45 Met Gly Tyr Ile Ser Asp Ser Gly Ser Thr Ser Tyr Asn Pro Ser Leu 50 55 60 Lys Ser Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Phe 65 70 75 80 Leu Gln Leu Asn Ser Val Thr Thr Glu Asp Thr Ala Thr Tyr Tyr Cys 85 90 95 Ala Asn Ser Phe Leu Arg Leu Arg Ser Tyr Phe Asp His Trp Gly Gln 100 105 110 Gly Thr Thr Leu Thr Val Ser Ser 115 120 <210> 148 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: LCVR; PD-L1 <400> 148 Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly 1 5 10 15 Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Asn Val Ala 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile 35 40 45 Phe Trp Ala Ser Thr Arg His Ile Gly Val Pro Asp Arg Phe Thr Gly 50 55 60 Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Val Gln Ala 65 70 75 80 Glu Asp Leu Ala Leu Tyr Tyr Cys Gln Gln His Tyr Ser Thr Pro Tyr 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 149 <211> 119 <212> PRT <213> artificial sequence <220> <223> Synthesis: HCVR; PD-L1 <400> 149 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Gly Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 35 40 45 Gly Trp Cys Ile Tyr Ile Gly Asn Asp Tyr Thr Asn Tyr Asn Glu Lys 50 55 60 Phe Lys Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala 65 70 75 80 Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Arg Ala Tyr Tyr Gly Ser Arg Val Asp Tyr Trp Gly Gln Gly 100 105 110 Thr Leu Val Thr Val Ser Ser 115 <210> 150 <211> 106 <212> PRT <213> artificial sequence <220> <223> Synthesis: LCVR; PD-L1 <400> 150 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Phe Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Asn Lys Tyr 20 25 30 Ile Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 His Tyr Thr Ser Thr Leu Gln Pro Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Arg Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Ile Ala Thr Tyr Tyr Cys Leu Gln Tyr Asp Asn Leu Tyr Thr 85 90 95 Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 <210> 151 <211> 119 <212> PRT <213> artificial sequence <220> <223> Synthesis: HCVR; PD-L1 <400> 151 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Gly Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 35 40 45 Gly Trp Cys Ile Tyr Ile Gly Asn Asp Tyr Thr Asn Tyr Asn Glu Lys 50 55 60 Phe Lys Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala 65 70 75 80 Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Arg Ala Tyr Tyr Gly Ser Arg Val Asp Tyr Trp Gly Gln Gly 100 105 110 Thr Leu Val Thr Val Ser Ser 115 <210> 152 <211> 104 <212> PRT <213> artificial sequence <220> <223> Synthesis: LCVR; PD-L1 <400> 152 Glu Ile Val Leu Thr Gln Ser Pro Val Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Gln Ser Ile Ser Asp Tyr Leu His Trp 20 25 30 Tyr Leu Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Lys Cys Ala 35 40 45 Ser Gln Ser Ile Ser Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser 50 55 60 Gly Ser Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe 65 70 75 80 Ala Val Tyr Tyr Cys Gln Asn Gly His Ser Phe Pro Tyr Thr Phe Gly 85 90 95 Gly Gly Thr Lys Val Glu Ile Lys 100 <210> 153 <211> 121 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: HCVR; PD-L1 <400> 153 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Met Ile His Pro Asn Ser Gly Gly Asn Asn Tyr Asn Glu Lys Phe 50 55 60 Lys Ser Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ser Trp Tyr Gly Ser Ser Pro Tyr Tyr Phe Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 154 <211> 107 <212> PRT <213> artificial sequence <220> <223> Synthesis: LCVR; PD-L1 <400> 154 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Asp Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Lys Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Gly Tyr Thr Leu Pro Trp 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 <210> 155 <211> 246 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: VH; TP-M2T8P5 <400> 155 Gln Val Gln Leu Val Gln Ser Gly Ser Glu Leu Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Gly Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe 50 55 60 Lys Gly Arg Phe Val Phe Ser Leu Asp Thr Ser Val Ser Thr Ala Tyr 65 70 75 80 Leu Gln Ile Ser Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ala Pro Pro Tyr Gly Tyr Asp Val Arg Phe Ala Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gln Val 115 120 125 Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val 130 135 140 Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr Tyr Ile 145 150 155 160 Tyr Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly 165 170 175 Ile Asn Pro Gly Asn Gly Gly Thr Asn Phe Asn Glu Lys Phe Lys Ile 180 185 190 Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr Met Glu 195 200 205 Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg 210 215 220 Arg Tyr His Gly Tyr Asp Gly Gly Leu Asp Tyr Trp Gly Gln Gly Thr 225 230 235 240 Leu Val Thr Val Ser Ser 245 <210> 156 <211> 238 <212> PRT <213> Artificial sequence <220> <223> Synthetic: VL; TP-M2T8P5 <400> 156 Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile Val His Ser 20 25 30 Asn Gly Asn Thr Tyr Leu Glu Trp Phe Gln Gln Arg Pro Gly Gln Ser 35 40 45 Pro Arg Val Leu Ile Tyr Lys Val Ser Asp Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Phe Gln Gly 85 90 95 Ser His Val Pro Trp Thr Phe Gly Arg Gly Thr Lys Leu Glu Ile Lys 100 105 110 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp 115 120 125 Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Pro Gly Gln 130 135 140 Arg Ala Thr Ile Thr Cys Arg Ala Ser Lys Ser Val Ser Thr Ser Gly 145 150 155 160 Phe Ser Tyr Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys 165 170 175 Leu Leu Ile Tyr Leu Ala Ser Asn Leu Glu Ser Gly Val Pro Ala Arg 180 185 190 Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn Pro 195 200 205 Val Glu Ala Asn Asp Thr Ala Asn Tyr Tyr Cys Gln His Thr Trp Glu 210 215 220 Leu Pro Asn Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 225 230 235 <210> 157 <211> 245 <212> PRT <213> Artificial sequence <220> <223> Synthetic: VL2 / VH1; TP-M4T8P5 <400> 157 Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile Val His Ser 20 25 30 Asn Gly Asn Thr Tyr Leu Glu Trp Phe Gln Gln Arg Pro Gly Gln Ser 35 40 45 Pro Arg Val Leu Ile Tyr Lys Val Ser Asp Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Phe Gln Gly 85 90 95 Ser His Val Pro Trp Thr Phe Gly Arg Gly Thr Lys Leu Glu Ile Lys 100 105 110 Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Gln Val Gln 115 120 125 Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys 130 135 140 Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr Tyr Ile Tyr 145 150 155 160 Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile 165 170 175 Asn Pro Gly Asn Gly Gly Thr Asn Phe Asn Glu Lys Phe Lys Ile Arg 180 185 190 Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr Met Glu Leu 195 200 205 Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Arg 210 215 220 Tyr His Gly Tyr Asp Gly Gly Leu Asp Tyr Trp Gly Gln Gly Thr Leu 225 230 235 240 Val Thr Val Ser Ser 245 <210> 158 <211> 245 <212> PRT <213> Artificial sequence <220> <223> Synthetic: VH2 / VL1; TP-M4T8P5 <400> 158 Gln Val Gln Leu Val Gln Ser Gly Ser Glu Leu Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Gly Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe 50 55 60 Lys Gly Arg Phe Val Phe Ser Leu Asp Thr Ser Val Ser Thr Ala Tyr 65 70 75 80 Leu Gln Ile Ser Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ala Pro Pro Tyr Gly Tyr Asp Val Arg Phe Ala Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 125 Val Phe Pro Leu Ala Pro Asp Ile Val Leu Thr Gln Ser Pro Ala Ser 130 135 140 Leu Ala Val Ser Pro Gly Gln Arg Ala Thr Ile Thr Cys Arg Ala Ser 145 150 155 160 Lys Ser Val Ser Thr Ser Gly Phe Ser Tyr Ile His Trp Tyr Gln Gln 165 170 175 Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Leu Ala Ser Asn Leu 180 185 190 Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp 195 200 205 Phe Thr Leu Thr Ile Asn Pro Val Glu Ala Asn Asp Thr Ala Asn Tyr 210 215 220 Tyr Cys Gln His Thr Trp Glu Leu Pro Asn Thr Phe Gly Gly Gly Thr 225 230 235 240 Lys Val Glu Ile Lys 245 <210> 159 <211> 679 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: VH; TP-M6T8P5 <400> 159 Gln Val Gln Leu Val Gln Ser Gly Ser Glu Leu Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Gly Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe 50 55 60 Lys Gly Arg Phe Val Phe Ser Leu Asp Thr Ser Val Ser Thr Ala Tyr 65 70 75 80 Leu Gln Ile Ser Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ala Pro Pro Tyr Gly Tyr Asp Val Arg Phe Ala Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 125 Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala 130 135 140 Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 145 150 155 160 Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 165 170 175 Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185 190 Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His 195 200 205 Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly 210 215 220 Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro 260 265 270 Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Gly 435 440 445 Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Val 450 455 460 Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Pro Gly Gln Arg Ala 465 470 475 480 Thr Ile Thr Cys Arg Ala Ser Lys Ser Val Ser Thr Ser Gly Phe Ser 485 490 495 Tyr Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu 500 505 510 Ile Tyr Leu Ala Ser Asn Leu Glu Ser Gly Val Pro Ala Arg Phe Ser 515 520 525 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn Pro Val Glu 530 535 540 Ala Asn Asp Thr Ala Asn Tyr Tyr Cys Gln His Thr Trp Glu Leu Pro 545 550 555 560 Asn Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala 565 570 575 Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser 580 585 590 Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu 595 600 605 Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser 610 615 620 Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu 625 630 635 640 Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val 645 650 655 Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys 660 665 670 Ser Phe Asn Arg Gly Glu Cys 675 <210> 160 <211> 219 <212> PRT <213> artificial sequence <220> <223> Synthesis: VL2 / CL; TP-M6T8P5 <400> 160 Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile Val His Ser 20 25 30 Asn Gly Asn Thr Tyr Leu Glu Trp Phe Gln Gln Arg Pro Gly Gln Ser 35 40 45 Pro Arg Val Leu Ile Tyr Lys Val Ser Asp Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Phe Gln Gly 85 90 95 Ser His Val Pro Trp Thr Phe Gly Arg Gly Thr Lys Leu Glu Ile Lys 100 105 110 Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 115 120 125 Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 130 135 140 Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 145 150 155 160 Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 165 170 175 Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 180 185 190 Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 195 200 205 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 161 <211> 237 <212> PRT <213> Artificial sequence <220> <223> Synthetic: VH1 / CH1; TP-M6T8P5 <400> 161 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr 20 25 30 Tyr Ile Tyr Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Asn Pro Gly Asn Gly Gly Thr Asn Phe Asn Glu Lys Phe 50 55 60 Lys Ile Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Arg Tyr His Gly Tyr Asp Gly Gly Leu Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro 210 215 220 Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly 225 230 235 <210> 162 <211> 675 <212> PRT <213> Artificial Sequence <220> <223> Synthesized: VH; TP-M6T8L8 <400> 162 Gln Val Gln Leu Val Gln Ser Gly Ser Glu Leu Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Gly Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe 50 55 60 Lys Gly Arg Phe Val Phe Ser Leu Asp Thr Ser Val Ser Thr Ala Tyr 65 70 75 80 Leu Gln Ile Ser Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ala Pro Pro Tyr Gly Tyr Asp Val Arg Phe Ala Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 125 Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala 130 135 140 Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 145 150 155 160 Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 165 170 175 Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185 190 Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His 195 200 205 Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly 210 215 220 Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro 260 265 270 Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Gly 435 440 445 Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln 450 455 460 Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val 465 470 475 480 Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Asp Asn Tyr Leu Asn Trp 485 490 495 Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Lys Tyr Thr 500 505 510 Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe...

Claims

1. A bispecific antibody, comprising: A first antigen binding domain, which comprises an antigen binding portion of an anti-TIGIT antibody, comprising: a heavy chain variable region comprising CDR1 shown in SEQ ID NO: 17, CDR2 shown in SEQ ID NO: 18, and CDR3 shown in SEQ ID NO: 19; and a light chain variable region comprising CDR1 shown in SEQ ID NO: 39, CDR2 shown in SEQ ID NO: 40, and CDR3 shown in SEQ ID NO: 41, and A second antigen binding domain, which comprises an antigen binding portion of an anti-PD-1 antibody, comprising: A heavy chain variable region comprising CDR1 shown in SEQ ID NO:56, CDR2 shown in SEQ ID NO:57, and CDR3 shown in SEQ ID NO:58; and a light chain variable region comprising CDR1 shown in SEQ ID NO:70, CDR2 shown in SEQ ID NO:71, and CDR3 shown in SEQ ID NO:

72. 2 . The bispecific antibody of claim 1 , comprising the amino acid sequence of SEQ ID NO:

171. The bispecific antibody of claim 1 , comprising the amino acid sequence of SEQ ID NO:

172. The bispecific antibody of claim 1 , comprising the amino acid sequences of SEQ ID NOs: 171 and 172. A nucleic acid encoding the bispecific antibody of claim 1 .

6. An expression vector comprising the nucleic acid of claim 5.

7. A host cell transformed with the expression vector according to claim 6.

8. A method for producing an antibody or an antigen-binding fragment thereof, comprising: Cultivating the host cell of claim 7 under conditions that allow production of the antibody or antigen-binding fragment thereof, and The antibody or antigen-binding fragment thereof is purified from the cells.

9. Use of the antibody according to claim 1 in the preparation of a medicament for treating a tumor in a subject in need thereof, wherein the tumor is a solid tumor.